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Mucosal surfaces in the lung interface with the outside environment for breathing 
purposes, but also provide the first line of defense against invading pathogens. The intricate 
balance of effective immune protection at the pulmonary epithelium without problematic 
inflammation is not well understood, but is an important consideration in complex lung diseases 
such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). 
Although IPF is a fibrotic interstitial lung disease of unknown origin and COPD is an obstructive 
lung disease, they do share some similarities. Both are heterogeneous and progressive in nature, 
have no cure and few treatment options, advance through unknown mechanisms, and involve an 
aberrant immune response. As research has focused into the role the immune system plays in IPF 
and COPD, it has become clear that disease progression is caused by a complex dysregulation of 
immune factors and cells across the tissue compartments of the lungs and blood.  
Data-driven modeling approaches offer the opportunity to infer protein interaction 
networks, which are able to identify diagnostic and prognostic biomarkers and also serve as the 
basis for new insight into systems-level mechanisms that define a disease state. Additionally, 
these approaches are able to integrate data from across multiple tissue compartments, allowing 
for a more holistic picture of a disease to be formed. Here, we have applied data-driven modeling 
approaches including partial least squares discriminant analysis, principal component analysis, 
decision tree analysis, and hierarchical clustering to high-throughput cell and cytokine 
measurements from human blood and lung samples to gain systems-level insight into IPF and 
COPD. 
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Overall we found that these approaches were useful for identifying signatures of proteins 
that differentiated disease state and progression better than current classifiers. We also found that 
integrating protein and cell measurements across tissue compartments generally improved 
classification and was useful for generating new mechanistic insight into progression and 
exacerbation events. In evaluating IPF progression, we showed that the blood proteome of 
progressors, but not of non-progressors, changes over time, and that our data-driven modeling 
techniques were able to capture these changes. Curiously, our models showed that complement 
system components may be associated with both COPD disease state and IPF disease 
progression. Lastly, though our analysis suggested that circulating blood cytokines were not 
useful for differentiating disease state or progression, preliminary work suggested that cell-cell 
communication networks arising from stimulated peripheral blood proteins may be more useful 
for classification and gaining mechanistic insight from minimally invasive blood samples. 
Overall, we believe that this approach will be useful for studying the mucosal immune response 
present in other diseases that are also progressive or heterogeneous in nature.  
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Chapter 1 Introduction 
 
Besides being the site of respiration, the lung is also a key site of immunity because it 
interfaces with the outside environment. However, there is still much that is not understood about 
how the body maintains proper protection without experiencing an excessive immune response at 
this surface1. The importance of this problem is highlighted by the increasing number of global 
cases of chronic respiratory disease from 1990 to 2017 and the rise in the incidences of asthma, 
interstitial lung diseases, and pulmonary sarcoidosis over the past 15 years2. This intricate 
balance of effective immune protection without dysregulation is affected in lung diseases 
idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). 
Although IPF and COPD differ in both their clinical presentation and their natural history, they 
are both progressive and heterogeneous diseases with few treatment options, and the mechanisms 
underlying development and progression are not well understood. Better understanding of the 
complex immunological mechanisms that are associated with disease state and disease 
progression will be a critical step on the path to development of better diagnostic and treatment 
options. This thesis aims to use systems-focused, data-driven modeling approaches to help 
identify signatures of key immune factors associated with IPF and COPD in order to gain 
increased insight into potential mechanisms associated with these two lung diseases. 
1.1 Idiopathic pulmonary fibrosis disease pathogenesis and treatment 
Idiopathic pulmonary fibrosis is a progressive and heterogeneous interstitial pneumonia 
of unknown origin with a median survival rate of 3-5 years3,4. The diagnosis process for IPF can 
be challenging, and there are few treatment options available to patients. It presents in patients as 
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shortness of breath (dyspnea), dry cough, and fatigue5. IPF is more commonly diagnosed in older 
populations who have a history of smoking or occupation-related exposure to inhaled particles, 
especially in men4, and there are also genetic variants that are associated with increased risk for 
the disease.  
Although the exact mechanisms behind disease pathogenesis are unknown, current 
hypotheses involve some environmentally-caused repetitive injuries to lung alveolar epithelial 
cells (AECs). Additionally, there are certain genetic predisposition towards IPF as well, which 
includes mutations in genes coding for surfactant proteins A2 and C6, single nucleotide 
polymorphisms (SNP) in the mucin 5B (MUC5B) gene (rs35705950)7–10, and SNPs in the Toll-
interacting protein (TOLLIP) gene7. Overall disease pathogenesis is attributed to a dysregulated 
healing response11 that results in both the collapse of alveoli, which decreases the surface area 
available for gas exchange in the lung, and in the fibrosis of the interstitial surfaces, which can 
spread and cause symptoms associated with restrictive lung diseases12. This response is enacted 
in part by neutrophils, macrophages, and T cells. Neutrophils have been reported to be increased 
in the bronchoalveolar lavage (BAL) fluid of IPF patients compared to healthy controls13 and 
classically secrete the protease neutrophil elastase (NE), pro-inflammatory cytokines, and 
reactive oxygen species (ROS)14. According to patterns seen in other chronic inflammatory 
diseases, macrophages may start out in the lung with a pro-inflammatory phenotype due to 
activation by lipopolysaccharide (LPS) or interferon γ (IFNγ), but as the disease progresses, 
macrophages activated by IL-13 may become more abundant and could be the cause of increases 
in CCL18 seen in IPF patients15,16. Although there is much literature that describes macrophage 
activation on the classically activated/M1 vs. alternatively activated/M2 axis, other studies have 
shown that macrophage activation is more complex than originally understood and is better 
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described as a spectrum rather than an axis17–19, and must be kept in mind when discussing 
cellular mechanisms. Th1 and Th2 CD4+ T cells have also been historically reported as being 
associated with IPF, with newer studies linking Th17, Th9, and Tregs to IPF pathogenesis as 
well, although the balance of these cells’ action in humans is still not well understood16. In this 
environment, some AECs are reprogrammed to transition into mesenchymal cells, whereas some 
experience senescence or apoptosis. The transition of the epithelial cells to a more mesenchymal 
state and the increase in the number of IL-13-activated macrophages result in the secretion of 
pro-fibrotic cytokines and growth factors that attract fibroblasts to the interstitial space 
surrounding the alveoli. Once recruited, the fibroblasts can also differentiate into myofibroblasts 
if they experience an environment characterized by high mechanical stress or high concentrations 
of signaling molecules such as transforming growth factor β1 (TGF-β1) or specialized matrix 
proteins such as the fibronectin ED-A splice variant20. Myofibroblasts are a type of mesenchymal 
cell with the ability to secrete extracellular matrix (ECM) proteins like fibroblasts, and can also 
generate contractile forces through the production of α-smooth muscle actin (α-SMA), like 
smooth muscle cells21. Additionally, others have reported that myofibroblasts in IPF may also 
arise from other cell sources, such as epithelial cells that experience epithelial to mesenchymal 
transition (EMT)22, lung-resident mesenchymal cells23, or potentially from bone marrow 
progenitor recruitment in murine models of pulmonary fibrosis24. However, as El Agha et al. 
have summarized over multiple studies, the origin of the myofibroblast may determine if it has a 
pathogenic effect in the development of IPF or not25. Once present, both fibroblasts and 
myofibroblasts secrete high levels of ECM and other pro-fibrotic signaling cytokines to 
encourage more ECM production and fibroblast growth26.  
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IPF progression, like the disease state itself, is both heterogeneous and not well 
understood. Patients experience progression as increased shortness of breath and cough, which is 
accompanied by decreased quality of life27. Progression is generally tracked in clinical trials 
through lung function measurements such as forced vital capacity (FVC) and the diffusion 
capacity of the lung for carbon monoxide (DLCO)27,28. Unfortunately, in IPF, once lung function 
is lost, it cannot be regained. Patients heterogeneously lose lung function over time, with some 
patients experiencing steep declines in lung function, others progressing slowly but steadily, and 
others experiencing times of relative stability interspersed with periods of steep decline3,29. The 
causes of those periods of extreme worsening may be directly due to an infection or a 
comorbidity, or could be caused by an acute exacerbation of IPF (AE-IPF), which could have 
been triggered by an external stimulus or could have an unknown cause27,30. AE-IPF events can 
present as increases in shortness of breath, cough, fever, and/or sputum production3, and are 
associated with up to 46% of the deaths in IPF30. They are more common in patients with 
advanced disease, though this could be due to patients with advanced disease being more likely 
to seek treatment30. Much like the slower progressive periods in IPF, the mechanisms behind 
AE-IPF events remain unclear, though it is hypothesized that neutrophils or anti-inflammatory 
macrophages potentially activated by IL-4 or IL-13 could be involved due to their presence in 
the lungs of IPF patients experiencing an exacerbation31,32.  
To improve patients’ quality of life, in the past decade clinicians and researchers have 
focused on discovering new diagnostic and prognostic markers as well as pharmacological 
treatment options to better patient outcomes. Since a proper diagnosis of IPF can be a challenge, 
streamlining this process has been the goal of many international pulmonary organizations. As 
reported by Raghu et al., the current guidelines for IPF diagnosis involve first ruling out any 
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other environmental or genetic causes of the fibrosis33. If no other potential cause of the fibrosis 
can be identified, then chest high-resolution computed tomography (HRCT) scans are taken and 
analyzed for the presence of usual interstitial pneumonia (UIP) patterns, which includes fibrosis 
in a honeycomb pattern that is primarily present in the subpleural and basal regions of the lung. 
There are then multidisciplinary discussions with pulmonologists, radiologists, and pathologists 
over the patient’s history and HRCT scans, especially in cases where the UIP pattern is not 
obvious, to gauge next steps. For patients with indeterminate UIP patterns on their HRCT scans 
and no history of a co-existing rheumatological disease, a surgical lung biopsy may be 
recommended to confirm the presence of the UIP pattern in the lung tissue itself33 in order to 
completely validate an IPF diagnosis. While a biopsy is not always required for an IPF diagnosis, 
this procedure does present a challenge because not all patients are healthy enough to undergo a 
lung biopsy due to the risk of further injury that could result in a progressive event. Thus the 
current diagnostic guidelines could result in an unclear diagnosis in some patients33.  
Challenges associated with the diagnosis process for IPF involve the low prevalence of 
the disease due to high lethality rates (it is estimated to affect between 10-60 people out of 
100,00026), the large number of other diseases that share the same presenting symptoms as IPF, 
and the lack of biomarkers specific for the disease. The presenting symptoms of IPF are very 
similar to more common lung afflictions, such as asthma or pneumonia, as well as other 
interstitial lung diseases (ILDs) or other immunological diseases affecting the pulmonary 
environment (such as hypersensitivity pneumonitis or sarcoidosis). The Interstitial Lung Disease 
Patient Diagnostic Journey (INTENSITY) survey reported that out of 600 ILD patients, over half 
(55%) received at least one misdiagnosis before receiving their current diagnosis34. Misdiagnosis 
is problematic because it prevents patients from receiving helpful treatment in a timely manner 
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and could mean that they receive potentially harmful treatment based on their incorrect 
diagnosis. Thus, researchers have begun exploring potential molecular biomarkers from 
peripheral blood or the lungs that could help in the diagnosis of IPF and also predict the course 
of the disease. Some promising single biomarkers have been identified (matrix metalloproteinase 
7 (MMP-7)35,36, surfactant protein D (SP-D)36,37, human mucin-1 (MUC1/KL-6)36) that can 
differentiate IPF from some ILDs or IPF from healthy controls, but biomarkers that are specific 
to only an IPF diagnosis have not yet been identified38. On the prognostic biomarker side, blood 
MMP-739,40, CCL1841, KL-636,42, and SP-D43,44 have shown promising results. However, it has 
been difficult to replicate these findings in other cohorts38,45, especially when validating the exact 
concentration cut off of single biomarkers to use for diagnostic or prognostic purposes46, and 
thus there are currently no biomarkers recommended for clinical use33.  
There has been great improvement in treatment options for IPF patients in the past 
decade, but currently there is still no cure other than lung transplantation. It was originally 
thought that IPF was mostly an inflammatory disease until it was reported in the PANTHER-IPF 
(Prednisone, Azathioprine, and N-Acetylcysteine: A Study That Evaluates Response in IPF) 
study that patients on an immunosuppressive, anti-inflammatory three-drug combination had 
increased risk of death and hospitalization as compared to the placebo group47. Since then, two 
anti-fibrotic drugs, pirfenidone48 and nintedanib49, were approved for the treatment of IPF. 
Believed to act through different mechanisms, both drugs have been shown to temporarily slow 
disease progression (as measured by decline in FVC), but current studies did not report 
significant improvements in quality of life or shortness of breath and were not powered to 
investigate the drugs’ effect on AE-IPF occurrence or mortality50. Altogether, the result is that 
the only current option for an IPF cure is a lung transplant. However, this procedure comes with 
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a high risk of rejection (median survival of 4.5 years post-transplantation51) and is not 
recommended for patients over 70 years of age52. 
1.2 Chronic obstructive pulmonary disease pathogenesis 
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease associated 
with smoking that is currently the fourth leading cause of death in the United States53. It was 
estimated that at least 174 million people were living with COPD worldwide in 2015 (although 
underdiagnosis is common54,55), and that it resulted in the death of 3.2 million people that same 
year56. COPD is a costly disease, with an estimated healthcare-related spending of $36 billion in 
2010 that is only projected to increase57. COPD is diagnosed via lung spirometry and patient 
history/experiences, with COPD patients meeting the following criteria: (1) a ratio of the 
recorded post-bronchodilator forced expiratory volume in one second (FEV1) to FVC 
(FEV1/FVC) that is less than 70%; (2) the presence of symptoms such as cough, sputum 
production, shortness of breath, and wheezing; and (3) significant exposure to harmful stimuli, 
such as cigarette or biomass smoke58,59. According to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines, disease severity can be characterized by 
comparing the measured FEV1 to the FEV1 that is predicted based on the patient’s age, sex, and 
height. The lower the measured FEV1 is compared to the predicted, the more severe the airflow 
obstruction and the higher the GOLD stage, with stages ranging from GOLD 1 (patients with 
FEV1 ≥ 80% predicted) to GOLD 4 (patients with FEV1 ≤ 30% predicted)
58. Although all COPD 
patients share similar spirometry patterns and general symptoms, the underlying biological 
processes causing these test results and symptoms can vary across patients. Some patients may 
experience these symptoms due to emphysema-related processes, in which alveolar tissue is 
destroyed, leading to gas trapping and hyperinflation; whereas others may experience symptoms 
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due to small airways disease-related processes, which involves airway remodeling and narrowing 
at the bronchiole level60.  
Although COPD is most commonly associated with smoking, the exact factors that lead 
to disease development and that are involved in disease pathogenesis are not well understood. 
Not all smokers develop COPD, and other risk factors for developing the disease include 
genetics, environmental exposure (workplace or biomass fuels exposure, for example), and poor 
lung growth and development60–62. In general, the disease is believed to develop due to repeated 
exposure to harmful stimuli, though most of the research into disease pathophysiology comes 
from studying the effects of cigarette smoke. It is hypothesized that reactive oxygen species 
present in cigarette smoke accumulate in the lung and lead to an increased expression of genes 
involved in mucus secretion, inflammation, and anti-protease inactivation63. COPD is 
characterized by increased pulmonary and systemic inflammation, especially with severe 
disease60, and this inflammation involves mediators from both the adaptive and the innate 
immune system. On the innate side, macrophages have been found to be increased in the sputum 
and bronchoalveolar lavage (BAL) fluid of COPD patients64. It is hypothesized that due to the 
oxidant/anti-oxidant dysregulation, epithelial cell injury caused by cigarette smoke, and 
underlying genetic and epigenetic factors65,66, macrophages increase secretion rates of pro-
inflammatory cytokines and chemokines to recruit other immune cells into the lung and also 
display decreased phagocytic responses66,67. Pro-inflammatory macrophages are commonly 
found within the lung tissue itself, but macrophages that are anti-inflammatory in function have 
also been reported in the epithelial lining fluid of the alveoli64. More research into the spectrum 
of macrophage activation is needed to fully understand the significance of the location of these 
different macrophage populations in COPD. Neutrophils are also a major source of inflammation 
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in COPD and are increased in the sputum and BAL of patients66. Neutrophil secretions add to the 
tissue destruction associated with emphysema by secreting neutrophil elastase and proteinases, 
and a higher number of the cells in the sputum is associated with increasingly severe disease63,68. 
From the adaptive immune response, CD4+ and CD8+ T cells are both increased in the lungs of 
COPD patients, with Th1 T cells especially contributing to the pro-inflammatory environment66. 
Unfortunately, cessation of smoking is only able to slow FEV1 decline in COPD patients, but 
does not result in a decrease of inflammation in the lung69,70. 
COPD symptomology is also characterized by acute exacerbation (AE-COPD) events, 
which are deadly, with inpatient mortality rates reported to be between 3.9-7%71–73. They are the 
most costly event associated with the disease55, with each hospital visit due to exacerbation 
averaging an estimated $40,00073. AE-COPD events are characterized by acute increases in 
inflammation and in symptoms severity such as cough, sputum production and shortness of 
breath that does not return to baseline levels without either a change in medication or a hospital 
stay58. The effects of exacerbations can be permanent, as reported in a longitudinal study where 
only 75% of patients returned to their baseline peak expiratory flow rates within 35 days of 
experiencing an AE-COPD event, and 7% of patients did not experience a full return to baseline 
values 90 days after exacerbation74. Overall, AE-COPD events can lead to a downward spiral of 
worsening symptoms: they have a negative impact on the patient’s quality of life, increase the 
rate of lung function decline, and are associated with hospital stays and death75. As another 
example of the heterogeneity of the disease, there may be a subset of “frequent exacerbator” 
patients who experience more exacerbations than the average COPD patient, which is defined as 
more than two per year76,77. For these frequent exacerbator patients, the negative impacts of 
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exacerbations are even greater78; however, it has also been shown that frequent exacerbators may 
not consistently experience two exacerbations every year79.  
Current treatment options for COPD aim at managing symptoms and preventing 
exacerbations80, but better definitions of COPD subgroups may hold the key to the development 
of more effective and personalized treatment options in the future. Common pharmacological 
treatments prescribed for the stable state of COPD include a combination of long-acting β2 
agonists (LABAs), long-acting muscarinic antagonists (LAMAs), and inhaled corticosteroids 
(ICS), depending on the patient’s symptoms and exacerbation risk80. Pharmacologic treatments 
for severe exacerbations include antibiotics for bacterial infection-associated exacerbations, 
systemic corticosteroids, and bronchodilators81. Due to the heterogeneity of the disease, it can be 
difficult to find an effective treatment regimen for each patient. Looking forward, one of the 
goals for clinicians and researchers is to identify and define subpopulations of COPD patients in 
order to easily prescribe personalized treatment. Some researchers and clinicians focus on 
subpopulations that can be identified through biomarkers, as these patients may all share 
common mechanisms of action for disease pathogenesis and will be explored in depth below, 
whereas others focus on groups of patients who exhibit similar symptoms (e.g. frequent 
exacerbators and the GOLD ABCD classification based on symptom severity and exacerbation 
history58), as these patients may share a common phenotype82. Identifying these subgroups of 
patients is of importance so that more personalized treatments can be administered. Shifting 
gears to disease progression, although AE-COPD events are common and are associated with 
progression, the precise definition of these events is still debated by physicians, as COPD 
patients may experience changes in therapy that are not caused by the presence of an 
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exacerbation83. Thus, a stronger definition or marker of exacerbation would aid clinicians in 
prescribing the correct treatments to patients.   
To aid in identification of COPD subgroups and AE-COPD events, researchers have been 
focusing on genetic, cellular, and proteomic biomarkers that could help distinguish between 
patients with COPD and smokers without airway obstruction, help define patient subgroups 
within COPD, and help understand and predict exacerbation events. In terms of markers for 
COPD, alpha-1 antitrypsin (A1AT) deficiency, which is caused by a mutation in the SERPINA1 
gene, is commonly reported in COPD patients (both ex-smokers and never smokers) and may 
also be responsible for a faster rate of emphysema development after exposure to cigarette 
smoke84. In terms of potential COPD patient subgroups, it has been reported that high levels of 
eosinophils are associated with a subset of COPD patients that tends to respond well to inhaled 
corticosteroid (ICS) in terms of FEV1 decline85,86 and exacerbation frequency86,87, but this has 
not been seen in all studies85. It has also been reported that some COPD patients may be 
characterized by an IL-17 airway epithelial response, and that these patients are less responsive 
to corticosteroids88. For AE-COPD events specifically, many studies have reported single 
biomarkers that are associated with the exacerbated state as opposed to the stable state (e.g. 
blood C-reactive protein (CRP)89–91, sputum IL-1β92,93, and blood growth differentiation factor 
15 (GDF-15)90,91). However, these markers are not always unique to AE-COPD alone89,94, and 
replication across multiple cohorts has been difficult95. Currently plasma fibrinogen is the only 
marker that is associated with AE-COPD, but it can only be used as an enrichment tool for 
clinical trials studying exacerbation96. A new focus in the field has involved taking a 
computational approach to the analysis of imaging scans to better view and predict disease 
progression. Computed tomography (CT) scans have recently been reported to be able to identify 
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the presence of small airway damage in COPD with the use of parametric response mapping 
(PRM) analysis, which could identify unexpected damage in patients and could be used to track 
disease progression97. It has also been reported that many patients entering the hospital for AE-
COPD events present with consolidation (the presence of liquid in the lung where air should be) 
on their chest X-rays, and that this is associated with higher mortality and may require different 
therapeutic steps83. The next steps in this area are to explore if these imaging patterns are 
associated with biological expression of genes, cells, or proteins that could lead to mechanistic 
insight into disease progression. Overall, positive steps have been made towards better 
identification of COPD patients, subgroups of COPD patients, and exacerbations, yet the 
challenge still remains to identify robust biomarkers and therapies. 
1.3 Systems biology approaches to immunological disorders 
Although it is clear that IPF and COPD do not act through the exact same mechanisms, 
they do share some similarities. As discussed above, pathogenesis of both diseases involves 
tissue reorganization, as seen in the aberrant collagen deposition in IPF and the airway 
remodeling or breakdown in COPD. Additionally, there is evidence that immune dysregulation 
and inflammation are involved to some extent in both, although inflammation may play a greater 
role over time in COPD than in IPF, especially in the disease natural history26,47,66,68. Lastly, our 
current understanding of each disease has led to similar focus areas in the related research: 
identification of diagnostic and prognostic biomarkers is of key importance in each disease, as is 
determination of the key mechanistic underpinnings of disease state and progression for the 
purposes of developing more targeted treatments.  
Current difficulties in identifying biomarkers and treatment options suggests it may be 
possible that no single factor entirely accounts for disease development or progression. As IPF 
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and COPD are complex, immunological diseases and the associated disease progression in both 
is multifaceted and heterogeneous, it is plausible that both the development and progression of 
both conditions result from disrupted systems of immune cells and cytokine communication 
networks rather than individual events. Approaches to infer these key players and the associated 
networks could provide valuable new insight into systems-level relationships driving each 
disease and the associated progressive events.  
Systems biology-focused computational approaches, including data-driven modeling, 
may aid in identifying key networks of immune cells and factors involved in lung disease. These 
approaches add value in that they allow for evaluation of how components may interact together 
in a physiological system of interest, rather than as individual proteins, genes, or cells in isolated 
environments98. The increasing ease and decreasing cost of collecting quality “omics” data from 
biological systems has made the application of these analytical approaches more accessible over 
the past 20 years99. Data-driven modeling approaches can be applied to high-throughput data to 
identify small signatures of proteins, cells, or genes that covary with each other and are 
associated with clinically relevant groups of interest. Importantly, these approaches do not rely 
on prior knowledge of the system in order to identify these signatures. Additionally, 
unsupervised modeling approaches could be used to identify potentially novel subgroups within 
a patient population100. Through the use of knowledge-based bioinformatics databases and 
experimental follow-up and validation, the identified signatures can then be linked to 
mechanisms or cell types involved in disease phenotypes or pathogenic states. The identification 
of critical players in the network and the linkage to mechanisms provide starting points for 
potential diagnostic or prognostic criteria, insight into specific disease biology, and identification 
of potential targets for combinatorial therapeutic intervention101. In the future, these tools can 
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also be used to help differentiate heterogeneous responses to drugs and can connect these 
responses to the potential underlying biology with the patient population99. 
Data-driven modeling approaches have already been applied with success to identify 
signatures associated with inflammation and infectious disease susceptibility in mucosal tissues 
of the female reproductive tract102,103, in identifying potential sub-groups of systemic lupus 
erythematosus (SLE) patients104,105, and in gaining deeper understanding into abnormal CD4+ T 
cell and fibroblast response in rheumatoid arthritis (RA)106,107. These approaches have likewise 
been recently applied to better understand IPF and COPD disease state and disease progression. 
For example, in IPF, researchers have identified and validated a data-driven signature of 15 
transcripts measured in lung samples that accurately distinguished healthy controls and IPF 
subjects108. In another study, a combinatorial classifier of 5 plasma proteins (MMP-7, MMP-8, 
MMP-1, TNRSF1A, and IGFBP1) was found via decision tree analysis to differentiate healthy 
controls and IPF patients with 98.6% sensitivity and 98.1% specificity35. This same study also 
reported MMP-7 and MMP-1 expression as increased in IPF compared to patients with 
hypersensitivity pneumonitis, but not in COPD or sarcoidosis35. In IPF progression, one study 
applied multivariate analysis to identify a signature of plasma proteins that differentiated IPF 
patients by progression-associated outcomes (e.g. decline in FVC and DLCO) and were 
associated with epithelial cell function109. In COPD, Christenson et al. identified a signature of 
transcripts associated with the response of airway epithelial cells to IL-17A exposure that was 
increased in a subset of COPD patients in two independent COPD studies, and corresponded 
with more severe airway obstruction in these patients88. For COPD disease progression, Bafadhel 
et al. used feature selection and unsupervised modeling techniques to identify signatures of 
proteins associated with four biologic clusters of COPD exacerbations: bacterial, eosinophil- or 
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viral- predominant, or “pauciinflammatory”. These model-identified biological clusters were 
found to be very similar to previously defined clinical phenotypes of exacerbations92.  
While data-driven models have been promising in identifying potential diagnostic and 
prognostic markers and associated mechanisms, the limitation in current applications in IPF and 
COPD is that the approaches used have emphasized only the additive significance of each 
protein in differentiating clinical groups, rather than co-variance, which may improve 
classification ability and can better assist with network inference110–112. Additionally, there is 
currently a lack of studies that incorporate data from multiple tissue compartments into single 
models. Based on the number of previously identified markers of disease state and disease 
progression from the blood, it is likely that although IPF and COPD are localized in the lung, 
these diseases also exert measurable systemic changes. It is then plausible that systemic factors 
may also influence the pulmonary environment in return, and that characterizing these cross-
tissue compartment proteomic and cellular networks will lead to a deeper understanding of the 
natural history of COPD and IPF. 
1.4 Structure of thesis 
With this background in mind, the goal of this study was to identify key relationships 
between cytokines, secreted factors, and immune cells in the blood and lungs of human patients 
that suggested new systems-level mechanisms of action that underpin the disease state and 
disease progression of IPF and COPD. We decided to focus our analysis on proteins and cells in 
IPF and COPD because these are biologically active factors that directly reflect the current state 
in patients. We also wanted to highlight relationships between proteins across tissue 
compartments as, to our knowledge, there is a lack of published work in this area. We 
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accomplished our goal through the following three aims, with part A of each aim focused on IPF 
and part B focused on COPD: 
Aim 1 will use quantitative models of high-throughput data to infer protein relationships 
in the blood that define patients’ disease state and progression status. 
Aim 2 will use computational systems analytical techniques to infer relationships in the 
lungs from omics samples and datasets that are associated with disease state and progression. 
Aim 3 will use data-driven analytical techniques to integrate multiple types of data across 
various tissue compartments and assays to characterize proteomic, transcriptomic, and cellular 
relationships associated with disease state and progression. 
Completion of these aims will be presented in the following format: Chapter 2 presents 
published work that describes how these approaches can be used to identify a proteomic blood 
signature that differentiates healthy and IPF patients with high accuracy (Aim 1A). The related 
supplemental materials for this work are presented in Appendix A. Chapter 3 describes 
published work in which these approaches were applied to identify temporal and cross-tissue 
compartment signatures of blood and bronchoalveolar lavage (BAL) proteins that were able to 
differentiate IPF progressors and non-progressors (Aim 1A and 3A). The related supplemental 
materials are presented in Appendix B. Chapter 4 presents unpublished work of signatures of 
BAL proteins that differentiated healthy and IPF patients, as well as IPF progressors and non-
progressors, which highlighted the importance of lung cytokines in IPF progression status (Aim 
2A). Chapter 5 includes published work to identify mechanistic hypotheses related to acute 
exacerbations of COPD (Aim 1B, 2B, and 3B), with the related supplemental materials presented 
in Appendix C. Chapter 6 presents unpublished work, where plasma and BAL signatures 
successfully differentiated COPD disease state and severity (Aim 1B, 2B, and 3B). The 
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supplementary materials for this work are presented in Appendix D. Chapter 6 also presents 
preliminary results illustrating how evaluation of immune cell-cell communication networks in 
peripheral blood mononuclear cells (PBMCs) may be useful in evaluating lung disease (Aim 
1B). Chapter 7 contains a discussion of the key findings discovered throughout all the aims. 
Chapters 2, 3, and 5 are based off of previously published manuscripts and are presented 
in this thesis with minimal changes compared to their published counterparts. Appendix E 
contains details and figures on sets of models that were not included in this thesis and 
explanations of why we made these decisions. 
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Chapter 2 The Peripheral Blood Proteome Signature of Idiopathic Pulmonary Fibrosis Is 
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Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial pneumonia. The 
disease pathophysiology is poorly understood and the etiology remains unclear. Recent advances 
have generated new therapies and improved knowledge of the natural history of IPF. These gains 
have been brokered by advances in technology and improved insight into the role of various 
genes in mediating disease, but gene expression and protein levels do not always correlate.   
Thus, in this paper we apply a novel, large scale, high throughput aptamer approach to identify 
more than 1100 proteins in the peripheral blood of well-characterized IPF patients and normal 
volunteers. We use systems biology approaches to identify a unique IPF proteome signature and 
give insight into biological processes driving IPF. We found IPF plasma to be enriched for 
proteins involved in defense response, wound healing and protein phosphorylation when 
compared to normal human plasma. Analysis also revealed a minimal protein signature that 
differentiated IPF patients from normal controls, which may allow for accurate diagnosis of IPF 
based on easily-accessible peripheral blood. This report introduces large scale unbiased protein 
discovery analysis to IPF and describes distinct biological processes that further inform disease 
biology.   
2.2 Introduction 
Idiopathic Pulmonary Fibrosis (IPF) is the most common idiopathic interstitial 
pneumonia and is a fatal progressive disease with a median survival of 2 to 3 years3. The 
etiology of IPF remains unclear and, despite recent advances in therapy, IPF persists as an 
incurable disease48,49. IPF is characterized by certain clinical features with radiological and 
histopathological findings of usual interstitial pneumonia3. The disease results in progressive 
fibrotic remodeling of the pulmonary parenchyma with loss of structural integrity, impaired gas 
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exchange, and respiratory failure. The pathophysiology of IPF features a paradigm that involves 
injury, loss of the epithelial cell barrier with aberrant re-epithelialization, fibroblast activation, 
and unregulated myofibroblast deposition of extracellular matrix components6.  
The natural history of IPF is variable and patients can experience different and dynamic 
clinical courses with phenotypes ranging from accelerated disease with early mortality to slowly 
progressive disease113. Considerable resources have been employed to facilitate prediction and 
early identification of these phenotypes to improve transplantation strategies and the selection of 
appropriate patients for therapeutic trials.  Studies have identified proteins and chemokines that 
may discriminate between disease phenotypes and predict clinical outcomes35,41,114. Several 
genomic expression profiles have reported associations with disease progression in IPF115,116 and 
the peripheral blood transcriptome may discriminate between mild and severe disease graded by 
diffusion capacity117. Genetic risk loci include single nucleotide polymorphisms in the Toll 
interacting (TOLLIP) gene, toll like receptor (TLR) 3 gene and MUC5B promoter7,118,119. These 
key advances have elucidated new potential mechanisms and therapeutic targets and have 
advanced the role of “omics” in IPF. However, a greater understanding of the relationship 
between genomic risks and the mechanistic impact on IPF pathophysiology is required. For 
instance, disease susceptibility is increased by the MUC5B polymorphism yet survival is 
improved120.  The genome is subject to post transcriptional manipulation by micro-RNA 
(miRNA). Altered levels of miR-200 and miR-21 have reported associations with fibrogenesis in 
experimental models and human IPF patients121,122. Furthermore, circulating miRNA’s have been 
found in the blood of IPF patients and several miRNAs are differentially expressed in rapidly 
progressive disease123. Micro-RNA may act as regulators of disease progression and therefore 
the transcriptome and genome may be subject to significant modifications in IPF. An accurate 
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“snapshot” of disease biology may require analysis of protein or the “proteome” in IPF patients.  
IPF is heterogeneous with distinct individual variation in the clinical courses that patients 
encounter. It is plausible that distinct and dynamic biological processes manifest as a common 
clinical phenotype, as evidenced by the UIP pattern on histopathology and imaging.  The 
application of a new approach focused on identifying these processes or “molecular endotypes” 
may facilitate improved understanding of disease biology, molecular pathways, and the 
mechanisms behind the IPF clinical phenotypes124,125. 
Studies of the IPF proteome to date have focused on bronchoalveolar lavage fluid 
(BALF) and lung tissue analysis126–129. Novel targets have been reported including CCL24126, 
and putative molecular pathways have been identified including the unfolded protein response 
through proteomic studies127. While BALF may be desirable for analysis given it is an accessible 
component of the lung environment, it is acquired through an invasive endoscopic procedure and 
subject to variability in representative sampling and processing. Furthermore, many patients may 
be unable to undergo the sampling procedure; thus, accurate analyses from peripheral blood 
would be optimal for patients. New proteomic assays have been developed that utilize modified 
aptamers termed SOMAmers© (slow off rate modified aptamers)130. This assay can readily 
analyze over 1,000 proteins at varying levels of abundance in the peripheral blood. The 
SOMAmer© platform has been employed in biomarker discovery in several diseases to date131–
135. We have previously published a panel of 6 SOMAmer© measured proteins which accurately 
predicts disease progression in IPF136. In this paper, for the first time, we apply aptamer 
technology to identify on a large scale the differentially expressed proteins in the blood of IPF 
patients compared to normal controls. We then use this information to describe in detail the 
biological processes and molecular pathways that may discriminate the disease biology of IPF. 
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The ultimate goal of this work is not to identify or validate particular proteins as biomarkers, but 
rather to understand what biological pathways are aberrant in IPF vs. control patients based on 
the peripheral blood proteome. 
2.3 Results 
2.3.1 The peripheral proteome of IPF patients is distinct from controls 
The demographics and clinical characteristics of study subjects are summarized in 
Supplementary Table A.S1 in Appendix A. This population of IPF patients was a sub cohort of 
the COMET trial. The initial proteomic analysis included all 1129 available analytes which span 
a wide variety of biological processes and molecular pathways. Relevant comorbidities are 
reported in Supplementary Table A.S2 in Appendix A. We applied analysis (see schematic in 
Supplemental Figure A.S1) to the blood proteins measured in the SOMAscan assay in order to 
find differences in the blood protein profiles of healthy and fibrotic patients. From a total of 1129 
plasma proteins, 203 were found to have a mean value that was significantly different (both 
upregulated and downregulated) than the mean value of the same analyte in control patients, with 
a Bonferroni corrected α of 1% (P < 0.0000089) (Fig 2.1A). The top 10 significantly different 
values (all significant after Bonferroni correction with P < 4E-19) included glycogen synthase 
kinase-3 alpha/beta (GSK3A/GSK3B; 3.73 fold change), proto-oncogene tyrosine-protein kinase 
Src (SRC; 3.85 fold change), complement C1r subcomponent (C1R; 4.39 fold change), 
Proprotein convertase subtilisin/kexin type 7 (PCSK7; fold change 2.07), cGMP-specific 3',5'-
cyclic phosphodiesterase (PDE5A; 4.44 fold change), sphingosine kinase 1 (SPHK1; 4.92 fold 
change), tyrosine-protein kinase BTK (BTK; 10.45 fold change), B-cell activating factor (BAFF; 
fold change 2.13), nascent polypeptide-associated complex subunit alpha (NACA; 2.28 fold 
change), and GTP-binding nuclear protein Ran (RAN; 10.78 fold change). Interestingly, these 10 
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proteins that were most significantly different between control and IPF patients were all 
increased in the IPF patients. 
Figure 2.1. The peripheral plasma in IPF is distinct from normal controls.  
(a) Volcano plots highlight fold change (x axis) and the significance level the y axis of the blood proteins measured by the 
SOMAmer Aptamer assay in the COMET study. Points in red indicate proteins that are significantly different in the healthy 
versus IPF patients when correcting for multiple comparisons using the Bonferroni method with a corrected P-value of 0.01. 
Points in blue are the top ten most significant proteins when age is not considered. (b) Volcano plot with age adjustment. Points 
in red indicate proteins that are significantly different between healthy and IPF patients when adjusted for the age difference 
between the two groups and when correcting for multiple comparisons using the Bonferroni method with a corrected P-value of 
0.01. (c) Hierarchical clustering of age-adjusted blood proteins that were determined to be significantly different and biologically 
relevant between healthy and IFP patients show visually distinct blood proteomes between healthy and IPF patients. With the 
exception of two individuals, this subset of proteins in the blood was able to perfectly differentiate between healthy and IPF 
patients. This abundance of each protein is shown in color, with red meaning overabundant proteins, white unchanged, and blue 
being underabundant proteins, all compared to the mean (color bar scale is to the left of the figure). Hierarchical clustering of 
proteins was generated by unsupervised average linkage using Pearson’s correlation as the distance metric. 
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We next applied a secondary method to account for age differences between control and 
IPF cohorts. This screen identified 48 proteins which were expressed at significantly elevated or 
upregulated levels ( 1.5 fold) in the blood of IPF patients at screening when compared to 
controls (Supplementary Table A.S3). This represents 4.3% of total screened analytes. The 
screening process further identified 116 proteins which were expressed at significantly reduced 
or downregulated levels (0.75 fold) in the blood of IPF patients when compared to controls 
(Supplementary Table A.S4). This represents 10.3% of the screened analytes. A list of all 
significant proteins with their fold expression is reported in Supplementary Table A.S5. These 
biologically relevant, age-adjusted, significantly different proteins were then highlighted in a 
volcano plot (Fig 2.1B). The top ten significantly different, age-adjusted proteins were 
hepatoma-derived growth factor-related protein 2 (HDGFRP2; fold change 0.06), inactivated 
complement 3b (iC3b; fold change 0.53), tyrosine-protein kinase FYN (FYN; fold change 0.16), 
pulmonary surfactant-associated protein D (SFTPD; fold change 0.23), eukaryotic translation 
initiation factor 5 (EIF5; fold change 0.26), prefoldin subunit 5 (PFDN5; fold change 0.25), 
tyrosine-protein phosphatase non-receptor type 11 (PTPN11; fold change 0.33), prostaglandin 
G/H synthase 2 (PTGS2; fold change 0.30) 40S ribosomal protein S7 (RPS7; fold change 0.19), 
interleukin-8 (IL8; fold change 0.034). Interestingly, when the effects of age were addressed 
when performing the t-tests, the top ten significantly different proteins were all increased in 
healthy patients.   
To better visualize how this age-adjusted, biologically relevant protein signature 
differentiated the two groups, we performed hierarchical clustering on the 48 upregulated and the 
116 downregulated, age-adjusted, significantly different proteins (identified in Fig 2.1B) 
between healthy and IPF patients. The result was almost ideal differentiation of the healthy and 
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IPF groups (Fig 2.1C). Overall this analysis indicated visually distinct proteomes could be 
measured in healthy and IPF patients using a subset of 164 analytes within the SOMAscan 
Assay®.  
 The two most common co-morbidities in this patient cohort were gastroesophageal reflux 
disease (GERD) and obstructive sleep apnea (OSA) (Supplementary Table A.S2). Principal 
component analysis demonstrates that the greatest differences in the proteomic data arise from 
variation between the healthy and IPF groups, with no apparent clustering due to the co-
morbidities (Supplementary Figure A.S2). Comorbidity information was not available for the 
healthy controls. 
2.3.2 Enrichment and network analysis of the upregulated IPF plasma proteome 
The next step was to utilize our differentially expressed proteins to gain systems level 
insight into the disease biology of IPF. This was achieved through enrichment analysis using the 
online DAVID software tool. DAVID associates proteins to hierarchically clustered functional 
terms (Gene Ontology, Kegg Pathway), and an enrichment score is calculated. The most 
significantly enriched processes included protein amino acid phosphorylation, VEGF signaling, 
and intracellular signaling cascade (see Fig 2.2A).    
We next looked at possible networks and relationships between these proteins using the 
ClueGo application in Cytoscape. Proteins are clustered within enriched terms (Gene Ontology, 
Kegg Pathway) and the degree of similarity between clusters is calculated using Kappa statistics. 
The significantly enriched clusters included platelet activation (P = 17.0E-12), the regulation of 
cardiac muscle hypertrophy (P = 2.9E-6) and complement and coagulation cascades (P = 53.0E-
6) (Fig 2.2B). The level of agreement between each cluster and term is reported by Kappa 
statistics (supplemental Fig A.S3). Statistical values for each reported term are listed in 
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Supplemental Table S6. In order to biologically validate our proteomic pathway discovery 
findings, we analyzed threshold values of transcriptomic data from peripheral blood cells in the 
same patients and report that VEGF-related genes correlate with VEGF-related proteins as 
measured by aptamers (data not shown). These differentially expressed VEGF-related genes 
Figure 2.2. Enrichment and network analysis of the upregulated IPF plasma proteome.  
(a) DAVID enrichment analysis was employed to select the most significantly enriched terms within the sample of upregulated 
proteins (n = 48). Bonferroni corrected P value, Benjamini-Hochberg (BH) P value and False Discovery Rates (FDR) are 
reported. Kappa statistics reporting similarity to most significant term (low > 0.25, moderate 0.25-0.5, high 0.5-0.75, very high 
0.75-1). (b) ClueGO visualization and analysis of biological role (GO, Kegg pathways) was undertaken. GO terms are mapped 
in clusters by Kappa statistics [Hexagon=Kegg pathway, Ellipse=Gene ontology term, arrow depicts direction of association]. 
The major overview term (smallest P value within the cluster) is depicted in color. Node size depicts Bonferroni corrected P 
value < 0.0005 for all terms reported. Further details can be found in online supplement/Appendix A. 
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when analyzed by Kegg pathway are enriched in biological pathways that are plausibly related to 
VEGF signaling, providing biological validation for our findings. 
2.3.3 Enrichment and network analysis of the downregulated IPF plasma proteome 
The downregulated proteins were analyzed for enrichment using the DAVID online 
software tool. The most significantly enriched terms (GO ontology, Kegg pathway) included 
Figure 2.3. Enrichment and network analysis for the downregulated IPF plasma proteome. 
 
(a) DAVID enrichment analysis was employed to select the most significantly enriched terms within the sample of 
downregulated proteins (n=116). Bonferroni corrected P value, BH P value and FDRs are reported. Kappa statistics reported 
similarity to most significant term (low > 0.25, moderate 0.25-0.5, high 0.5-0.75, very high 0.75-1). (b) ClueGO visualization 
and analysis of biological role (GO, Kegg pathways) was undertaken. GO terms are mapped in clusters by Kappa statistics 
[Hexagon = Kegg pathway, Ellipse = Gene ontology term, arrow depicts direction of association]. The major overview term 
(smallest P value within cluster) is depicted in color. Node size depicts Bonferroni corrected P value < 0.0005 for all terms 
reported. Further details can be found in Appendix A. 
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defense response, anti-apoptosis and immune response (see Fig 2.3A). Cytoscape and ClueGo 
were then utilized to examine possible networks and relationships between enriched terms and 
their associated proteins. These significant clusters included acute inflammatory response (P = 
740.0E-9), response to peptide hormone (P = 3.4E-15), phagocytosis (P = 1.8E-6), regulation of 
endopeptidase activity (P = 14.0E-12), leukocyte proliferation (P = 25.0E-9), ERK1/2 cascades 
(P = 150.0E-12), granulocyte chemotaxis (P = 22.0E-9), positive regulation of a response to an 
external stimulus (P = 74.0E-24), TNF signaling pathway (P = 4.2E-6), proteoglycans in cancer 
(P = 530.0E-9), and cytokine activity (P = 140.0E-15) (Fig 2.3B). Kappa statistics for similarity 
between gene, terms and clusters can be found in Supplement Figure A.S4. Statistical values 
for each reported term are listed in Supplemental Table A.S7.   
2.3.4 A unique protein signature involved in immune processes differentiates IPF patients 
from controls 
We next wanted to find a minimum set of proteins that best differentiated the healthy and 
IPF patients based on covariance, or relationships between proteins. This signature could 
potentially be used as a diagnostic tool based on non-invasive measurements made from 
peripheral blood. To identify the minimum multivariate protein signature that differentiated 
healthy and IPF patients, we used the Least Absolute Shrinkage and Selection Operator 
(LASSO) method as a feature selection tool, followed by Partial Least Squares Determinant 
Analysis (PLSDA) to assess the usefulness of the identified signature. LASSO identified an age-
adjusted signature of eight proteins that best differentiated the healthy patients from the patients 
with IPF. A PLSDA model of these eight selected proteins classified the two groups perfectly, 
with 100% calibration accuracy and 100% cross-validation accuracy, as well as 100% sensitivity 
and specificity for both the healthy and the IPF groups. Latent variable 1 (LV1) was able to 
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completely differentiate between healthy patients (negative scores on LV1) and patients with IPF 
(positive scores on LV1; Fig 2.4A). Two of the eight proteins were loaded positively on LV1 
(Fig 2.4B), indicating that they were positively associated with the IPF patients, whereas six 
proteins  were loaded negatively on LV1, indicating that they were negatively associated with 
Figure 2.4. LASSO/PLSDA identified a minimum protein signature of 8 age-adjusted proteins that best differentiated 
healthy and IPF patients.  
(a) LASSO identified an 8-protein signature that differentiated healthy (purple) and IPF (cyan) patients, with 100% calibration 
accuracy and 100% cross-validation accuracy, with 100% sensitivity and specificity for both healthy and IPF patients. Latent 
variable 1 (LV1) accounted for 71.48% of the variance in the data, and latent variable 2 (LV2) accounted for 6.15% of the 
variance in the data. (b) The loadings plot indicates protein contributions to the LASSO-identified signature, with positive 
loadings positively associated with IPF, and negative loadings comparatively reduced in IPF. (c) Hierarchical clustering further 
emphasizes the visual difference between healthy and IPF patients based on the LASSO-identified signature. Abundance of 
each protein is shown in color, with red indicating overabundance, white unchanged, and blue indicating underabundant 
proteins compared to the mean. Color bar scale is to the left of figure. 
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the IPF patients (Fig 2.4B). Not surprisingly, all of the proteins identified by LASSO were also 
found to be significantly different between healthy and IPF patients in the volcano plot (Fig 
2.1B). LASSO and PLSDA were able to successfully separate individuals that were healthy from 
individuals with IPF; this suggests that the eight proteins in the signature may have relationships 
that are of biological interest. The LASSO-signature does include proteins that have clear 
immunological functions: inactivated (iC3b) and tumor necrosis factor ligand superfamily 
member 14 (TNFSF14 or LIGHT). This further suggests the potential importance of immune 
processes in the pathogenesis of IPF and warrants further investigation. 
In order to better visualize patient clustering using our LASSO-identified signature, we 
performed hierarchical clustering and created a heat map of the LASSO-identified protein 
signature (Fig 2.4C). The result was readily-identifiable, near-perfect clustering of the healthy 
and IPF patients, with only one patient being misclassified. Interestingly, the two proteins in the 
hierarchical cluster that were overabundant in the IPF patients are the same two proteins that 
PLSDA identified as being positively associated with the IPF patients. Recalling that all eight of 
the proteins were also included in the biologically relevant, age-adjusted significantly different 
protein panel, these findings validate the LASSO-identified blood protein signature as being the 
preferred signature to differentiate the two groups of patients, and also support the idea that there 
are large differences in the blood proteome seen in healthy and IPF patients. We also analyzed 
the LASSO-identified protein signature using GO terms for biological process and molecular 
function. The most significantly upregulated functional annotation cluster involved peptidase 
inhibitors, endopeptidase regulators and catalytic activity (FE = 3.46, Bonferroni corrected P 
value = 0.0135) (Supplementary Figure A.S5).  Overall these results provide proof-of-concept 
and suggest value for these approaches in the future development of a non-invasive diagnostic or 
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prognostic assay for IPF. This could be especially useful for a diagnosis of IPF with relatively 
normal pulmonary function levels and/or atypical radiological findings. 
2.4 Discussion 
IPF remains a disease of unknown etiology with poorly understood pathophysiological 
mechanisms. Major advances have occurred in recent years through hypothesis-driven studies of 
potential biomarkers of the genome, transcriptome, chemokines and cytokines. In this paper we 
apply novel modified aptamer technology to produce large scale studies of proteins of variable 
abundance in the blood of IPF patients and normal controls for the first time. This novel 
approach to IPF has generated new hypothesis-provoking insight regarding the possible key 
functional biological abnormalities in IPF. The design and main focus of this study was to 
identify differentially expressed proteins in the blood of IPF patients compared to normal healthy 
controls and, through the employment of systems biology and bioinformatics tools, generate 
knowledge about the enriched biological processes that these proteins may represent. 
Analysis of the downregulated protein profile identified a role for defense response 
encompassing a reaction to the presence of a foreign body or injury with an associated attempt to 
restrict damage and initiate repair. This is the most significantly enriched process within the 
downregulated protein panel. These data suggest that compared to a normal host, IPF patients 
have reduced levels of circulating proteins that support host defense. Indeed, the cohort of 
patients studied in this work (COMET study cohort) was previously employed in a project that 
supported a role for dysbiosis in the lung and disease progression. Alterations in the microbiome, 
namely an increase in Streptococcal and Staphylococcal operational taxonomic units were 
associated with disease progression in IPF137. Molyneaux et al. have reported an association 
between disease progression and increased bacterial burden in the lung138. An increased quantity 
 32 
of Streptococcus species was noted.  Knippenberg et al. using murine models have demonstrated 
a mechanism by which a pneumococcal toxin, pneumolysin, exacerbates pulmonary fibrosis139. 
Our study of the proteome at trial screening suggesting a reduction in processes supporting host 
defense, supports a potential role for pathogens, particularly given further findings in the 
downregulated proteome involving the regulation of responses to external stimuli.  These data 
enrich the evidence for a potential role for dysbiosis in IPF progression.    
Features of acute inflammation including leucocyte chemotaxis, proliferation and 
phagocytosis are subject to downregulation in the blood compared to normal controls in our 
study. Several proteins involved in regulating the response to wounding appear inhibited in the 
plasma of patients with IPF compared to controls. We hypothesize that this finding is indicative 
of the recurrent injury and loss of the alveolar epithelial barrier. The proteome findings in this 
study support the paradigm of recurrent injury or wounding with aberrant repair. Indeed, our 
findings support an intrinsic impairment of the immune response to stimuli which may, in turn, 
promote insufficient or even exuberant responses to improve pathogen clearance but worsen 
bystander damage. The response of Toll like receptors (TLRs) and other pathogen recognition 
receptors to pathogen associated molecular patterns (PAMPs) and danger associated molecular 
patterns (DAMPs) is crucial to mounting a response to infection and injury140. IPF patients may 
have impaired responses to DAMPs and PAMPs. Studies of pathogen recognition receptors 
involved in responses to PAMPs/DAMPs including TLR 3 and TOLLIP have reported 
associations with IPF pathophysiology7,119. Furthermore, the role of immunosuppression is 
associated with poorer survival and higher levels of hospitalization in IPF patients47. The 
addition of agents responsible for attenuated immune responses may contribute negatively to a 
disease biology that features impaired responses to PAMPs and DAMPs. 
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The upregulated protein profile identified T cell co-stimulation as a process 
discriminating between normal and IPF patients. The role of T cell co-stimulation in regulation 
of lung fibrosis is controversial and complicated by the fact that measurements have been based 
on samples taken from different human compartments versus murine models. Studies to date 
have supported a role for decreased expression of inducible T cell co-stimulator (ICOS) in 
peripheral blood mononuclear cells (PBMCs) as a marker of disease progression and a predictor 
of poor survival outcomes115,116.  However, animal models of bleomycin-induced pulmonary 
fibrosis reported higher levels of ICOS ligand (ICOSL) expression on macrophages and B cells 
in ICOS deficient mice compared to wild type which correlated with higher levels of fibrosis, 
thus highlighting a role for ICOSL expression in positively regulating pulmonary fibrosis. ICOS 
deficient mice had attenuated pulmonary fibrosis upon bleomycin challenge141. The role of ICOS 
and T cell co-stimulation warrants further study given our findings of enrichment of this process 
in the upregulated proteins when comparing IPF patients to normal controls. We have shown that 
ICOS may be secreted by activated T lymphocytes137 and hypothesize that the loss of ICOS 
expression on cells may correlate with elevated plasma levels and that this may be accompanied 
by reduced transcription. Taken together, these changes suggest a crucial regulatory step in the 
pathobiology of IPF. Interestingly, the positive regulation of T cell activation is notably enriched 
within the downregulated plasma proteome in IPF patients suggesting that overall, IPF patients 
may have impaired T cell activity and this may be linked to disease biology, potentially via 
impaired defense against pathogens such as herpesviruses142. 
Protein phosphorylation is a fundamental mechanism of signal transduction and is 
achieved by kinase activity. The high signal for phosphorylation in our upregulated proteome 
may represent heightened kinase activity and both these processes are enriched within the 
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upregulated proteome. In vitro studies and animal models have produced robust evidence to 
support a central role for protein kinase activity in pulmonary fibrosis, particularly tyrosine 
kinase activity including platelet derived growth factor (PDGF), epidermal growth factor (EGF), 
fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF)143. Nintedanib, a 
novel and approved tyrosine kinase inhibitor for IPF, robustly inhibits VEGF receptor, PDGF 
receptor, and FGF receptor with resultant modification of IPF fibroblast biology and improved 
patients outcomes49,144,145. VEGF signaling was additionally enriched within the upregulated 
plasma proteome of IPF patients in our work, consolidating its role in IPF pathogenesis. A key 
downstream event of ligation between these tyrosine kinases and their receptors is 
autophosphorylation and phosphatidylinositide 3-kinase activity146,147. ErbB signaling 
enrichment is also notable. These are a family of tyrosine kinase receptors, which include Her1 
(epidermal growth factor receptor (EGFR)), Her2, Her3, and Her4. Several of these receptors 
have reported roles in epithelial remodeling and proliferation, and are found to play significant 
roles in models of fibrosis148–150. Further dysfunction within this pathway is supported by the 
finding of enrichment within the downregulated proteome for EGFR (Her1) signaling. EGFR is 
vital for normal epithelial repair so downregulation of this pathway could indicate impaired 
wound healing. Alternatively, we cannot rule out the possibility that EGFR signaling within the 
lung promotes fibrosis, but that the signature is lost in peripheral blood. Further investigation of 
the role of ErbB signaling in the pathogenesis of IPF is likely needed. 
Platelet activation leads to the release of several profibrotic mediators and IPF patients 
have reported evidence of increased platelet reactivity and activation in a previous study151. It is 
possible that this is reflective of the IPF plasma environment. Complement and coagulation 
cascades have reported associations with IPF. Complement receptor polymorphisms may be 
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associated with the development of IPF152. Furthermore, complement can augment epithelial 
injury in pulmonary fibrosis through crosstalk with Transforming Growth Factor-β (TGF-β)153. 
Gu et al. demonstrated that the inhibition of both complement component C3a and C5a receptors 
can lead to the arrest of fibrosis and may have therapeutic potential in IPF154. The enrichment 
within the plasma proteome of platelet activation and complement cascades is suggestive of 
ongoing injury that is detectable in the blood and will require further study. 
The LASSO/PSLDA proteome signature we have identified includes novel proteins that 
have no previous reported associations with IPF. Armed with these target proteins however, it is 
interesting to speculate on their putative roles in pulmonary fibrosis. TNFSF14 (Tumor necrosis 
factor ligand superfamily member 14 or LIGHT) is an inflammatory molecule and a member of 
the TNF superfamily that our analysis also shows to be downregulated in IPF plasma compared 
to normal. Seemingly contradictory, the genetic deletion of LIGHT attenuates bleomycin-
induced pulmonary fibrosis in animal models through the abolition of Thymic stromal 
lymphopoietin (TSLP) expression155. In addition, Herro et al. demonstrated that the 
administration of recombinant LIGHT to murine models produced features of fibrotic lung 
disease similar to the bleomycin fibrotic phenotype, via a TSLP-dependent mechanism. Human 
bronchial epithelial cells challenged with LIGHT in vitro generate TSLP production155. LIGHT 
appears to have potential as a regulator of fibrosis and its role in IPF requires further exploration. 
LIGHT can function as a mediator of herpes viral cell entry, hence its acronym Herpes Virus 
Entry Mediator (HVEM), and one may speculate a further mechanistic role for LIGHT in this 
context given the evolving roles of herpes virus in fibrotic lung disease exacerbations142, but it 
may be informative to compare circulating vs. tissue measurements. Glycogen synthase kinase-3 
alpha/Glycogen synthase kinase-3 beta(beta (GSK3A/GSK3B) are negative regulators of glucose 
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homeostasis, Wnt signaling, and transcription factors, and this protein is positively associated 
with IPF. GSK3A/GSK3B inhibition in bleomycin-exposed mice has been shown to reduce 
alveolitis, lung fibrosis, and alveolar cell apoptosis156. GSK3A/GSK3B inhibition also decreased 
the production of monocyte chemoattractant protein-1 (MCP-1/CCL2) and tumor necrosis factor-
α (TNF-α) by lung macrophages after bleomycin exposure in this study. Plasma serine protease 
inhibitor (SERPINA5), a molecule we find at elevated levels in IPF relative to control patients, 
has been shown to be upregulated in the intra-alveolar space of patients with interstitial lung 
diseases (IPF included), and is involved in the inhibition of fibrinolysis, especially in IPF157. A 
reduction in fibrinolysis causes more collagen, fibrin, and other extracellular matrix fibers to 
accumulate in the intra-alveolar space of these patients, leading to a stiffer lung and to formation 
of a matrix where fibroblasts can proliferate and release more collagen158. 
The acquisition of a distinct signature in the blood proteome of IPF patients that allows 
for discrimination between IPF and healthy controls is a significant proof of concept discovery.  
While we recognize that a blood test is not necessary to diagnose IPF patients from healthy 
volunteers, our work suggests that this methodology could be employed to help diagnose IPF 
from other forms of chronic lung disease. This will require further validation with larger 
numbers of patients, and exploration in other chronic lung diseases to determine whether 
differential signatures are producible in similar diseases. If true, the potential for change in 
clinical practice is considerable. The use of peripheral blood to identify disease-specific 
signatures may result in obviating the need for biopsy in patients who present with imaging 
features that are not consistent with IPF or possibly improve diagnostic confidence in patients 
who are not suitable for a surgical biopsy. Previous studies of plasma proteins in IPF patients 
identified both MMP-7 and MMP-1 as predictors of disease progression that were differentially 
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expressed compared to normal plasma35. While there remain significant methodological 
differences between studies, we have found that MMP-7 is also upregulated in IPF plasma 
compared to normal. 
There are several limitations to our study. The study numbers are limited and the IPF 
cohort, while extensively characterized, was not subject to death over the course of 80 week 
follow up. This population may not be fully representative of the IPF disease spectrum and we 
are not able to adjust for all potential confounding variables including co-morbidities within the 
IPF population. The absence of a validation cohort is a weakness; however, the main goal of this 
work was to generate hypotheses based on the proteomic data accrued. The use of slow off rate 
modified aptamers is novel and the aptamer results may not correlate with other protein 
measurement platforms. The aptamers bind to non-linear sequences with very high specificity for 
the selected target; this may explain some of the variance when measuring identical targets with 
other platforms such as ELISA130. However, several studies have demonstrated very high levels 
of agreement between the modified aptamer platform and ELISA136,155. 
Although we did not have a validation cohort to test the accuracy of our PLSDA model, 
we did investigate model accuracy through cross-validation. This involved excluding a small 
portion of the data (called the test set), building a model based on the rest of the data, and testing 
the accuracy of the model using the test set. By repeating this process many times and using 
different test sets, we were able to obtain the cross-validation accuracy by averaging the 
accuracy of each individual model. Thus despite the fact that there was not a validation cohort, 
we were still able to report a metric of model accuracy, which was calculated based on testing 
the model with unseen data. The final model we have reported on performed perfectly during 
cross-validation testing with 100% cross-validation accuracy. 
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Our work identified biological processes that discriminate IPF from healthy controls and 
generates hypotheses and new targets for investigation into disease mechanisms. Our study 
patients were recruited to a clinical trial with the highest standards of diagnostic approach and 
management. The prime purpose of this work was to introduce the approach of large scale 
unbiased biomarker screening and the generation of subsequent mechanistic hypotheses.   
However, given the proposed single organ nature of IPF, the biological signal detectable in blood 
is dilute and may not accurately reflect ongoing change within the lung. However, the peripheral 
blood has been employed in several biomarker studies in IPF to date35,114,116 and represents an 
easily-accessible compartment for analysis. The fact that the identified proteome clustered 
differently between IPF and controls gives some confidence that analyses of peripheral blood 
may be useful. 
In conclusion, this work furthers the evolving evidence supporting impaired host defense 
as a key marker of IPF disease biology and validates some of our current understanding. We 
generate further hypotheses about novel potential therapeutic targets and introduce a new 
approach to biomarker studies in IPF.  The ability to identify a minimal signature that allows 
clinicians and researchers alike to discriminate IPF cases from normal serves as a proof of 
principle that this approach may have potential in defining other forms of chronic interstitial lung 
disease and the further evaluation of molecular endotyping in pulmonary fibrosis. 
2.5 Methods 
2.5.1 Study population 
Subjects included in this analysis were a subset of patients who participated in a 
prospective observational study correlating biomarkers with disease progression 
(clinicaltrials.gov, clinical trials ID no. NCT01071707) (Correlating Outcomes with biochemical 
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Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis - COMET). This cohort 
consisted of 60 patients who had samples available for analysis for at least 3 follow up time 
points, but this report focuses only on the baseline samples. Inclusion criteria required patients to 
be aged 35-80 years with a diagnosis of IPF. Exclusion criteria included a diagnosis of IPF that 
was >4 years prior to screening, a diagnosis of collagen-vascular disorder, FEV1/FVC<0.6, 
evidence of active infection at screening, or comorbid conditions other than IPF likely to result in 
death within one year. Subject follow up was for 80 weeks. Informed consent was obtained from 
all participating patients. The study protocol was reviewed and approved by the institutional 
review board of each participating center and methods were carried out in accordance with the 
relevant guidelines and regulations. Participating centers included: University of California Los 
Angeles. Los Angeles, CA, United States—University of California, San Francisco. San 
Francisco, CA, United States—National Jewish medical and Research Center, Denver, CO, 
United States—University of Chicago, Chicago, IL, United States—University of Michigan Ann 
Arbor, MI, United States—Cleveland Clinical Foundation, Cleveland, OH, United States—
Temple University, Philadelphia, PA, United States—Brown University, Providence, RI, United 
States—Vanderbilt University, Nashville, TN, United States. Patients were enrolled from March 
2010 to March 2011.  Blood samples and demographic data were also acquired from healthy 
human controls (n = 21). Demographics are displayed separately for IPF patients and healthy 
normal participants, with mean and standard deviation for the continuous predictor age and the 
number and percentage enrolled for the categorical variable gender. Statistical significance of 
differences between the two groups of people for age and gender were assessed via Student’s t 
test and Pearson’s Chi-squared test, respectively (Supplementary Table A.S1). Patients were 
diagnosed as having IPF using a multidisciplinary approach as per published international 
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guidelines3. In brief, the diagnosis of IPF was on the basis of features on computed tomography 
(CT) scans of the chest or usual interstitial pneumonia (UIP) pathology confirmed by lung 
biopsy. Cases were reviewed with expertise from radiologists, pathologists and clinicians at the 
local enrolling center. The number of biopsy proven cases was 35 of 60 patients, representing 
57% of the study cohort. All cases and controls were of Caucasian ethnicity. 
2.5.2 Sample acquisition and preparation 
Peripheral blood was collected in EDTA-containing vacutainers at study centers and 
samples were shipped by overnight mail using cold packs to the University of Michigan.  
Samples were collected at 3 time points, namely screening, week 48 and week 80. Samples from 
healthy human controls were obtained from MedImmune and analyzed simultaneously with the 
COMET specimens. Whole blood was centrifuged at 2500 rpm for 10 minutes and plasma was 
collected and frozen at -80°C in small aliquots. Samples were shipped to SomaLogics for 
analysis on the SOMAscan® panel (1129 analytes). Plasma samples were diluted at 3 different 
concentrations for analysis on the aptamer array at the optimal concentrations for each 
SOMAmer©. 
2.5.3 SOMAscan assay 
The SOMAscan® proteomic assay has been described extensively in previous 
publications130. In brief, each of the listed proteins is measured using a modified aptamer reagent 
and measured quantitatively in relative fluorescence units (RFU’s) using a custom Agilent 
hybridization chip.  Normalization and inter-run calibration were performed according to 
SOMAscan v3 assay data quality-control procedures as defined in the SomaLogic good 




2.5.4 Statistical analysis of SOMAscan assay results 
Proteomic data is reported quantitatively as RFU’s for 1129 analytes in 60 IPF patients 
and 21 healthy controls. For a graphic summary of our investigative approach see Supplemental 
Figure A.S1.  
The initial approach first identified 203 proteins that differentiated IPF from controls.  
Relative fold change in blood protein levels were calculated by dividing the average intensity in 
IPF samples by the average intensity in the healthy samples. Statistical analysis between the 
healthy and IPF patients was performed by a standard two-tailed and two-sample t-test. 
Graphical representation of the proteomic data was created using GraphPad Prism software 
(v6.01 for Windows, GraphPad Software, La Jolla, CA). Significantly different proteins were 
those that passed a set false discovery rate threshold of 1%. Hierarchical clustering of 
significantly different proteins was generated by unsupervised average linkage hierarchical 
clustering using Pearson’s correlation coefficient as the distance metric159. 
Upon comparison of epidemiological factors between the two groups, we found age to be 
slightly increased in the normal group. To account for this and identify age-adjusted proteomic 
differences, we performed linear regression with all biomarkers and age as predictors based on 
comparison between the IPF and normal cohort, and assessed mean analyte differences between 
IPF patients and controls adjusted for age. To account for multiple comparisons, we considered 
Benjamini-Hochberg false discovery rate methods160, but eventually decided upon a more 
conservative Bonferroni correction to maintain an overall type I error of 0.01 and more 
aggressively screen analytes from the pool of candidates161,162. Altogether, this resulted in a 
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refined volcano plot showing the age-adjusted proteome. Hierarchical clustering was then used 
to visualize how these proteins differentiated the healthy and IPF patients. 
2.5.5 Analysis of the differentially expressed IPF proteome with DAVID and Cytoscape 
To identify significantly enriched biological process that differentiated IPF from control, 
those proteins that passed initial screening steps (a Bonferroni correction and linear regression 
modelling for age) were catalogued into “upregulated” and “downregulated” profiles. In brief, 
proteins that were meaningfully “upregulated” or “downregulated” were deemed to have 
potentially significant biological roles in IPF patients compared to the control cohort. A fold 
increase over control mean of 1.5 and a fold decrease below control mean of 0.75 were used as 
thresholds for “upregulated” and “downregulated” proteins, respectively. These criteria selected 
out 48 upregulated proteins and 116 downregulated proteins when comparing IPF patients to 
controls (Supplementary Table A.S2 and A.S3). Certain proteins were measured in 
combination (see Supplementary Table A.S2 and A.S3). Certain proteins, i.e. inactivated or 
splice variants, measured by the SOMAscan array do not have unique UniProt identifiers 
available, and therefore the parent protein UniProt Identifier is reported. Functional annotation 
and visualization was employed using the Cytoscape (v3.3.0) software environment and the 
ClueGO (v2.2.5) plugin application163,164. In brief, for ClueGo analysis, Gene ontology levels 
and Kegg Pathways were explored with medium specificity and a Kappa score of >0.4. The 
Bonferroni correction was employed for each P value calculation. GO fusion was used to reduce 
redundancy with child-parent term fusion. P value of 0.05 was regarded as significant. 
Visualization was applied with Overview term labelling and term P value for nodal size.  
Functional annotation clustering and enrichment analysis was performed using Gene Ontology 
(GO) biological processes (BP FAT), molecular function (MF FAT), Kyoto Encyclopedia of 
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Genes and Genomes (KEGG). Enrichment analysis was undertaken by submitting these proteins 
to the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/)165,166. Enrichment analysis was performed on the basis of 
uniprot_accession as identifier and gene list as list type, medium stringency and Bonferroni 
correction was applied. Enrichment chart analysis was performed using Gene Ontology (GO) 
biological processes (BP FAT), GO molecular function (MF FAT) and Kyoto Encyclopedia of 
Genes and Genomes (KEGG). The top functional annotation clusters with significant enrichment 
scores were identified.  
2.5.6 Identification of a minimal IPF proteomic signature with hierarchical clustering and 
PLSDA 
The Least Absolute Shrinkage and Selection Operator (LASSO) method159 was used to 
identify a minimum, age-adjusted protein signature that best differentiated IPF and normal 
proteomes and was implemented using Matlab software167 (Mathworks, Natick, MA). K-fold 
cross-validation was used to generate the model that had the lowest possible mean squared error 
for prediction. Associated features for this model were chosen as the minimum set of biomarkers.  
In order to allow for age-adjustment in the LASSO model, age was forced into the model as a 
parameter and assigned zero penalty. PLSDA assessed the usefulness of the LASSO-identified 
protein signature for differentiating healthy and IPF patients. Data were normalized with mean 
centering and variance scaling, and cross-validation was performed by iteratively excluding 
random subsets in groups of 9-10 data points during model calibration. Excluded data samples 
would then be used to test model predictions. Hierarchical clustering of LASSO-identified 
proteins was generated by unsupervised average linkage hierarchical clustering using Pearson’s 
correlation coefficient as the distance metric.  
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2.5.7 Investigating the effect of comorbidities in IPF had on the LASSO and PLSDA 
analysis 
To investigate whether or not the comorbidities present in some IPF patients affected the 
feature selection by LASSO or the clustering in PLSDA, we performed a principal component 
analysis (PCA) on all of the measured blood proteins in the healthy and IPF patients. PCA was 
chosen as the method of analysis due to the lack of knowledge of the comorbidities seen within 
the healthy cohort. Gastroesophageal reflux disease (GERD) and obstructive sleep apnea (OSA) 
were examined based on their prevalence in the IPF patients (34 patients with GERD and 12 
patients with OSA). 
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 Idiopathic pulmonary fibrosis (IPF) is a progressive and heterogeneous interstitial lung 
disease of unknown origin with a low survival rate. There are few treatment options available 
due to the fact that mechanisms underlying disease progression are not well understood, likely 
because they arise from dysregulation of complex signaling networks spanning multiple tissue 
compartments. To better characterize these networks, we used systems-focused data-driven 
modeling approaches to identify cross-tissue compartment (blood and bronchoalveolar lavage) 
and temporal proteomic signatures that differentiated IPF progressors and non-progressors. 
Partial least squares discriminant analysis identified a signature of 54 baseline (week 0) blood 
and lung proteins that differentiated IPF progression status by the end of 80 weeks of follow-up 
with 100% cross-validation accuracy. Overall we observed heterogeneous protein expression 
patterns in progressors compared to more homogenous signatures in non-progressors, and found 
that non-progressors were enriched for proteomic processes involving regulation of the 
immune/defense response. We also identified a temporal signature of blood proteins that was 
significantly different at early and late progressor time points (p<0.0001), but not present in non-
progressors. Overall, this approach can be used to generate new hypotheses for mechanisms 
associated with IPF progression and could readily be translated to other complex and 
heterogeneous diseases.  
3.2 Introduction 
Idiopathic pulmonary fibrosis (IPF) is a heterogeneous and irreversible interstitial 
pneumonia, with symptoms including progressive cough, shortness of breath, and ultimately 
respiratory failure, with a median survival of only 3-5 years post diagnosis5. The disease is 
believed to be caused by a dysregulated wound healing response to various epithelial injuries 
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leading to fibrosis of the lung interstitium5. Two medications (nintedanib49 and pirfenidone48) are 
effective treatments for IPF; both are able to temporarily slow disease progression without 
reversing established fibrosis168. Thus, lung transplantation is currently the only option to cure 
IPF3, even though this procedure has the highest failure rate of all organ transplantation options 
(54% at 5 years169). Better understanding of mechanisms underpinning progression of pulmonary 
fibrosis could lead to improved outcomes via identification of new therapeutic targets. 
To add to the complexity surrounding IPF, disease progression is also heterogeneous, 
with some individual patients experiencing long-term stability and others rapid loss of lung 
function. A number of longitudinal cohort studies have been created with the goal of better 
characterizing IPF pathobiology using proteomic measurements137,170–172. These efforts have 
identified individual proteins, including blood MMP-739,40, CCL1841, and blood surfactant 
protein D43,44, as potential prognostic biomarkers. However, it has been difficult to replicate 
these findings across multiple cohorts36,45, especially when attempting to validate specific, 
prognostically-relevant cut-off concentrations45,46. 
One potential explanation for failure to validate a specific prognostic biomarker is that 
disease progression is driven by dysregulated proteomic signaling networks rather than 
individual proteins. This hypothesis is supported by the multiple known actions of the two FDA-
approved drugs that slow IPF progression: nintedanib173 and pirfenidone173. The use of 
quantitative approaches to capture individual proteins within large clinical “omics” data sets has 
become a useful way to find new proteins associated with disease progression. Groups of 
proteins associated with progression that were identified by these approaches were characterized 
by biologically relevant functions, such as involvement in the immune system111,114,136, tissue 
reorganization109,114,136, and epithelial cell function109. While these results have highlighted 
 48 
potential prognostic biomarkers and biological functions associated with IPF progression, many 
of the techniques used in these discoveries emphasize the additive significance of each protein’s 
individual ability to differentiate progression status but do not capture protein “signatures”, or 
take into account potential protein networks associated with progression. In addition, none of 
these large scale blood proteomics studies investigated quantitative proteomic relationships 
across other tissue compartments such as the lung. 
Data-driven (“machine learning”) modeling approaches are able to integrate data across 
multiple tissue compartments and assays to identify signatures of factors that are associated with 
the disease state92,102. They serve as valuable tools for network inference by identifying co-
varying factors that aid in generating new hypotheses for mechanisms of action based on protein 
interaction pathways rather than individual proteins. Once identified and validated, these 
signatures may be used for diagnostic or prognostic purposes, or for generating new hypotheses 
for future experimental work. We have previously used these approaches to successfully identify 
a blood protein signature that differentiated healthy and IPF patients with high accuracy174, as 
well as signatures based on blood and sputum proteins and blood cell markers that differentiated 
stable and exacerbated chronic obstructive pulmonary disease (COPD) patients175. 
In this work, we applied data-driven modeling approaches to blood and bronchoalveolar 
lavage (BAL) samples from patients enrolled in the COMET-IPF (Correlating Outcomes with 
Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis) study to 
gain insight into cross-tissue compartment and temporal mechanisms of action associated with 
IPF progression. We identified a signature of blood and BAL proteins that differentiated IPF 
progressors and non-progressors with high accuracy. This signature indicated more 
heterogeneous progressor subgroups compared to non-progressors, and that proteins elevated in 
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non-progressors were enriched for regulation of immune, defense, and inflammatory responses. 
Lastly, using measurements across multiple time points, we were able to identify a signature 
indicative of temporal changes in the blood of progressors that was not present in non-
progressors. Overall these results provide insight into mechanisms of IPF progression that could 
be investigated further in follow-up murine studies. 
3.3 Results 
3.3.1 Only a small number of individual blood proteins are differentially expressed across 
IPF progressors and non-progressors 
We evaluated a subset of participants (n=59) with an IPF diagnosis enrolled in the 
COMET IPF study. Participants were defined as progressors (n=34) if at the end of the 80 week 
study they had experienced death, lung transplantation, an acute exacerbation of IPF (AE-IPF), 
or a drop in forced vital capacity (FVC) of >10% or in diffusing capacity of the lung for carbon 
monoxide (DLCO) of >15%137. Otherwise participants were defined as non-progressors (n=25; 
demographics in Supplemental Table B.S1). Three blood draws from these 59 participants at 
week 0/baseline, 48, and 80 were used to measure the concentration of 1129 proteins (enriched 
for inflammation and cancer involvement) with SOMAmer© (slow off rate modified aptamer) 
technology (SomaLogic). One baseline (week 0) BAL sample was also collected from 51 
individuals (31 progressors and 20 non-progressors, 50 of whom also had a baseline blood draw 
included in this analysis; demographics in Supplemental Table B.S2), and the concentration of 
29 cytokines were measured with Luminex technology. There were no significant differences in 
demographic variables between the progressors and non-progressor groups, and all patients 
survived until the end of the 80-week study. Correlations in periostin SOMAmer aptamer and 
ELISA measurements within these samples have previously been published136. To build on this, 
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in Supplemental Table B.S3 we report significant Pearson’s correlations (all p < 0.03) between 
Figure 3.1. Schematic illustrating the number of 
samples and the computational tools used in 
analyses focusing on (a) comparing the inclusion of 
data from across multiple tissue compartments 
into data-driven models, and (b) comparing 
expression of proteins in the same patients over 
time. 
P, progressor; NP, non-progressor; BAL 
bronchoalveolar lavage; LASSO, least absolute 
shrinkage and selection operator; PLSDA, partial 
least squares discriminant analysis; VIP, variable 
importance in projection; DAVID, database for 
annotation, visualization, and integrated discovery; 
PC1, principal component 1. 
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SOMAmer and ELISA concentrations for CCL22, CCL18, and CCL2, but not for IL-10 or 
CXCL12 (both p > 0.45). Our analysis pipeline is illustrated in Figure 3.1: Figure 3.1A focuses 
on analyses of baseline (week 0) expression of proteins in the blood and/or BAL samples of 
COMET patients, and Figure 3.1B focuses on analyses of the temporal change in blood protein 
expression (week 0, week 48, and week 80).  
We first determined which of the measured baseline (week 0) 1129 blood and 29 BAL 
proteins were individually differentially expressed between IPF progressors (n=30) and non-
progressors (n=20; demographics of these 50 patients are found in Table 3.1). A two-sample t-
test was applied to each protein expression in progressors and non-progressors and revealed that 
28 blood proteins were significantly different across the two groups; 17 proteins were increased 
in the progressors (fold change greater than 1) (Figure 3.2A; blue markers indicate a p < 0.05 
and red indicate p < 0.01). The ten most significantly different blood proteins included E-
Cadherin (cadherin E; fold change 1.19); DC-SIGN (CD209 antigen; fold change 1.30); a2-
macroglobulin (fold change 1.24); ficolin-2 (FCN2; fold change 0.86); interleukin 17D (IL-17D; 
fold change 0.91); legumain (LGMN; fold change 0.87); C5b,6 complex (fold change 0.93); 
apolipoprotein B (ApoB; fold change 1.38); and neuroligin-4, X-linked (NLGNX; fold change 
1.24). Except for TGM3 (protein-glutamine gamma-glutamyltransferase E; fold change of 2.47), 
all significant proteins had fold change values that ranged from 0.80 to 1.48. No BAL proteins 
Table 3.1. Demographic and lung function test descriptions from progressors and non-progressors whose baseline blood 
and BAL protein measurements were used in creating models based on the combination of blood and BAL proteins. 
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were found significantly differentially expressed (Figure 3.2B). No proteins in blood or BAL 
were significant after application of the Bonferroni correction for multiple comparisons.   
3.3.2 Data-driven analyses identify best signatures in single tissue compartments that 
differentiate IPF progression status 
Due to the low number of significantly differentially expressed proteins in the univariate 
analysis, we next explored whether data-driven modeling techniques could identify signatures of 
proteins from single tissue compartments that differentiated IPF progressors and non-
progressors. Our analysis pipeline that focused on baseline (week 0) expression of proteins in the 
blood and/or BAL samples of COMET patients is visualized in Figure 3.1A. We used the least 
absolute shrinkage and selection operator (LASSO159) as a feature selection tool to identify a 
signature of baseline (week 0) blood proteins that would best differentiate COMET participants 
based on progression status at 80 weeks. For every LASSO model in this analysis, k-fold cross-
a b 
Proteins with a fold change greater than one are increased in progressors; fold changes less than one indicates elevation in non-
progressors. Blue protein markers have a p-value < 0.05 after a two-tailed, two-sample t-test; red markers indicate p-value < 0.01 
after the same test. No blood or BAL proteins were significantly different between progressors and non-progressors after 
adjusting for multiple comparisons using the Bonferroni correction. 
 
Figure 3.2. Volcano plot of blood (a) and BAL (b) proteins measured in COMET progressors and non-progressors. 
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validation (k=10; see Methods) was performed to prevent over-fitting. Feature selection was 
accomplished in the BAL proteins through the use of variable importance in projection (VIP) 
scores. We then employed partial least squares discriminant analysis (PLSDA176) in order to 
visualize the separation power of the identified signatures. By highlighting co-varying 
relationships within protein signatures, PLSDA aids in generating new hypotheses about 
proteomic pathways associated with each group. For every PLSDA model in this analysis, we 
calculated calibration and k-fold cross-validation accuracy (k=10) to use as metrics of model 
performance for comparing PLSDA models generated from data in different tissue compartments 
(see Methods). LASSO identified a signature of 61 blood proteins that differentiated 25 non-
progressors and 34 progressors (demographics in Supplemental Table B.S1); a PLSDA model 
based on this signature had 100% calibration and 96.53% cross-validation accuracy, and 97.06% 
sensitivity and 99.56% specificity for progressor identification (Supplemental Figure B.S1A 
and B.S1B; ROC curves in Supplemental Figure B.S2). The PLSDA model based on 12 VIP-
selected baseline (week 0) BAL proteins differentiated 20 non-progressors and 31 progressors 
(demographics in Supplemental Table B.S2) with 78.55% calibration and 67.82% cross-
validation accuracy (Supplemental Figure B.S3A and B.S3B; ROC curves in Supplemental 
Figure B.S4). Although these models performed with moderate to excellent accuracy, we 
wanted to explore the unique biological insight that might be gained from a model based on the 
combination of the data from the two tissue compartments. 
3.3.3 Cross-tissue compartment signature differentiates COMET participants based on 
progression status 
We combined measurements of the 1129 blood proteins and 29 BAL proteins from 
baseline samples to identify a cross-tissue compartment signature of co-varying proteins 
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associated with progression. LASSO identified a signature of 54 baseline (week 0) proteins (51 
Figure 3.3. The LASSO-identified signature based on blood and BAL proteins separated progressors and non-progressors 
with high accuracy and significantly outperformed analyses based on individual factors. 
(a) PLSDA scores plot based on blood and BAL proteins highlights strong differentiation between progressors (cyan) and 
non-progressors (purple); the model separated the two groups with 100% cross-validation and calibration accuracy. (b) The 
loadings on latent variable 1 (LV1) captured 8.75% of the total variance in the data, with negatively loaded proteins being 
comparatively increased in progressors and positively loaded proteins being comparatively reduced. (continued on next page) 
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in blood and 3 in BAL) that best separated progressors and non-progressors (comparison of 
protein signature expression in progressors and non-progressors can be found in Supplemental 
Figure B.S5). A PLSDA model based on this signature classified the two groups with 100% 
cross-validation and calibration accuracy (Figure 3.3A), with 100% sensitivity and specificity 
for each group (ROC curves in Supplemental Figure B.S6) and with positive and negative 
predictive values of 100%. Latent variable 1 (LV1) differentiated progressors (negative scores on 
LV1) from non-progressors (positive scores on LV1) (Figure 3.3B). Interestingly, we did not 
find significant Pearson’s correlations between the scores on LV1 in this signature and the 
concentration of KL-6 (r= 0.15, p=.31), MMP7 (r = -0.08, p=0.60), or CCL18 (r = 0.04, p=0.77), 
which were other previously identified individual biomarkers of progression. However, we did 
see a significant correlation between the LV1 scores and the change in FVC percent predicted 
over the 80 weeks of the study (r = 0.534, p = 0.00011, Pearson’s correlation coefficient).  
We compared this model to cross-validated PLSDA analyses based on single significant 
proteins identified in the volcano plot, as well as a cross-validated PLSDA model based on the 
collection of the 28 differentially expressed blood proteins in the volcano plot (ROC curves for 
last model shown in Supplemental Figure B.S7). The model based on the LASSO-identified 
signature had significantly higher calibration accuracy than all of the analyses based on the 
individual proteins and the collection of the differentially expressed proteins (Figure 3.3C; 
Cochran’s Q test with McNemar’s post hoc test). In terms of cross-validation accuracy, the 
Figure 3.3 caption continued (c) Comparison of the calibration accuracies between analyses based on data-driven 
signatures and univariate factors. The LASSO-selected PLSDA model based on blood and BAL proteins had significantly 
higher calibration accuracy than all analyses based on single proteins and a model based on the collection of all 28 
significantly different proteins identified in Figure 3.2 (Cochran’s Q test with McNemar’s post hoc test; * indicates p < 0.05 
and *** indicates p < 0.001). (d) Comparison of cross-validation accuracies between analyses based on data-driven 
signatures and univariate factors. The LASSO-selected PLSDA model based on blood and BAL proteins had significantly 
higher cross-validation accuracy than all analyses based on single proteins and trended towards better cross-validation 
accuracy than a model based on the 28 proteins identified in Figure 3.2 (one-way ANOVA with Tukey’s post hoc test; * 
indicates p < 0.05 and *** indicates p < 0.001). (e) Comparison of sensitivity between the LASSO-selected PLSDA model 
based on blood and BAL proteins and previously published models of IPF progression (serum fibulin-1177, plasma MMP-
7178, plasma SP-A178, and an additive combination of blood factors136. (f) Comparison of specificity between the LASSO-
selected PLSDA model based on blood and BAL proteins and previously published models of IPF progression. 
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LASSO-identified model also significantly outperformed analyses based on all of the individual 
Proteins, and trended towards outperforming the model based on the collection of the 28 
differentially expressed proteins (Figure 3.3D; one-way ANOVA). 
We also compared this model to other previously published single markers and 
combinations of markers that were shown to differentiate IPF progression status. The model 
based on our signature had 100% sensitivity and specificity, which outperformed previously 
published models that predicted IPF progression based on single factors (serum fibulin-1, 70% 
sensitivity and 71% specificity177; plasma MMP-7, 45.3% sensitivity and 68.5% specificity178; 
and plasma SP-A, 60.9% sensitivity and 53.9% specificity178), as well as a previously published 
model based on an additive combination of blood factors, where a score of ≥7 on the created 
index had a 66% sensitivity and 100% specificity for progression136 (Figure 3.3E, 3.3F). 
We next sought to determine if the PLSDA model based on the combination of blood and 
BAL proteins was a better classifier than models based on signatures of blood or BAL proteins 
alone. The model based on blood proteins alone and the model based on blood and BAL proteins 
combined had significantly higher calibration accuracy than the model based on BAL proteins 
alone (Supplemental Figure B.S8A, p = 0.0016 for marked comparisons; Cochran’s Q test with 
McNemar’s post hoc test applied to calibration accuracy of patients that were included in all 
three models). McNemar’s post hoc test could not be applied when comparing the calibration 
accuracies of the blood protein model and the combination model because all patients were 
classified correctly in both models. When comparing cross-validation accuracies across the three 
models, again the model based only on BAL proteins performed significantly worse than the 
blood protein model and the combination model (Supplemental Figure B.S8B, p = 0.0001 for 
the blood protein vs. BAL protein model comparison and p < 0.0001 for the BAL protein vs. 
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combination model comparison, one-way ANOVA with Tukey’s post hoc test applied to cross-
validation accuracy based on all patients in all three model). 
One reason the model based on BAL proteins had lower calibration and cross-validation 
accuracies might involve the high number of measured blood versus BAL proteins (1129 blood 
proteins vs. 29 BAL proteins). To investigate the potential effect of signature size on model 
accuracy, we created two new PLSDA models: one based on the top 12 loaded features of the 
blood signature; and the other based on the top 11 loaded proteins (all of which were blood 
proteins) and the top loaded BAL protein in the combination signature, for a total of 12 proteins 
in this shortened combination signature. When comparing the calibration accuracies of these 
models with the same signature size, there was no significant difference between the 
performance of the BAL protein model and the shortened blood protein model (p = 0.78, 
Cochran’s Q test with McNemar’s post hoc test). However, the calibration accuracy of the 
shortened combination model trended towards being significantly better than both of the BAL 
protein and the shortened blood protein models (p = 0.052 for both comparisons, Cochran’s Q 
test with McNemar’s post hoc test, Supplemental Figure B.S9A). There were no significant 
differences in cross-validation accuracy across any of the models, but again the shortened 
combination model trended towards significantly outperforming the BAL protein model (p = 
0.12, one-way ANOVA with Tukey’s post hoc test; Supplemental Figure B.S9B). Overall this 
suggests that the model based on blood proteins alone may have performed well due to the large 
panel of proteins measured, though the combination model still trends towards being 
significantly better than the BAL model even when the signature is shortened. We next explored 
the biological significance of the combination signature. 
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3.3.4 Non-progressors have enriched regulation of immune and defense response, and 
protein expression patterns suggest more heterogeneity in progressors 
The database for annotation, visualization and integrated discovery (DAVID165) 
determined the proteins that were comparatively increased in the non-progressors in the LASSO-
identified signature based on blood and BAL proteins were significantly enriched for processes 
involving immune and defense response regulation (Figure 3.4, enrichment score (ES) 4.83). 
Other functions enriched in non-progressors included cell signaling and regulation of basic cell 
processes (Supplemental Figure B.S10A, ES 2.57), and regulation of inflammatory, defense, 
and immune responses (Supplemental Figure B.S10B, ES 2.50). DAVID identified that 
proteins that were comparatively increased in progressors were only enriched for stress response 
regulation (Supplemental Figure B.S11, ES 2.05). 
We next used hierarchical clustering to visualize the individual expression of the proteins 
in the blood and BAL protein signature across all the patients. We saw four clusters that 
corresponded to the two groups, with one cluster composed only of non-progressors and three 
clusters that were mostly progressors (Figure 3.5). Only 5 non-progressors were misclassified 
out of 50 patients total (90% classification accuracy; 100% sensitivity and 75% specificity for 
Figure 3.4. DAVID enrichment analysis of the blood and BAL LASSO-identified proteins that were comparatively 
elevated in the non-progressor group in the PLSDA loadings plot showed enrichment for pathways involved in the 
regulation of the inflammatory, defense, and immune responses after application of the Bonferroni correction 
(enrichment score 4.83). 
Black squares indicate protein involvement in a particular pathway, while white squares indicate non-involvement. 
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identification of progressors). There were minor differences in classification accuracy of the 
PLSDA model and hierarchical cluster, likely due to underlying algorithmic differences 
associated with unsupervised identification of groups via the Pearson distance metric 
(hierarchical clustering) vs. supervised identification of groups based on maximized covariance 
in protein expression (PLSDA). Interestingly, there was heterogeneity within the progressor 
cluster, which was characterized by expression of different proteins. One of the progressor 
clusters had many apolipoproteins overexpressed compared to the mean (apolipoproteins E2, E3, 
and B), as well as cadherin E and DC-SIGN. Other progressors had high expression levels of 
Figure 3.5. Hierarchical clustering of the COMET IPF patients by the LASSO-identified blood and BAL protein 
signature highlights a single group of non-progressors (purple) and three groups of progressors (cyan) with distinct 
expression levels of various proteins in the signature. 
Only 5 out of the 50 patients were misclassified. Protein expression level is shown in the color scale on the left of the figure, 
with red indicating higher concentration compared to the mean, and blue lower concentration compared to the mean. 
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proteins that were also highly expressed in the first group of progressors (apolipoproteins E3 and 
B, and cadherin E), as well as proteins that were expressed highly in the non-progressor cluster 
(CTLA-4, MPIF-1/CCL23, and IL-17B receptor). The third group of progressors was 
characterized by high expression of TNFSF15 (also known as vascular endothelial growth 
inhibitor) and PSD7 (26S proteasome non-ATPase regulatory subunit 7). The presence of the 
three progressor groups in the hierarchical cluster may suggest heterogeneity among progressors 
compared to relative homogeneity among non-progressors, however based on the small sample 
size in this data it is not possible to determine whether these groups arise from other co-variates 
and/or random effects. We did evaluate whether any of the progressor clusters could be 
explained by other clinical and radiological variables collected during the COMET study, 
including progression metric (e.g. through AE-IPF or a >10% drop in FVC, etc.), smoking status, 
each participant’s genotyping at the MUC5B rs35705950 and the TOLLIP rs5743890 SNPs, and 
the presence of ground glass and honeycombing in their baseline CT scan. We did not find any 
apparent clustering by any of these other variables (Supplemental Figures B.S12A-H). 
3.3.5 Non-progressors exhibit fewer and stronger protein correlations at baseline (week 0) 
than progressors 
Interestingly, when we used correlation networks to explore relationships between 
proteins in the LASSO-identified signature based on blood and BAL proteins, we found the 
network based on signature expression levels in progressors had a larger number of overall 
weaker correlations than the network based on non-progressors. The protein correlation network 
based on progressors’ protein expression (Figure 3.6A) contained seven proteins with at least 
four significant correlations to other proteins. We speculate that the presence of numerous 
proteins with high numbers of significant correlations (i.e. hub proteins) may suggest a network 
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with multiple potential drivers, especially when compared to the correlation network based on 
non-progressors’ protein expression (Figure 3.6B), which only contained two proteins with four 
or more significant correlations. Blood caspase-2, CTLA-4, and ApoB, and BAL IL-4 were hub 
proteins in the progressor network, while blood CTLA-4 and ApoB were the hub proteins in non-
progressors. When comparing the two networks, it was clear that there were fewer (45 
correlations vs. 33 in the non-progressor network), but significantly stronger (higher absolute 
value; p = 0.0002, two-sample t-test) correlations present in the non-progressor network. 
3.3.6 Trajectory principal component analysis (PCA) identified significant differences in 
the temporal signature of progressors that were not present in non-progressors 
Finally, we found a time-dependent shift in protein expression in progressors that was not 
present in non-progressors. Our temporal analysis pipeline is illustrated in Figure 3.1B. We used 
LASSO and associated cross-validation to identify signatures that differentiated three time points 
of blood protein expression (week 0/baseline, week 48, and week 80) within progressors and 
Figure 3.6. Protein correlation networks of the LASSO-identified blood and BAL protein signature present in progressors 
(a) and non-progressors (b) suggest that non-progressors have a higher degree of control over their proteomic networks 
than progressors. 
 
A line connecting two proteins indicates the presence of a significant (p<0.05) correlation, as calculated by Pearson’s 
correlation coefficient. Brighter and thicker lines indicate stronger, more significant correlations, respectively. The value of the 
correlation coefficient for both networks is displayed in the color bar scale on the right, with red indicating a positive 
relationship and blue a negative relationship. Node size is proportional to degree of connectivity. 
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non-progressors. We then created trajectory principal component analysis (PCA) models179 
based on these signatures to judge temporal separation. The trajectory PCA based on progressor 
measurements found significant differences in the temporal signature for week 0 and week 80 
measurements, with week 48 time points falling in between the other two (Figure 3.7A). A one-
way ANOVA with Tukey’s post hoc test found that week 0 progressor scores on principal 
component 1 (PC1) were significantly different than scores from week 48 and week 80 (p < 
0.0001 for both comparisons). We also created a kernel density plot based on the progressor 
scores on PC1 to further illustrate the differences in the spread of scores between week 0 and 
week 80 (Figure 3.7B). The accompanying loadings plot (Figure 3.7C) indicated a relative 
Figure 3.7. Trajectory PCA highlights changes in blood protein expression over time in progressors that is not seen in 
non-progressors. 
(a) A trajectory PCA model based on three time points of progressor blood protein measurements highlights the change in 
protein expression patterns over time in IPF progressors. The week 0 scores on principal component 1 (PC1) were found to be 
significantly different from both the week 48 scores (p < 0.001) and the week 80 scores (p < 0.001) by one-way ANOVA with 
Tukey’s post hoc test. The week 48 and week 80 scores were not found to be significantly different from one another by the 
same test (p = 0.16). (b) The kernel density plot of the scores on PC1 provides another way of viewing the differences in the 
scores distribution on PC1 of across all three time points of progressors. (c) The LASSO-identified signature separates the three 
time points of progressor measurements while capturing 49.95% of the natural variance in the data across the first two principal 
components. (d) A trajectory PCA model based on three time points of non-progressor protein measurements does not show 
clear separation across the three time points. None of the scores on PC1 of the three time points were significantly different 
from each other after one-way ANOVA with Tukey’s post hoc test (all p > 0.05). (e) The kernel density plot of the scores on 
PC1 highlights the overlapping of the scores on PC1 from the three time points of non-progressors.  
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increased expression of inactivated complement C3b (iC3b) compared to matrix 
metalloproteinase 9 (MMP-9), methionine aminopeptidase 2 (AMPM2), cofilin-1, protein 
tyrosine kinase 6 (PTK6), and protein FAM107B at week 80, but relative increase of MMP-9, 
AMPM2, cofilin-1, PTK6, and protein FAM107B compared to iC3b at week 0. In contrast, a 
trajectory PCA model for non-progressors (Figure 3.7D) and a one-way ANOVA with Tukey’s 
post hoc test indicated there were no significant differences in PC1 scores across the three time 
points (p > 0.05 for all comparisons; loadings plot shown in Supplemental Figure B.S13). The 
kernel distribution plot of the non-progressors’ scores on PC1 highlights how all three time 
points are spread out among the same range of scores (Figure 3.7E). 
3.4 Discussion 
In this work we have identified cross-tissue compartment and temporal proteomic 
signatures that highlight differences between IPF progressors and non-progressors and generated 
new hypotheses for potential mechanisms of IPF progression. We discovered a multivariate 
signature based on proteins from the blood and lung tissue compartments that differentiated IPF 
progressors and non-progressors with 100% cross-validation and calibration accuracy and 100% 
sensitivity and specificity in a PLSDA model. This signature performed significantly better than 
analyses based on single proteins and a signature of BAL proteins. Through the use of other 
computational tools, we found that non-progressors were enriched for regulation of immune 
regulatory processes, and that the proteome of progressors had significantly weaker and a larger 
number of correlations than that of non-progressors. Using data from across multiple time points, 
we were able to identify significant proteomic differences in IPF progressors between week 0 
and week 80 measurements that were not present in non-progressors. These results illustrate the 
value of data-driven modeling approaches for integrating measurements over different tissue 
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compartments and experimental assays, and suggested potential prognostic signatures for 
progressive IPF for future validation. 
The combined use of LASSO with PLSDA allowed us to find small signatures out of 
hundreds of proteins that were able to accurately differentiate clinical groups of interest. PLSDA 
and LASSO were able to incorporate data from multiple tissue compartments and assays in the 
same model to enable a more holistic understanding of IPF progression. The signature of co-
varying blood and BAL proteins that we reported has the highest cross-validation and calibration 
accuracy compared to models based on single proteins, and either outperformed or matched the 
sensitivity and specificity of previously reported markers of IPF progression. Evaluating 
signature components allowed for further investigation of potential proteomic relationships and 
pathways associated with progression. Our identified signature was enriched for processes 
involving immune system regulation in non-progressors, which echoes results from other 
studies109,111,136, and also included 4 of the 6 proteins previously identified in the COMET cohort 
as an index of IPF progression136. The complement cascade has also previously been associated 
with IPF disease severity111. Interestingly, our identified signature did not include MMP-7, 
which has been linked to IPF progression in several other studies35,109,114, though some proteins 
in our signature did have proteolytic function (legumain, PSD7). 
There were several limitations associated with this study. While we were able to integrate 
SOMAmer- and Luminex-based measurements in our models, the SomaLogic platform 
measured many more proteins than the Luminex platform, potentially biasing results toward 
blood measurements and toward the functions of the 29 BAL cytokines measured with Luminex. 
Larger (in the case of BAL proteins) and less directed screens of blood and BAL proteins in 
future experiments may uncover more unbiased signatures. Another consideration is that aptamer 
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measurements do not always significantly correlate with ELISA concentrations, which could be 
due to different actions and binding sites of aptamers vs. antibodies. All subjects in the COMET 
study lived through the study end date, which means that our presented hypotheses might not 
representative of end-stage IPF patients. Although the model based on both blood and BAL 
proteins was found to be the most accurate at differentiating IPF progression status, this model 
would not currently be useful as a prognostic test due to 1) challenges associated with obtaining 
BAL measurements; and 2) the large number of proteins currently in the signatures. However, 
because our model is able to investigate covariation in protein expression across tissue 
compartments, we do believe that the analysis is useful for generating new insight into potential 
systemic and proteomic relationships associated with IPF progression. The blood protein 
signature identified here holds more promise as a prognostic signature (cross-validation accuracy 
of 96% was only moderately lower than the combined model); however, it would still require 
reduction in the number of proteins before it would be useful. Furthermore, development of a 
true prognostic signature for clinical use would require validation in new, larger cohorts. To our 
knowledge there is currently no appropriate validation cohort available, and the SOMAmer 
platform is no longer accessible for academic use. Therefore, we are unable to confirm the 
diagnostic or prognostic merit in any of the identified signatures. We did employ cross-validation 
which suggests that future validation of prognostic biomarkers could be valuable. 
 We identified signatures in our study to investigate potential mechanistic differences 
between IPF progressors and non-progressors, and found several emerging trends. A prior 
knowledge database (DAVID) indicated that significantly enriched processes in non-progressors 
involved regulation of immune or defense system responses, suggesting that this regulation is 
potentially lacking or deficient in progressors. We speculate that this idea that non-progressors 
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have better control of proteomic processes was also reflected in the protein correlation networks, 
where non-progressors had fewer hub proteins and fewer significant correlations present, but 
these correlations were significantly stronger than those in the progressor network. We 
hypothesize that this finding indicates a more stable protein network in non-progressors that 
would be difficult to perturb. Stronger correlations could also indicate that non-progressors have 
finer control over the expression of these proteins, suggesting that the biological pathways these 
proteins are involved in are less dysregulated than they are in progressors. Additional 
experimental analysis would be needed to confirm these ideas. 
IPF progressors were characterized by more heterogeneous proteomic expression across 
tissue compartments. Heterogeneity was suggested by both the correlation network (the large 
number of significant but weak correlations present in progressors), and also in the hierarchical 
cluster, which exhibited three progressor clusters that were characterized by unique expression 
patterns of proteins.  We speculate this may suggest potential subgroups (endotypes) are present 
within the progressors; however, this study did not have the power to eliminate the effects of 
other co-variates or random influence. One progressor cluster showed increased expression of 
many apolipoproteins, in addition to DC-SIGN, E-cadherin, ficolin-1, and other proteins. 
Intriguingly, another cluster of progressors exhibited increased expression of both proteins that 
were also highly expressed in the non-progressor cluster and proteins that were highly expressed 
in another progressor cluster. We investigated this group of progressors but did not find a 
significant difference in the time from COMET enrollment to date of progressive event between 
this group and the other two groups of progressors identified in the hierarchical cluster. 
Unsupervised analytical and clustering techniques could be used in other larger studies to better 
characterize and confirm potential endotypes of IPF progressors. 
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Intriguingly, proteins from the complement system were signature components in both 
the temporal-focused and in the tissue compartment analyses. We observed that progressors at 
later time points (48 or 80 weeks post-baseline) were characterized by comparatively increased 
expression of iC3b compared to other proteins in the signature. iC3b plays a critical role in 
pathogen binding and clearance, and also regulates other functions including phagocytosis and 
IL-12 secretion180,181. To our knowledge there have been no studies directly focused on IPF and 
iC3b, but complement 3 (C3)’s involvement in IPF has been previously studied, with C3 gene 
expression reported to be higher in the lungs of IPF patients vs. those of healthy controls182. 
Likewise, C3 deficient mice exhibited reduced lung injury after exposure to bleomycin than their 
wild type counterparts182, and depletion of the serum complement system inhibited bleomycin-
induced lung collagen deposition in rats183. Although these studies investigated C3 expression 
and fibrosis, in our data progressor iC3b expression was positively and significantly correlated 
with progressor C3 expression over all time points (Pearson’s correlation coefficient, ρ = 0.52, p-
value = 2.1*10-8), suggesting that changes in iC3b expression levels may reflect similar changes 
in C3 concentration. Although appearances of iC3b in identified signatures suggest an 
association with IPF progression, future experimental and clinical studies would be needed to 
confirm any mechanistic role. 
In conclusion, we were able to use systems-focused, data-driven modeling approaches to 
identify temporal and cross-tissue compartment proteomic signatures that led to increased insight 
into mechanisms associated with IPF progression. Overall, this work highlighted the ability of 
quantitative, systems-focused analytical techniques to aid in generating novel hypotheses for 
proteomic mechanisms associated with IPF progression. We envision these approaches could be 
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easily applied to integrate spatiotemporal data in clinical samples from other diseases that have a 
progressive and/or heterogeneous patient population.     
3.5 Methods 
3.5.1 Ethical approval statement 
All clinical investigations were conducted according to the Declaration of Helsinki. The 
human study protocol was approved by the institutional review board of all participating centers 
and methods were carried out in accordance with the relevant guidelines and regulations 
(University of California Los Angeles, Los Angeles, CA, United States; University of California, 
San Francisco, San Francisco, CA, United States; National Jewish Medical and Research Center, 
Denver, CO, United States; University of Chicago, Chicago, IL, United States; University of 
Michigan Ann Arbor, MI, United States; Cleveland Clinic Foundation, Cleveland, OH, United 
States; Temple University, Philadelphia, PA, United States; Brown University, Providence, RI, 
United States; Vanderbilt University, Nashville, TN, United States). 
3.5.2 Subject population 
The Correlating Outcomes with Biochemical Measurements to Estimate Time 
Progression in IPF study (COMET-IPF) (clinical trials ID no. NCT01071707) was a multi-
center, prospective observational cohort aimed at identifying markers of IPF progression. All 
data and samples used in this study were de-identified.  The study design has been described 
previously137,174, but in brief, eligible patients were aged 35-80 with a multidisciplinary IPF 
diagnosis (confirmed by clinical history, chest computed tomography (CT) scan, and a lung 
biopsy when necessary). Subjects with an IPF diagnosis >4 years prior to screening, diagnosed 
collagen-vascular disorder, FEV1/FVC < 0.60, evidence of active infection at screening, or 
comorbid conditions likely to result in death within one year were excluded. Informed consent 
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was obtained from all participating patients. Progression during an 80-week follow-up period 
was dichotomized by the composite occurrence of a relative decline in FVC of ≥10% or in the 
diffusion capacity of the lungs for carbon monoxide (DLCO) of >15%, acute exacerbation, lung 
transplant, or death. Seventy-one patients were originally screened for inclusion in the COMET 
cohort, of which 60 were included in the analysis described here. Patients were excluded from 
analysis based on a lack of blood samples at all three time points or missing data such as DLCO 
or 6 minute walk test as described in the original study137. 
3.5.3 Sample acquisition and measurements 
Peripheral blood samples were collected from 60 COMET patients at three time points 
(week 0/baseline, week 48 and week 80). Slow off-rate modified aptamers (SOMAmer©) 
technology was used to measure 1129 proteins present in blood samples at each collection time 
point. A small number of blood proteins in fifteen of these samples were later also measured by 
ELISA; the concentrations of the two platforms were correlated using Pearson’s correlation 
coefficient. 
Bronchoscopy was performed at enrollment in patients who were clinically stable and 
without evidence of active infection. Luminex FlexMAP 3D (Luminex Corporation, Austin, TX) 
technology was used to measure 29 cytokines/chemokines in the BAL samples. Samples below 
the lower limit of detection were set to be ½ the lowest minimum detectable concentration across 
the standard curves of all analytes. Before inclusion in any analyses, all BAL protein 
concentrations were normalized to total protein concentration as quantified by a Pierce 
bicinchoninic acid (BCA) Protein Assay Kit (Pierce Protein Biology, Rockford, IL). 
For more details on peripheral blood and BAL sample collection, please see Appendix B. 
3.5.4 Data processing 
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Before beginning any analysis, a PCA model was created to identify potential negative 
drivers in the multivariate model. Negative drivers were defined as samples which 
disproportionally drove the final model such that model parameters solely explained the driver’s 
variance, and were characterized as samples with a Hotelling’s Reduced T2 statistic value > 5. 
The sample with the highest Hotelling’s Reduced T2 statistic greater than 5 was subsequently 
removed and another PCA model was generated based on the remaining data. This process was 
iteratively implemented until all samples produced Hotelling’s Reduced T2 statistics <5, resulting 
in 4 unique datasets with the following features: (1) baseline blood proteins (59 samples; 34 
progressors and 25 non-progressors; demographics detailed in Supplemental Table B.S1), (2) 
BAL proteins (51 samples; 31 progressors and 20 non-progressors; demographics in 
Supplemental Table B.S2), (3) baseline blood and BAL proteins (50 samples; 30 progressors 
and 20 non-progressors; demographics in Table 3.1), (4) temporal-dependent blood proteins for 
trajectory PCA (102 progressor and 71 non-progressor time point measurements in total). The 
associated univariate analyses contained the same spread of samples. All proteins, both those 
measured by SOMAmer aptamers and by Luminex, were measured in both progressors and non-
progressors and included in the initial LASSO analysis. 
3.5.5 Statistical analysis of differential protein expression in clinical cohorts 
Two volcano plots illustrated individual blood and BAL proteins that were significantly 
and differentially expressed across IPF progressors and non-progressors. Relative fold-changes 
in blood and BAL protein levels were calculated by dividing the average expression of each 
protein in progressors by that in non-progressors. Statistical analysis between protein expression 
in the cohorts was performed by standard two-sample t-tests. P-values < 0.05 were regarded as 
significant. 
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3.5.6 Identification of proteomic signatures with feature selection tools and PLSDA 
PLSDA was used in conjunction with feature selection tools to determine the protein 
signature which best differentiated clinical cohorts in various datasets. Prior to any analysis, data 
were normalized with mean centering and variance scaling. The LASSO was used when finding 
the minimum signature based on SOMAmer blood protein data. For all LASSO models, k-fold 
cross-validation (k=10) was used to generate the model with the lowest possible mean squared 
error for prediction, such that random subsets were iteratively excluded from the data set during 
model calibration and were later used to evaluate model predictions. VIP scores identified the 
differentiating signature of BAL proteins, with a VIP cutoff score for inclusion in the model of 
≥1. All PLSDA models were built using k-fold cross-validation (k=10) and were orthogonalized 
to improve interpretability. ROC curves were generated based on the classification ability of a 
PLSDA model. 
3.5.7 Analysis of differentially expressed proteome with DAVID 
The Database for Annotation, Visualization, and Integrated Discovery (DAVID) was 
used to identify significantly enriched biological processes based on the protein signatures 
identified by multivariate methods. Protein signatures which resulted from these approaches 
were sorted into profiles based on their relative expression levels in progressor or non-progressor 
cohorts. The sign of the PLSDA loadings on LV1 determined if the protein was comparatively 
increased in progressors (negative loadings) or non-progressors (positive loadings). The resulting 
clustering and enrichment diagrams from DAVID were created by searching through Gene 
Ontology (GO) biological processes (BP FAT), GO molecular function (MF FAT), and Kyoto 
Encyclopedia of Genes and Genomes (KEGG). Only the clusters and pathways which were 
significant after applying the Bonferroni correction within DAVID were reported. 
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3.5.8 Comparison of PLSDA model performance parameters 
In order to quantitatively compare calibration accuracy across multiple PLSDA models, 
each model of interest was probed to determine whether it correctly or incorrectly classified each 
individual patient. Patients who were not included in all of the models to be compared were 
unable to be included in this comparative analysis of calibration accuracy, which only affected 
the comparison of models based on multiple tissue compartments. A matrix of matched sets of 
proportions was generated where each patient’s classification state (e.g. correctly or incorrectly 
classified by the model) was represented as dichotomous values for each of the models of 
interest. These proportions were then compared using Cochran’s Q test in conjunction with 
McNemar’s post hoc test; significance was defined as the adjusted p<0.05. 
To compare cross-validation accuracy between models, we split the total data into ten 
groups (5-6 samples in each group) and then iteratively generated PLSDA models based on nine 
groups of data (training set), and tested the model with the unused group of data (test set). We 
recorded if these test samples were accurately classified by the model, and compared the percent 
accuracy from all ten groups associated with one overall PLSDA model to percent accuracy of 
other PLSDA models. Statistical significance between models was evaluated by a standard one-
way ANOVA with Tukey’s post hoc test. P-values <0.05 were deemed significant. 
3.5.9 Visualization of classification ability of LASSO-identified signature using clustering 
Hierarchical clustering of the LASSO-identified signature based on blood and BAL 
proteins was generated with supervised average linkage clustering. Pearson’s correlation 
coefficient was used as the distance metric. Samples were colored by progression status as well 
as other clinical, radiologic, and genetic variables. 
3.5.10 Exploration of network interactions between progressor and non-progressor cohorts 
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Protein correlation networks were constructed separately for progressors and non-
progressors using pairwise Pearson’s correlation coefficients between protein expression in the 
LASSO-identified signature within the two groups. Edge color and thickness correspond to 
coefficient value and statistical significance, respectively, with only significant correlations (p < 
0.05) being shown. Node size is proportional to its degree of connectedness. 
3.5.11 Investigating temporal dependences in progressor/non-progressor protein signatures 
LASSO identified the minimum blood signature that differentiated the three collection 
time points (week 0, 48 and 80) in progressors and non-progressors separately. Trajectory PCA 
models179 were then created based on each of these signatures. A one-way ANOVA with 
Tukey’s post hoc test was used to evaluate the significance of temporal differences in protein 
expression by comparing the scores on PC1 at each collection time point. P-values < 0.05 were 
considered significant. 
3.5.12 Visualization of time-dependent scores with density plots 
PC1 scores from each of the three time points in the trajectory PCA were fit to a kernel 
distribution. The kernel distribution was reconstructed into a probability density function using 
the fitdist function with the normal smoothing function and the default bandwidth value. 
3.5.13 Software summary 
All volcano plots, hierarchical clustering, heat maps, correlation networks, and density 
plots were completed using Matlab (v2016b, Matlab, Natick, MA). LASSO was implemented 
using Matlab software167. PCA and PLSDA models, ROC curves, and VIP score calculations 
were generated using the PLS toolbox available in Matlab® (v8.2.1, Eigenvector, Mason, WA). 
All statistics, with the exception of Cochran’s Q test, were performed using Prism version 7.00 
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and version 8.00 (GraphPad software, San Diego, CA). Cochran’s Q test with McNemar’s post 
hoc test was done in R software version 3.5.1 (R Core Team, Vienna, Austria).
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Chapter 4 Unpublished IPF Results 
Contributions. The COMET investigators, and Jeff Curtis and Christine Freeman were 
involved in collecting the BAL samples from the IPF patients and the healthy patients. Vibha 
Lama stored the COMET IPF BAL samples, and Drs. Curtis and Freeman stored many of the 
healthy BAL samples. 
4.1 Introduction 
In addition to the published work presented in Chapters 2 and 3, we have also generated 
additional models of IPF disease state and progression that have not been published. Key results 
in this chapter focus on analysis of BAL proteins, as well as the application of another data 
analysis tool to the IPF blood and lung protein data. The goal of this work was to identify 
proteomic signatures that could differentiate clinical groups and help us gain insight into 
processes involved in IPF disease state and progression. 
Although IPF is a disease that is localized to the lung, collecting lung tissue biopsies that 
could allow for deeper insight into pathways associated with disease state or progression can be 
dangerous due to the potential injury or exacerbation events that could result from sample 
collection. Another technique for the collection of samples that describe the pulmonary 
environment in a less injury-inducing fashion is the bronchoalveolar lavage (BAL) procedure. 
This procedure involves the injection of sterile saline into the lung followed by immediate 
collection, which provides a sample of the epithelial lining fluid (ELF), secreted cytokines, and 
cell types present inside the lung. Although this procedure still requires entry into the lung 
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environment through the trachea, there is lower risk for potential tissue damage when performed 
correctly for the BAL procedure than the surgical lung biopsy.  
However, the BAL sample collection process is variable, which has resulted in very few 
reports of BAL protein biomarkers for IPF. The quantitation issues associated with the BAL 
procedure are caused by variations in lung structure across patients that affect the amount of 
saline that is recollected after the flush; the unknown quantity of ELF that is collected with each 
saline flush; and potential contamination from bronchi-level lung cells184. Due to these factors, it 
has been difficult to deal with the unknown ELF dilution factor and identify proteins that can 
separate groups of interest, even though these samples come from the tissue compartment of 
injury. There has been some success using BAL samples in IPF: previously, IL-33 and thymic 
stromal lymphopoietin (TSP) concentrations in BAL were reported to be able to differentiate IPF 
from other interstitial lung diseases185. Additionally, monocyte chemoattractant protein 1 (MCP-
1), thymus- and activation-regulated chemokine (TARC/CCL17), and macrophage-derived 
chemokine (MDC) have been reported to be associated with poor outcomes in IPF186. However, 
there have been others who have reviewed results of studies focused on BAL samples that have 
concluded that measurements from BAL samples alone are not enough to diagnose patients with 
ILDs187–189.  
A potential reason why there are so few BAL proteins associated with disease state or 
progression could involve how both the BAL samples and the resulting proteomic data have been 
approached. There have been few studies where greater than ten BAL proteins were measured in 
each sample for IPF disease state or progression investigations126,190–193, although this seems to 
be changing as multiplex protein assays become more common and attainable. Additionally, the 
approaches taken when analyzing BAL data often involved looking at proteins one at a 
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time185,186,190,191,193–196, with only few studies considering how covariation or networks might lead 
to increased differentiation ability or increased biological insight126,192. The design of past 
experiments in this way could have potentially contributed to the lack of proteomic network-
level inferences made about lung processes involved in IPF disease state and progression. Based 
on this underutilization of BAL samples in the literature, we have applied our data-driven 
modeling techniques to identify signatures of BAL proteins that were able to differentiate IPF 
disease state and disease progression, and additionally created more cross-tissue compartment 
models using different classification algorithms, all of which led to increased insight into the 
potential role cytokines may play in IPF progression. 
4.2 Results 
4.2.1 BAL signature identified that differentiates healthy and IPF patients 
Two-sample, two-tailed t-tests were used to identify 3 proteins out of the 29 measured 
proteins which were significantly differentially expressed across the healthy and IPF 
populations: interferon α2 (IFNα2), IL-7, and IL-15 (p = 0.00012, p = 2.66*10-11, and p = 0.034, 
respectively). Variable Importance in Projection (VIP) scores selected and partial least squares 
discriminant analysis (PLSDA) visualized a signature of 4 out of 29 measured BAL proteins that 
differentiated healthy (n = 5) and IPF (n = 51) patients with 97.06% cross-validation and 
calibration accuracy (Figure 4.1A). Latent variable 1 (LV1) differentiated healthy (purple; more 
negative scores on LV1) from IPF patients (cyan; more positive scores on LV1) (Figure 4.1B). 
We then compared the calibration and cross-validation accuracy of the VIP-selected model to 
that of PLSDA analyses based on single differentially expressed proteins, and a PLSDA model 
based on all three of the significant proteins discovered. We saw that the VIP-selected model had 
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much higher calibration (Figure 4.1C) and cross-validation (Figure 4.1D) accuracy than 
analyses based on IFNα2 or IL-7, but tended to be slightly (1%) worse than analyses based on 
IL-15 alone and based on all three significant proteins.  





Figure 4.1. VIP-selected signature of BAL proteins classifies IPF disease state better than or just as good as single 
proteins. 
(A) The PLSDA scores plot separated healthy (purple) and IPF (cyan) subjects with 97.06% calibration and cross-validation 
accuracy. (B) The loadings on latent variable 1 (LV1) captured 50.56% of the variance in the data. Proteins loaded negatively 
on LV1 are comparatively decreased in IPF. Comparisons of calibration (C) and cross-validation (D) accuracies associated 
with models and analyses based on univariate-identified proteins shows that the VIP signature is better than or nearly as good 
as these models. 
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Due to the low number of proteins that were significantly differentially expressed across 
the progressors and non-progressors (Figure 3.2b), we then turned to data-driven modeling 
techniques to identify signatures of covarying proteins that could differentiate the two groups. As 
discussed in Chapter 3, we used VIP scores to select a signature of 12 BAL cytokines that 
differentiated IPF progressors (n = 31) and non-progressors (n = 20) with 78.55% calibration and 
67.82% cross-validation accuracy in a PLSDA model (Supplemental Figure B.S3a and 
B.S3b)197. The cytokine data included in this model were first normalized to protein albumin 
levels in the BAL samples using a bicinchoninic acid (BCA) assay (BCA-normalized BAL 
cytokines). This BCA-normalized model performed better than a model based on a signature of 
non-normalized BAL proteins, but performed significantly worse than models based on blood 
proteins alone and a model based on blood and BAL proteins combined (Chapter 3). We 
hypothesized that this might be due in part to the small number of BAL proteins measured 
compared to blood proteins, and that a targeted panel of BAL proteins (cytokines and 
chemokines) were measured compared to the less directed panel of blood proteins measured. 
While better characterization of potential cross-tissue compartment proteomic 
relationships can help create a holistic understanding of IPF progression, we also wanted to focus 
on gaining insight into the potential lung mechanisms associated with progression because the 
lungs are the main tissue compartment of injury in IPF. We created correlation networks based 
on the expression of the VIP-selected BAL protein signature in progressors (Figure 4.2A) and 
non-progressors (Figure 4.2B). In the progressor network, the proteins with the highest number 
of significant correlations to other proteins included MCP-1, IL-8, granulocyte colony 
stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), and 
epidermal growth factor (EGF). 
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4.2.3 Gradients of proteins were not able to differentiate progression status better than 
single cytokines 
We next investigated if the differential expression of proteins across the blood and the 
lungs could lead us to a deeper understanding of IPF progression. Standardized gradients have 
been successfully identified as being positively associated with higher disease risk in HIV, 
another immunological disease affecting a mucosal surface103. We applied decision tree analysis 
(DTA) to IPF to identify the gradient relationships that were best in differentiating progressors 
and non-progressors and the hierarchy of importance of these relationships in classifying the two 
groups. To calculate the gradients, we logarithmically transformed the raw blood and BAL 
protein data separately before standardizing the data by setting the mean of each protein to be 
zero and the standard deviation to be one. After that, we took these values and subtracted BAL 
protein – blood protein to find the gradient. This means that when interpreting the gradient 
A B 
Figure 4.2. Correlation network of the VIP-selected BAL protein signature present in (A) progressors and (B) non-
progressors. 
 
Proteins connected by two lines are significant (p < 0.05) correlated by Pearson’s correlation coefficient. Node size reflects the 
number of significant correlations to other proteins. Brighter and thicker lines indicate a stronger, more significant correlation, 
respectively. The value of the correlation coefficient for both networks is displayed in the color bar scale on the right, with red 
indicating a positive relationship and blue a negative relationship. 
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values, a positive gradient value indicates a protein is higher in DTA highlighted eotaxin, 
followed by IL-4, as being the two most hierarchically important gradients involved in 
classifying IPF progressors and non-progressors (Figure 4.3). This model separated progressors 
and non-progressors with 76% cross-validation and 92% calibration accuracy. Interestingly, the 
majority of all progressors were found in one leaf, described by having a lower BAL eotaxin 
concentration compared to plasma, a lower BAL IL-4 concentration compared to plasma, and a 
higher BAL TNF-β concentration compared to plasma. Although we found that the DTA model 
based on the gradient concentration across the lung and blood tissue compartments nominally 
outperformed DTA models based on only blood or only BAL protein expression, the calibration 
Figure 4.3. Decision tree analysis based on gradients of protein concentrations across tissue compartments highlights 
hierarchical importance of gradient concentrations in differentiating progressors (P) and non-progressors (NP), with 
eotaxin being the most hierarchically important blood-lung gradient involved in differentiating the two groups, followed 
by IL-4.  
All gradients were calculated by logarithmically transforming the protein expression data, normalizing each protein to have a 
mean of zero and a standard deviation of one, and then subtracting BAL protein – blood proteins. A positive gradient is 
indicative of a higher concentration of the protein in the BAL sample. 
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and cross-validation accuracies of these models were very close to each other and were not 
significantly different (data not shown). 
4.3 Discussion 
In this work, we identified signatures of cytokines measured in BAL samples that were 
able to differentiate healthy and IPF patients, as well as IPF progressors and non-progressors. We 
were successfully able to detect and measure the concentrations of cytokines in BAL samples 
collected from IPF patients by doubling the volume used in our Luminex assay. We 
hypothesized that lung chemokines may play a role in IPF progression, and that these 
chemokines recruited cell types that suggested that multiple mechanisms of tissue reorganization 
may be at play in progression. These results illustrate the value of coupling Luminex 
measurements with data-driven modeling techniques in order to gain increased insight into 
proteins and potential mechanisms associated with IPF disease state and progression. 
To our knowledge, this was the first time that a signature of BAL cytokines had been 
identified that could differentiate IPF from healthy patients. This model outperformed all 
analyses based on differentially expressed proteins except for models based on IL-15, for which 
our VIP-selected signature was less accurate than by only 1%. We hypothesize this occurred 
because IL-15 was highly significantly different across the healthy and IPF groups (p = 2.66*10-
11, two-sample t-test). Overall, using signatures of lung proteins to differentiate disease state in 
IPF may be able to serve as a complementary tool and confirm co-variation between proteins that 
were already identified in univariate analysis, which could allow us to gain increased insight into 
the pulmonary environment of IPF.  
We hypothesized that chemokines are important in IPF progression from our results of 
protein correlation coefficient networks based on the BAL protein signature that differentiated 
 83 
IPF progressors and non-progressors in Chapter 3197. In the progressor correlation network 
based on the VIP-selected BAL protein signature, the hub proteins included MCP-1, IL-8, GM-
CSF, G-CSF, and EGF. These cytokines attract and support the growth of neutrophils (GM-CSF 
and IL-8), are chemoattractive for and stimulate the growth of monocytes (MCP-1), and increase 
fibronectin secretion in IPF fibroblasts (EGF). The interactions between these hub proteins and 
cell types are intriguing given current hypotheses surrounding IPF pathogenesis and progression: 
when recruited to the lung tissue, monocytes secrete pro-fibrotic inflammatory cytokines16 and 
can differentiate into macrophages198, which are associated with IPF pathogenesis199; neutrophils 
may be involved in regulating lung fibrosis levels through their role in ECM regulation via 
secretion of neutrophil elastase and in balancing levels of matrix metalloproteinases (MMPs) and 
tissue inhibitors of metalloproteinases (particularly MMP-8200), although their exact contribution 
to IPF fibrosis remain unclear201; EGF has been shown to cause IPF fibroblasts to secrete 
increased levels of fibronectin202. Taking these functions and the correlation network together, 
this suggests that progressors may undergo tissue reorganization through multiple pathways, and 
that each pathway is potentially affected by each other. Follow-up on these results with in vivo 
models of fibrosis will be key to see if these mechanisms are affected by each other, and if all of 
them are associated with fibrosis. 
When applying decision tree analysis to the IPF progression data, we saw that gradients 
of cytokines were only slightly better at differentiating IPF progressors and non-progressors 
compared to expression data from single tissue compartments alone. We found the IL-4 gradient 
to be somewhat surprising, as it would be expected based on the literature that alveolar 
macrophages secrete higher levels of IL-4 than compared to smokers and controls203, and that IL-
4 is increased in the BAL of IPF patients compared to controls204. This DTA result could be due 
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to the preprocessing that had to be performed before the creation of the DTA model because the 
blood and BAL proteins were measured using different platforms – the aptamer-based 
SomaLogic platform that reported blood protein concentrations in relative fluorescence units 
(RFUs), and the albumin-normalized antibody-based Luminex platform that reported BAL 
protein concentrations in pg protein/mg albumin. Overall, this result does not suggest that 
gradients of cytokines across the blood and lung tissue compartments are significantly better at 
differentiating IPF progression status.  
Limitations associated with this work come from the small sample size (especially in the 
case of the healthy patients), the nature of the COMET cohort, and the variability associated with 
obtaining BAL measurements. Healthy BAL samples are difficult to come by due to the 
invasiveness of the procedure, which is why so few healthy samples were included in this model. 
The low number of healthy samples is the reason why we did not perform any follow-up 
analyses on the signature, as the 5 healthy patients we were able to include may not be a 
complete representation of the healthy population at large. As stated in Chapter 3, all COMET 
IPF subjects lived through the end of the study, so hypotheses presented here may only apply to 
mild- to moderate-IPF and not end-stage IPF. We did not have access to new samples for model 
validation, but we did cross-validate our models whenever possible. Lastly, the BAL sample 
collection procedure is a variable process. We have done our best to account for this variability 
by normalizing protein concentrations measured by Luminex to the total protein albumin 
concentration measured by the BCA assay in each sample. We found that our models based on 
albumin-normalized protein concentrations performed better than models based on non-
normalized protein concentrations (data not shown), but it should be mentioned that there is no 
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consensus as to which BAL normalization technique best reflects the physiological concentration 
of the proteins in the lung lining fluid. 
4.4 Methods 
4.4.1 Human sample collection and protein measurements 
IPF BAL samples were collected from patients enrolled in the Correlating Outcomes with 
biochemical Markers to Estimate Time-progression in IPF (COMET) study (clinicaltrials.gov, 
clinical trials ID no. NCT01071707). Although the COMET study recruited 60 IPF patients, only 
51 IPF BAL samples were available when measuring protein concentrations (20 non-progressors 
and 31 progressors). Inclusion criteria and the definition of disease progression employed in this 
study have previously been described136,174. Informed consent was obtained from all participating 
centers, which included University of California Los Angeles. Los Angeles, CA, United States–
University of California, San Francisco. San Francisco, CA, United States–National Jewish 
Medical and Research Center, Denver, CO, United States–University of Chicago, Chicago, IL, 
United States–University of Michigan Ann Arbor, MI, United States–Cleveland Clinic 
Foundation, Cleveland, OH, United States–Temple University, Philadelphia, PA, United States–
Brown University, Providence, RI, United States–Vanderbilt University, Nashville, TN, United 
States. The study protocol was approved by the institutional review board of all participating 
centers and methods were carried out in accordance with the relevant guidelines and regulations. 
Bronchoscopy was performed at enrollment in patients who were healthy enough to undergo the 
procedure. BAL samples were collected and pooled from 4 installations of 50 mL sterile isotonic 
saline aliquots. Cell-free fluid was stored at -80°C.  
Four healthy BAL samples were collected at the Veteran’s Association Ann Arbor 
Healthcare System (VAAAHS), with the collection protocol approved by internal review boards 
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(IRBs) at the VAAAHS and at the University of Michigan Health System (UMHS). BAL was 
performed through 5 installations of 30 mL of sterile saline into each side of the lung, with all 
installations being then pooled at the end. The fifth healthy BAL sample was also collected at the 
UMHS. For this sample, 2-3 installations of 60 mL of sterile saline were flushed into the right 
lung, and all installations were later pooled. For all five healthy BAL samples, cell-free fluid was 
stored at -80°C until protein measurement occurred. 
All BAL samples were then collected and Luminex FlexMAP 3D technology (Luminex 
Corporation, Austin, TX) was used to measure 29 cytokines/chemokines in all BAL samples. For 
protein measurements in Luminex, we used a protocol that used ¼ of the recommended number 
of beads and sample to minimize bead and sample volume for the assay, which was inspired by 
Arnold et al.205. Due to low cytokine concentrations present in BAL samples206, we also ran BAL 
samples at 2X the normal volume for this protocol, which was 30 µL per well. Samples were run 
in duplicate, and those that were below the lower limit of detection were set to be ½ the lowest 
minimum detectable concentration across the standard curves of all analytes. Before inclusion in 
any analyses, all BAL protein concentrations were normalized to total protein concentration as 
quantified by a Pierce BCA Protein Assay Kit (Pierce Protein Biology, Rockford, IL).  
4.4.2 Quantitative modeling approaches 
The first step in the data-driven analysis was to determine if any samples negatively 
drove the creation of the data-driven models. All data were normalized by mean centering and 
variance scaling before any PCA models were built. Negative drivers were samples which 
disproportionally drove the final models of disease state or of disease progression such that 
model parameters solely explained the driver’s variance, and were characterized as samples with 
a Hotelling’s Reduced T2 statistic value > 5. The sample with the highest Hotelling’s Reduced T2 
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statistic that was greater than 5 were subsequently removed and another PCA model was 
generated based on the remaining data. This process was iteratively implemented until all 
samples produced Hotelling’s Reduced T2 statistics < 5. 
Once all negative drivers had been identified, we used PLSDA in conjunction with VIP 
scores to determine the protein signatures that best differentiated the healthy and IPF patients, 
and IPF progressors and non-progressors. Proteins that had a VIP score ≥ 1 were said to be 
important, and another PLSDA model was then built based only on the VIP-selected features. All 
data were normalized by mean centering and variance scaling before any PLSDA models were 
built. All PLSDA models were built using K-fold cross-validation (k = 10), and models were 
orthogonalized after VIP-selection to improve interpretability. The model of BAL proteins that 
differentiated healthy and IPF patients is discussed in depth in Chapter 3197.  
Protein correlation coefficient networks were constructed using pairwise Pearson’s 
correlation coefficient based on expression of the BAL proteins in the VIP-selected signature in 
progressors and non-progressors separately. A brighter and thicker line connecting two protein 
nodes indicates a stronger and more significant correlation, respectively, with only significant (p 
< 0.05) correlations being shown. Node size is proportional to its degree of connectedness. 
Cytokine gradients were calculated by first log10 transforming the 23 proteins that were 
measured both by Luminex technology in the BCA normalized BAL samples and by SOMAmers 
in the blood samples. The log10 transformed values were then standardized, and the gradient was 
calculated by subtracting blood values from BAL values such that a positive gradient indicated 
higher concentration in the BAL. A classification decision tree algorithm predicted the hierarchy 
of importance in gradient or raw concentration from single tissue compartments that were best at 
differentiating IPF progressors and non-progressors, with Gini Diversity Index being used as the 
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split criterion. Each tree was cross-validated using k-fold cross-validation with 10 folds. Trees 
were pruned to the level that exhibited the lowest calibration and cross-validation error. 
A two-tailed, two-sample t-test was used to determine significant differences in 
expression across the healthy and IPF groups. All quantitative models, decision trees, and 
statistical analyses were created using Matlab (v2016b, Matlab, Natick, MA). PCA, PLSDA, and 
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Introduction—Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of 
death in the United States, with high associated costs.  Most of the cost burden results from acute 
exacerbations of COPD (AE-COPD), events associated with heightened symptoms and 
mortality. Cellular mechanisms underlying AE-COPD are poorly understood, likely because they 
arise from dysregulation of complex immune networks across multiple tissue compartments.   
Methods—To gain systems-level insight into cellular environments relevant to exacerbation, we 
applied data-driven modeling approaches to measurements of immune factors (cytokines and 
flow cytometry) measured previously in two different human tissue environments (sputum and 
peripheral blood) during the stable and exacerbated state.   
Results—Using partial least squares discriminant analysis (PLSDA), we identified a unique 
signature of cytokines in serum that differentiated stable and AE-COPD better than individual 
measurements.  Furthermore, we found that models integrating data across tissue compartments 
(serum and sputum) trended towards being more accurate.  The resulting paracrine signature 
defining AE-COPD events combined elevations of proteins associated with cell adhesion 
(sVCAM-1, sICAM-1) and increased levels of neutrophils and dendritic cells in blood with 
elevated chemoattractants (IP-10 and MCP-2) in sputum. 
Conclusions—Our results supported a new hypothesis that AE-COPD is driven by immune cell 
trafficking into the lung, which requires expression of cell adhesion molecules and raised levels 
of innate immune cells in blood, with parallel upregulated expression of specific chemokines in 
pulmonary tissue. Overall, this work serves as a proof-of-concept for using data-driven modeling 




Chronic obstructive pulmonary disease (COPD) is a progressive and heterogeneous lung 
disease that is the fourth leading cause of death in the United States207, with yearly U.S. medical 
costs expected to increase to nearly $50 billion in 202057. A large portion of these costs is 
attributed to acute exacerbations of COPD (AE-COPD), characterized by increased symptoms 
(dyspnea, coughing, sputum production, and fatigue) beyond day-to-day variation that require 
treatment with antibiotics or corticosteroids208. Severe exacerbations (that require 
hospitalization) have an in-hospital all-cause mortality rate of 5-7%71,72, and account for most of 
the financial burden of COPD209. Accordingly, the prediction and treatment of AE-COPD events 
are top priorities. 
Nonetheless, pathogenic cellular mechanisms underpinning AE-COPD are largely 
undefined. Local tissue and systemic inflammatory pathways are hallmarks of COPD, and are 
further increased during AE-COPD. Most AE-COPD are also associated with evidence of viral 
or bacterial infections or both92,210,211, with upregulation of IL-8, TNF-α and reactive oxygen 
species in cells and tissue environments211. Some AE-COPD are also highly eosinophilic92. 
COPD patients with persistent systemic inflammation have higher mortality and exacerbation 
rates compared to non-inflamed patients212. AE-COPD frequency is reduced by several types of 
therapies, including inhaled corticosteroids (ICS), long-acting muscarinic antagonists, scheduled 
azithromycin, and roflumilast81,213–215. The success of these treatments, which share 
immunomodulatory effects, support acutely increased inflammation as contributing to AE-
COPD, though fundamental mechanisms driving AE-COPD remain elusive. 
Despite identification of individual cell types and cytokines that are differentially 
expressed between stable and exacerbated COPD216–218, no single factor entirely accounts for 
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AE-COPD, and therapies based on single targets have been unsuccessful. In the past 25 years, 
only one new class of medicine has been accepted for COPD treatment219. Plasma fibrinogen 
was recently qualified by the Food and Drug Administration as a prognostic biomarker, but only 
for subject enrichment in clinical trials of exacerbation and mortality96. Both serum C-reactive 
protein (CRP)89,220 and IL-6220,221 are upregulated in the secreted systemic environment during 
AE-COPD, but CRP alone is insufficiently sensitive as an AE-COPD biomarker222, and IL-6 
elevations are inconsistently associated with exacerbations223. New approaches to understanding 
cellular mechanisms underpinning AE-COPD pathogenesis are clearly required. 
As COPD is a complex condition exhibiting evidence of immunological 
involvement224,225, it is plausible that AE-COPD events result from disrupted networks of 
immune cells and cytokine communication, rather than from individual mediators. Data-driven 
modeling approaches offer the opportunity to infer these systems-level relationships by 
identifying small signatures of proteins or other cellular immune factors that co-vary with each 
other and are associated with disease state. These signatures can then be linked to mechanisms or 
cell types involved in phenotypes or pathogenic states, providing insight into specific disease 
biology and potential targets for follow-up experiments and therapeutic intervention. Partial 
Least Squares Discriminant Analysis (PLSDA) is a useful tool for highlighting covariance 
among variables that best classify groups of interest, which could lead to the identification of 
potential proteomic and cellular networks associated with AE-COPD. We have previously 
illustrated that PLSDA is able to identify and aid in visualizing biologically relevant proteomic 
and cellular signatures that may give insight into inflammatory pathways. We have used it to 
evaluate inflammatory signatures in the female reproductive tract mucosa102 and the blood of 
 93 
interstitial pulmonary fibrosis (IPF) patients174, in both cases identifying new biomarkers and 
generating novel insight into key cellular mechanisms. 
In this study we apply data-driven modeling approaches to gain insight into the proteomic 
networks and cellular mechanisms in blood and lung environments that underpin AE-COPD 
using a prospective cohort study91, which collected paired sputum and peripheral blood samples 
from COPD subjects when clinically stable and again before treatment for an AE-COPD. We 
show that data-driven modeling approaches are able to 1) identify cytokine networks that may be 
better for classifying AE-COPD than individual cytokines, 2) determine key relationships 
between cytokines in different tissue compartments, and 3) integrate information measured in 
different assays to provide a more complete picture of pathogenic processes involved in AE-
COPD.    
5.3 Methods 
5.3.1 Study design, ethics and subject populations 
All samples and data in this analysis derived from a published prospective observational 
trial (ClinicalTrials.gov NCT00281216)91, which followed subjects at increased risk of AE-
COPD for up to three years. Patients were recruited at the VA Ann Arbor Healthcare System 
(VAAAHS) and the University of Michigan Health System (UMHS). All parts of the study 
adhered to the Declaration of Helsinki and obtained approval of each site’s Institutional Review 
Board, with all subjects giving written consent to the study before any procedures occurred. At 
enrollment and quarterly, participants underwent spirometry, pulmonologist clinical evaluations, 
collection of peripheral blood and spontaneously expectorated sputum, and a post visit 
questionnaire. An exacerbation of COPD was said to occur if the subject reported an increase in 
dyspnea, cough or sputum production, and if the study physician ordered antibiotics or oral 
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steroid for the patient after a physical examination and chest radiographs to rule out pneumonia. 
Only if a diagnosis of AE-COPD was made were sputum and peripheral blood samples collected 
at these unscheduled visits. After all data and sample collection occurred, then each subject 
began treatment for AE-COPD. 
5.3.2 Sample collection, processing, and measurements 
Peripheral blood was used for both leukocyte immunophenotyping and to measure 40 
analytes in serum, which was stored at -80°C until analysis. Spontaneously expectorated sputum 
was immediately processed in a 9:1 mixture of distilled water to Sputolysin® (EMD Millipore, 
Billercia, MA) as described91, and the resulting supernatant was stored at -80°C until used to 
measure 36 analytes. Serum and sputum samples were unfrozen and protein concentrations were 
measured simultaneously either using a Luminex 200 System® (Luminex Corporation, Austin 
TX) or ELISA (GDF-15, IL-18, IL-23p19 and IFN-β)91. 
Whole blood was stained with directly conjugated monoclonal antibodies on the day of 
the visit as described in the text and supplemental information of Freeman et al.91 Cells were 
analyzed using a LSR II flow cytometer (BD Bioscience, San Jose, CA) as reported in 
McCubbrey et al.226, using FACSDiva software (BD Biosciences) data with automatic 
compensation and FlowJo software (Tree Star, Ashland, OR).   
5.3.3 Data processing and systems analysis 
Samples with multiple missing measurements were removed from analysis if missing 
values were recorded for more than 25% of the proteins that were measured in each assay (serum 
protein, sputum protein or blood cell marker); proteins were then removed if more than two 
measurements were missing for any one protein. We identified and illustrated individual proteins 
that were differentially expressed in stable and exacerbated states using a volcano plot. First, a 
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non-parametric, two-sided Wilcoxon paired signed rank test was used to determine significance 
in the non-normalized proteomic or cell marker expression during the stable and exacerbation 
states, with significance being defined as p < 0.05. Then, the relative fold change in protein or 
cell marker level was calculated by dividing the average concentration during exacerbation by 
the average concentration during stability. Each protein or cell marker was then plotted in one 
figure, with fold change on the x-axis and the p-value on the y- axis. Minor differences between 
these results and the previously published univariate results (Freeman et al.) can be attributed to 
variation in which subset of patients were included in each analysis91. 
PLSDA, which was performed using the Eigenvector PLS Toolbox in MATLAB, was 
used to identify and visualize signatures of multivariate cytokine and cellular markers that 
differentiated stable and AE-COPD176.  Taking a supervised approach, PLSDA assigns a loading 
to each variable and selects a linear combination of all variables (a latent variable) that best 
separates pre-defined groups. A higher value of a protein loading on a latent variable indicates 
the protein is of more importance in differentiating the groups of interest. Each sample is then 
scored based on its protein expression and are visualized in the scores plot. The loadings can be 
used for hypothesis generation based on how the subsets of the protein signature are associated 
with each of the groups in the scores plot. Each PLSDA model was cross-validated as a measure 
of model accuracy. Cross-validation was performed by iteratively excluding ~10% of the data for 
all models based on serum proteins only, ~17% of the data from the serum and sputum protein 
PLSDA model, and ~20% from the serum and sputum protein and blood cell marker PLSDA, 
which in each case resulted in 3-4 samples being excluded. The excluded data was then used to 
test the trained model. Care was taken when designing the training and test sets to ensure that no 
test set had more than one measurement from a unique patient. All missing data points included 
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in the PLSDA models were filled in by the Eigenvector software’s “best guess.” All models were 
orthogonalized to enable clear visualization of the results, and all data were mean centered and 
variance scaled before being used to create the model. Variable Importance in Projection (VIP) 
scores were used to reduce model dimensionality by determining the importance of each variable 
in differentiating the groups of interest227. Proteins with a VIP score < 1 were removed from the 
model, and a new PLSDA model was then built based on the remaining proteins or cellular 
factors.    
In order to facilitate a more quantitative comparison across PLSDA analyses, we 
calculated the cross-validation accuracy associated with each training and test set that was 
created during cross-validation. We then statistically compared cross-validation accuracies 
across the models based on different folds by using a one-way ANOVA with Tukey’s post hoc 
test. A p value of less than 0.05 was considered significant after application of Tukey’s test. 
We visualized the distinct proteomes associated with stable and AE-COPD events 
through unsupervised average linkage hierarchical clustering; Spearman’s correlation coefficient 
was used as the distance metric. Correlation heat maps were constructed based on the Spearman 
rank correlation calculated between the difference in cell marker and protein concentration from 
the stable to the exacerbated state, where correlation coefficients that had a p value of greater 
than 0.05 were set to be zero for the figure. When creating hierarchical clusters or correlation 
heat maps, all missing data points were imputed using the MATLAB function knnimpute, with 
the pairwise distances between patients calculated based on the Spearman rank correlation. 
All PLSDA models, VIP scores, Wilcoxon signed rank tests, hierarchical clusters, heat 
maps, and Spearman correlation testing were created or calculated using MATLAB (MATLAB, 
Natick, MA); PLSDA models and VIP scores were specifically generated using the PLS toolbox 
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in MATLAB (Eigenvector, Manson, WA). ANOVA and Tukey’s tests were performed using 
Prism version 7.00 (GraphPad Software, San Diego, CA). 
5.4 Results 
5.4.1 Patient enrollment and demographics 
We analyzed data from 13 COPD subjects who completed both the baseline visit and at 
least one AE-COPD visit. They were a predominantly middle-aged (mean age 67.9 years), male 
(9 of 11) group with advanced COPD (mean FEV1 33.4% predicted) comprised of both current 
and former smokers. Specifics of their demographics, clinical characteristics and in which data-
driven models their data were used is shown in Table 5.1. In summation, this study captured 18 
total paired stable and AE-COPD events among the 13 subjects, with some subjects experiencing 
more than one AE-COPD during the course of the study. 
5.4.2 Evaluation of individual immune factors associated with AE-COPD 
We first identified individual cellular immune factors and receptors that differed 
significantly between stable and AE-COPD, similar to our previously published work91. Out of 
35 serum proteins (see Materials and Methods in Section 5.2), five were found to be 
Table 5.1. Summary of demographic, smoking, and spirometry and model inclusion 
information.  
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significantly different (p < 0.05): interleukin 1 receptor 2 (IL-1R2; fold change 1.35), soluble 
intercellular adhesion molecule 1 (sICAM-1; fold change 1.33), soluble vascular cellular 
adhesion molecule 1 (sVCAM-1; fold change 1.27), growth differentiation factor (GDF-15; fold 
change 1.29) and interleukin 10 (IL-10; fold change 1.66) (Figure 5.1A). From 30 proteins 
measured in sputum, only CRP was significantly different between stable and AE-COPD (fold 
change 5.56) (Figure 5.1B). Three of 26 cellular markers measured by flow cytometry were 
differentially expressed: percent of CD4+ cells (%CD4+; fold change 0.61), CD4+ CD62L cells 
(CD4_CD62L, fold change 1.03), and CD4+ IL-18R cells (CD4_IL18; fold change 2.08) 
(Figure 5.1C). The expression of both CD62L and IL-18R indicate activation of CD4+ T cells. 
While the significance levels indicated in the volcano plots are based on average concentration 
data, the grouped scatter plots in Supplemental Figures C.S1, C.S2, and C.S3 track individual 
changes across the two COPD states in specific patients. All immune factors were significantly 
elevated during exacerbation with the exception of %CD4+ cells. Overall, these results reflect 
observations in the original study91, in which only a small number of proteins and individual 
blood cell types and activation markers were significantly different between stable and 
Figure 5.1. Individual proteins and cell populations measured in stable and exacerbated states. 
 
(A) Volcano plot illustrates serum proteins that are both differentially expressed (x axis) and significantly different (y axis) 
between the stable and exacerbated state.  Significance was determined using non-normalized data (Supplemental Figures 
C.S1, C.S2 and C.S3), and points in red indicate significantly different expression between the stable and exacerbated state via 
paired Wilcoxon signed rank test, with significance being defined as p < 0.05. (B) Volcano plot highlighting significantly 
different sputum proteins across the stable and exacerbated state. Significance was determined as described above (p < 0.05). 
(C) Volcano plot illustrating blood cell marker measurements that were significantly different between stable and AE-COPD. 
Significance was determined as described above (p < 0.05). 
A C B 
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exacerbation. None of the proteins or cell markers in the three volcano plots were found to be 
significant after application of the Bonferroni correction and many of the fold changes measured 
were small (close to 1). 
In our data there were three patients who had more than one exacerbation event.  We 
explored the effects of this by additionally analyzing the data after averaging multiple stable and 
multiple exacerbation measurements within the same patient. Overall, we found that our results 
were similar, both in individual significant proteins identified and in fold change in the 
exacerbated state (Supplemental Figure C.S4). 
Additionally, we also constructed a model of exacerbation based only on protein 
measurements in sputum samples. This VIP-selected PLSDA model performed with 91.67% 
calibration and 78.33% cross-validation accuracy and can be found in Supplemental Figure 
E.9. 
5.4.3 PLSDA identified a signature of serum proteins that differentiated stable and 
exacerbated COPD 
To obtain new insight into key systems-level relationships between networks of immune 
factors in sputum and blood that associated with AE-COPD, we next employed data-driven 
modeling approaches to integrate matched stable and exacerbation data in both blood and 
pulmonary immune environments from the same COPD patients. We first examined serum 
protein measurements alone with PLSDA176. PLSDA is a useful tool due to its ability to 
highlight covariance among variables that best classify groups of interest, which could lead to 
the identification of potential proteomic networks associated with AE-COPD. Calibration 
accuracy and k-fold cross-validation were used to assess model accuracy (see Materials and 
Methods in Section 5.2). To focus on the cytokines that were best at differentiating stable and 
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AE-COPD, we used variable importance in projection (VIP) scores227 as a feature selection 
technique. The value of using PLSDA with VIP feature selection is the identification of small 
protein “signatures” that differentiate groups of interest and are potentially biologically 
meaningful, which helps with generating new mechanistic hypotheses.  
We found that a two-latent variable PLSDA model based on the serum VIP-selected 
protein signature best classified stable and exacerbation points with 81.25% cross-validation 
accuracy and an 84.38% calibration accuracy (Figure 5.2A). Latent variable 1 (LV1) 
differentiated most stable visits (negative scores on LV1) from AE-COPD (positive scores on 
LV1; Figure 5.2B). Six of the seven proteins were loaded positively on LV1, indicating positive 
association with AE-COPD, while only tissue inhibitor of metalloproteinases (TIMP4) was 
loaded negatively on LV1, indicating negative association with AE-COPD. The six positively 
associated proteins were IL-1R2, sVCAM-1, sICAM-1, matrix metalloproteinase 9 (MMP-9), 
interferon gamma-induced protein 10 (IP-10, the chemokine also known as CXCL10), and IL-6. 
  We next compared the classification ability of this signature to the classification ability 
of the top individual factors identified in univariate analysis of these data91. The univariate model 
indicated that IL-10, IL-15, GDF-15, sICAM-1, and sVCAM-1 were individual factors that were 
significantly increased during exacerbation91. For the purpose of comparing multivariate with 
univariate results, we took each of the top significant individual mediators in previous analysis 
(sICAM-1, sVCAM-1, and IL-15) and assessed their individual ability to classify stable and AE-
COPD. We then made a PLSDA model where we combined all five significant proteins 
previously identified through univariate analysis. We compared the performance of these four 
analyses to our VIP-selected PLSDA model described above, using the cross-validation accuracy 
and the calibration accuracy as comparison metrics. The cross-validation accuracy of the VIP-
 101 
selected PLSDA model trended towards being higher than all analyses based on single 
significant proteins, but was only significantly better than the cross-validation based on IL-15 
alone (p < 0.01, one-way ANOVA with Tukey’s HSD) (Figure 5.2C). The VIP-selected PLSDA 
model did have the highest calibration accuracy out of all five accuracies that were compared 
Figure 5.2. VIP scores and PLSDA identified a signature of 7 serum proteins that differentiated a stable from 
exacerbation measurement in 16 paired stable and AE-COPD events experienced by 11 unique patients. 
(A) VIP scores identified a 7-protein serum signature that differentiated stable (purple) and exacerbation (orange) events with 
81.25% cross-validation accuracy and 84.38% calibration accuracy. Latent variable 1 (LV1) accounted for 25.00% of the 
variance in the data, and latent variable 2 accounted for 16.75% of the variance in the data. (B) The loadings plot shows how 
much each protein contributes to the signature, with positive loadings associated with exacerbation events, and negative 
loadings comparatively reduced in exacerbation. (C) Comparison of the differentiation between stable and exacerbated states 
based on individual factors vs. multivariate signatures. The VIP signature identified by the PLSDA models trended towards 
higher cross-validation accuracy than individual factors that were most significantly different. A one-way ANOVA determined 
that this signature was significantly better than IL-15 alone, with ** indicating a p-value less than 0.01 after Tukey’s test for 
multiple comparisons. (D) Comparison of the calibration accuracies for individual factors vs. the VIP signature identified by 





(Figure 5.2D). Overall, these figures serve to highlight the use of co-varying features, or 
“signatures,” in differentiating exacerbation events. 
5.4.4 Insight into cross-tissue compartment proteomic interactions associated with AE-
COPD 
To gain deeper insight into relationships between immune factors in lung and serum 
tissue compartments involved in AE-COPD, we used PLSDA to integrate data from serum and 
sputum measurements in stable and exacerbated states. We first evaluated proteins for which 
both paired sputum and serum results were available (n=9 matched stable and AE 
measurements), creating a PLSDA model based on 60 total analytes and employing VIP feature 
selection to eliminate those not contributing to differentiation. A one-latent variable PLSDA 
model separated exacerbation and stable measurements with a cross-validation and calibration 
accuracy of 88.89%, though a two-latent variable PLSDA model scores plot is presented to 
facilitate interpretation of group clustering (Figure 5.3A). LV1 largely differentiated the stable 
Figure 5.3. A one latent variable PLSDA model of VIP-selected proteins from the serum and sputum samples combined 
resulted in clear differentiation between stable and exacerbation measurements across 9 paired stable and AE-COPD 
events experienced by 7 unique patients. 
 
(A) PLSDA and VIP scores identified a signature of 19 proteins that differentiated the stable (purple) from exacerbation 
(orange) states with 88.89% cross-validation and calibration accuracy. Latent variable 1 accounted for 21.73% of the variance 
in the data. The scores plot shown is based on a two latent variable model to enable better visualization of group separation. (B) 
The loadings plot illustrates the protein contributions to the VIP-selected signature, with positive loadings positively associated 
with the exacerbation measurements, and negative loadings comparatively reduced during exacerbation. 
A B 
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state (negative scores on LV1) from AE-COPD (Figure 5.3B). Fourteen of the nineteen proteins 
were loaded positively on LV1, indicating positive association with AE-COPD, whereas five 
proteins were associated with stable COPD. Of the fourteen proteins that were positively 
associated with exacerbation, many of the serum proteins have been established as adhesion 
factors or chemokines (sICAM-1228, sVCAM-1229, IP-10230, MCP-2231), while most of the 
sputum proteins were known inflammatory factors (IL-6232, IL-1β233, TNFR-2234). Similar to the 
serum-only model, this signature suggests migration and activation of innate immune cells in the 
serum during exacerbation, yet the addition of sputum data to the model demonstrates the 
corresponding importance of lung inflammation and chemokine secretion. As classification 
accuracy of the combined serum-sputum model was better than either separately, these results 
highlight the importance of the parallel relationship between chemokine secretion in lung and 
innate immune cell activation in serum. 
5.4.5 Integration of data across experimental assays gives additional insight into the 
cellular and proteomic mechanisms associated with AE-COPD 
We also used our systems approach to integrate data across experimental assays by 
adding flow cytometry measurements, which were performed only on whole blood samples. We 
specifically explored whether PLSDA might help us integrate measurements made in different 
experimental assays. PLSDA and two rounds of VIP selection identified a one-latent variable 
model and a signature of eleven cell markers and proteins that differentiated stable COPD from 
AE-COPD with a cross-validation accuracy and a calibration accuracy of 87.5%. Differentiation 
between states (Figure 5.4A) was driven by the loadings on LV1, which separated most 
individuals by exacerbation status (Figure 5.4B). Nine of the cytokines and cell markers were 
loaded positively on LV1, indicating positive association with exacerbation, and two were loaded 
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negatively on LV1, indicating negative association with exacerbation. Cellular factors associated 
with exacerbation in the integrated PLSDA model included CD86 expression by BDCA-3+ 
dendritic cells (DC) and the percentage of CD15+ granulocytes (reported in the original study to 
be neutrophils)91. In contrast, the percent of CD4+ T-cells was found to be associated with the 
stable measurements in this model.   
We next compared the cross-validation accuracies across all three of the VIP-selected 
models that consisted of varying amounts of tissue compartment and assay data. Although none 
of these three models were significantly different from each other according to Tukey’s post hoc 
test (one-way ANOVA), inclusion of data from more tissues and assays in the model trended 
toward a tighter and higher range of cross-validation accuracies (Supplemental Figure C.S5). 
 To visualize the unbiased classification ability of this signature, we also employed 
hierarchical clustering and created a heat map (Supplemental Figure C.S6). We found this 
clustering algorithm based on distance metrics was not as useful for classification, with three 
Figure 5.4. A one latent variable PLSDA model based on two rounds of VIP selection from serum and sputum proteins 
and blood flow markers shows clear differentiation between stable and exacerbation events across 8 pairs of patient 
samples, which included 7 paired stable and AE-COPD events experienced by 6 unique patients and one stable and one 
exacerbation measurement that were not patient matched. 
 
(A) PLSDA and two rounds of VIP analysis identified a signature of eleven factors that differentiated the stable (purple) from 
the exacerbation (orange) events, with 87.5% calibration and cross-validation accuracy. Latent variable 1 (LV1) accounted for 
41.51% of the variance in the data. The scores plot shown is based on a two latent variable model to enable better visualization 
of group separation. (B) The loadings plot highlights factor contributions to the VIP-selected signature, with positive loadings 
positively associated with AE-COPD, and negative loadings comparatively reduced during an exacerbation event. 
A B 
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stable and four exacerbation samples misclassified out of sixteen total samples (56.25% 
classification accuracy). As our data contained measurements from three individuals with more 
than one exacerbation event, we also examined our scores plot after labeling the points with the 
patient’s exacerbation status and visit number. The resulting scores plot (Supplemental Figure 
C.S7) indicates no clear intra-patient clustering, though this study was not powered for a 
thorough statistical analysis in this direction.  
We further explored potential relationships between cell numbers and protein 
concentrations across the stable and exacerbated states in our identified signatures using 
Spearman rank correlation coefficients and a heat map. Overall we found that MMP-9 in the 
serum was positively correlated with CD4+ cells expressing the IL-18 receptor, and TIMP1 in 
the serum was positively correlated with CD4+ cells expressing the CD122 activation marker. 
The BDCA3+ CD86+ and the %CD15 neutrophils were not correlated with the other proteins in 
the signature, but were correlated with other measured proteins (Supplemental Figure C.S8).  
Overall, this suggests that changes in cell number from the stable to the exacerbated state may be 
related to simultaneous increases in concentration of some inflammatory proteins across the two 
states. 
5.5 Discussion 
Using systems analysis of paired data points from cellular factors measured in blood and 
sputum in exacerbated and stable COPD states, we identified a signature that differentiated AE-
COPD with >87% cross-validation accuracy. This signature trended towards being better than 
any previously identified individual cellular factors for differentiating stable and exacerbated 
COPD states, though more measurements would be needed to determine statistical significance. 
Biologically, the signature indicated that parallel increases in inflammatory cytokines and 
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chemokines in sputum environments, adhesion/chemoattractive cytokines in serum 
environments, and greater numbers of BDCA-3+ DC and an increased percent of CD15+ 
neutrophils in the blood were all associated with AE-COPD. These results highlight the value of 
computational approaches when integrating measurements across tissue compartments and from 
different experimental assays, and motivate use of these approaches to gain new perspective into 
cellular systems involved in this prevalent, lethal, but understudied disorder.   
One important strength of our approach is the ability to define parsimonious cellular 
signatures by selecting the most significant co-varying cellular immune factors. This approach 
may be valuable as a means of defining key cellular systems involved in disease progression, and 
using these to efficiently choose end-points in clinical trials and guide future experimental 
endeavors. This approach is especially useful for integrating cellular measurements made in 
multiple tissue compartments, which is important given the central role of sputum production in 
AE-COPD. Based on these findings, we propose a model of key networks in AE-COPD (Figure 
5.5) involving specific immune cell types, metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs), and chemokines. We discuss our findings in that framework. 
In terms of peripheral blood leukocyte participation in AE-COPD, we extend the 
observation from univariate analysis of these data91 that CD4+ T cells decreased in blood during 
exacerbation, which is compatible with trafficking to lung or regional lymph nodes (or both), by 
showing the importance of simultaneous increase in blood of BDCA-3+ DC. We have previously 
demonstrated the physical interaction of this DC subset with CD4+ T cells in lung tissue from 
COPD patients235. BDCA-3+ DC were previously termed mDC2, but are now designated as 
cDC1236; they are the counterpart of murine CD103+ DC, which are essential for cross-
presentation of viral antigens to CD8+ T cells. Our model suggests recruitment to the lungs of 
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cDC1, likely from the bone marrow, as a crucial step driving lung inflammation during AE-
COPD. The other type of leukocyte in our signature, neutrophils, has been shown by other 
studies to be linked to AE-COPD237, one of which related their numbers to exacerbation 
severity210.   
Key soluble factors in our signature agree with and extend previous individual 
associations of inflammatory mediators with AE-COPD. These not only include the anticipated 
agreement with previous univariate analysis of these data91, but also several serum proteins 
involved in adhesion and chemoattraction of inflammatory cells. Chief among these is the 
neutrophil chemoattractant IP-10/CXCL10, also found to be elevated in AE-COPD in two 
studies89,92. Our signature also included IL-6, a pro-inflammatory cytokine232 that has been 
vigorously investigated as a possible biomarker for AE-COPD. Increased IL-6 in serum and 
Figure 5.5. A hypothesis of cross-tissue mechanisms of action in the lungs and blood of patients experiencing an AE-
COPD. 
Adhesion molecules aid in moving immune cells from the blood to the lung, which is further promoted by the presence of the 
chemokine interferon gamma-induced protein 10 (IP-10) and monocyte chemoattractive protein 2 (MCP-2) in the sputum. 
sICAM: soluble intercellular adhesion molecule. sVCAM: vascular cell adhesion molecule. TIMP: tissue inhibitor of 
metalloproteinases. MMP: matrix metalloproteinase. R2: receptor 2. ECM: extracellular matrix. CD: cluster of differentiation. 
BDCA: blood dendritic cell antigen. 
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sputum during AE-COPD was reported by several large studies using longitudinal design92,238; 
this association was questioned in a systematic review which, however, included many studies of 
cross-sectional design239. Our results illustrate the superior power of comparing paired results 
from the same subjects across stable and exacerbated states. We also identified elevations in 
levels of sICAM-1 and sVCAM-1, truncated forms of transmembrane adhesion molecules that 
interact with leukocyte integrins. sVCAM is chemotactic for murine neutrophils in vitro240. 
sICAM-1 is expressed both by leukocytes and by activated endothelial cells, and levels of 
sICAM-1 correlate to endothelial cell ICAM expression in vitro230. Each of these proteins are 
elevated in stable COPD241,242, though to our knowledge, no study (other than our original data) 
has linked it to AE-COPD in longitudinal data. sICAM has been reported to be elevated in 
subjects admitted for AE-COPD compared with healthy control subjects243. Higher plasma 
sICAM-1 levels were also independently associated with emphysema progression in the Multi-
Ethnic Study of Atherosclerosis (MESA) Lung cohort, a general population sample244. 
Our signature identified elevated serum MMP-9 as a crucial feature of AE-COPD, in 
agreement with a previous study245. Also known as gelatinase B, MMP-9 is released by activated 
neutrophils246. It has an unique ability to induce self-perpetuating lung inflammation by 
degrading extracellular matrix, thus liberating the neutrophil chemoattractant tripeptide N-acetyl 
Proline-Glycine-Proline231. Along with IL-6, MMP-9 was one of 34 serum analytes found to be 
highly reproducible over a 6 week period of clinical stability in COPD patients247, further 
supporting our findings. Our MMP-9 finding is interesting in light of the disparity between the 
association with exacerbation of TIMP1, TIMP2, and TIMP3, which stoichiometrically inhibit 
MMP activity248,249, and TIMP4, which associated with the stable state in the VIP signature.  
Unlike the other three TIMP family members, which act as soluble inhibitors, TIMP3 is typically 
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bound to matrix sulfated glycosaminoglycans248, suggesting that its presence in the serum during 
AE-COPD might reflect matrix degradation.  
All of our models identified IL-1R2 as a crucial serum factor increased during AE-
COPD, in agreement with two studies from the group in Maastricht of patients admitted for AE-
COPD250,251. IL-1R2 (Gene ID: 7850) is an early response gene252 whose product is a decoy 
receptor that inhibits activity of its three ligands: IL-1α, IL-1β, and the type I IL-1 receptor. 
Together with associations for TIMP1-3, our results highlight the importance of counter-
regulatory factors during AE-COPD. Although all the subjects in the original dataset were 
successfully treated as outpatients with resolution, not all patients regain lung function following 
AE-COPD; an intriguing possibility is that those who do not recover entirely might exhibit 
relatively deficient up-regulation of IL-1R2 and TIMPs during AE-COPD. 
There are several limitations to this analysis. Although our original study91 recruited a 
larger group of subjects, many sought treatment for AE-COPD locally, rather than returning 
when acutely ill. Additionally, some measurements had to be excluded from this analysis due to 
missing data. Collectively, these factors reduced our sample size, making it all the more 
noteworthy that our approach identified AE-COPD cellular signatures that could be used to gain 
biological insight. However, the small sample size did limit our ability to find signatures that 
could be used in diagnostic contexts. Even though our identified signature trended towards being 
better than individual factors, it was only statistically significant in one case. Furthermore, 
additional unknown test data in different patient cohorts would be needed to truly assess 
signature classification ability for diagnostic purposes. A second limitation is the necessary 
dependence on proteins measured in the original study, which used a “candidate gene” approach 
based in part on prior knowledge, and not an unbiased screen of the entire proteome.  Because 
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our original study involved flow cytometric analysis of peripheral blood leukocytes collected in 
part during AE-COPD, there is, to our knowledge, no current exacerbation cohort available for 
validation testing.  However, to prevent model overfitting as much as possible, we did employ 
internal cross-validation.  
  Results of this work support exciting future research in several directions. First, if 
similar data from other cohorts of paired stable and exacerbation measurements were to become 
available, generated models could be tested and validated. Data-driven approaches such as these 
could be applied as a classification tool to identify differences in exacerbation endotypes or in 
AE-COPD events resulting from different upstream causes (including viruses, bacteria, etc.), 
thus providing insight into systems-level mechanisms of action that could result in personalized 
treatment options. Unbiased data-driven models applied to multiplex COPD data from across 
tissue compartments may also prove useful to characterize COPD endotypes.      
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Chapter 6 Proteomic Signatures and Immune Cell-Cell Communication Patterns in a 
Large Clinical Cohort Associated With COPD Disease State and Severity 
 
Contributions. The SPIROMICS investigators were involved in collecting the blood and 
BAL samples from the SPIROMICS smokers, never smokers, and COPD subjects. Drs. Curtis 
and Freeman collected whole blood from subjects for PBMC isolation, stored these samples until 
stimulation, and, along with lab manager Valerie Stolberg, assisted in the PBMC stimulation 
experiments planning and execution.  
6.1 Introduction 
Following work presented in Chapter 5, we generated additional models of COPD cell-
cell communication networks, disease state, and disease severity that have not been published. 
For this work we had access to data and samples from smokers, never smokers, and COPD 
subjects enrolled in the Subpopulations and Intermediate Outcomes in COPD Study 
(SPIROMICS)253, which was extremely valuable due to the cohort’s large size (2,981 subjects 
recruited to the overall study), the variety of clinical data and matched biological samples 
available from some patients, and the 5 year follow up visit for these patients associated with the 
SPIROMICS II study which are currently underway. The SPIROMICS II visits are of key 
interest to us because they will involve the collection of another set of clinical measurements 
(FEV1, CT scans, etc.) and biological samples (blood, BAL, etc.) from many of the original 
subjects, which would allow for investigations into progression. Although 2,981 subjects 
participated in SPIROMICS overall, a subset of these subjects also qualified for enrollment in 
the Bronchoscopy study and had BAL samples collected on top of blood, sputum, and CT scan 
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measurements (n = 215)254. In the end, around 190 smokers, never smokers, and COPD subjects 
(mostly classified with mild to moderate COPD) were enrolled in the Bronchoscopy substudy. 
These matched blood and BAL samples from subjects allowed us to fulfill Aims 2B and 3B by 
creating data-driven models based on BAL proteins alone and based on blood and BAL proteins 
combined. Once identified, we were able to further investigate the signatures’ potential 
biological meaning in the context of COPD disease state and severity. Additionally, with help 
from Drs. Curtis and Freeman at the Veteran’s Affairs Ann Arbor Healthcare System 
(VAAAHS), we were also able to collect whole blood samples from another group of smokers, 
never smokers, and COPD subjects visiting the VAAAHS and isolate peripheral blood 
mononuclear cells (PBMCs) from these samples. We then compared differences in PBMC 
communication networks of the three groups in response to various immune stimuli by creating 
data-driven models of the secreted proteins during these stimulations, which satisfied Aim 1B. 
As discussed in Chapter 1, the mechanisms that underlie COPD disease state and 
progression are complex and not well understood, and thus new approaches must be taken in 
order to gain insight into this area. Some of the difficulty in studying COPD comes from the 
heterogeneity associated with the disease. Examples of this heterogeneity include the lack of 
concrete biomarkers for COPD or exacerbations94,255,256; the current conversations about defining 
an early COPD state, which focus on how it is still unknown why some people (especially 
smokers) develop COPD when others do not257,258; and the research into different underlying 
endotypes that could result in the same COPD phenotype94,259,260. The conversations about early 
COPD come from the fact that smokers and COPD subjects may be more similar than we 
currently realize, as it has been seen that smokers without airway obstruction are still more likely 
to experience negative respiratory events when compared to never smokers261,262. This could 
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mean that models of COPD disease state that contain smokers, never smokers, and COPD 
subjects may hold more diagnostic or prognostic value than our model of healthy and IPF 
subjects (Chapter 2 and 4). To investigate these topical questions about COPD further, other 
large longitudinal cohorts of smokers, never smokers, and COPD subjects have been created in 
addition to SPIROMICS, such as the Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate End-points (ECLIPSE) study263 and COPDGene264.  
The SPIROMICS cohort enabled us to apply data-driven modeling approaches to 
integrate matched lung and blood protein data collected from enrolled subjects, similar to our 
approach in IPF (Chapters 2-4). With the SPIROMICS samples, as we did in IPF, we wanted to 
create models that took advantage of proteins that were measured in bronchoalveolar lavage 
(BAL) samples to gain insight into lung-specific signatures associated with disease state or 
progression. There has been more work with BAL protein data in COPD disease state and 
progression than in IPF265–273, but few studies have measured more than 10 proteins in each 
sample274–277, and fewer still that have focused on the use of multiple BAL proteins to 
differentiate clinical groups278,279. To our knowledge, although single cytokines across blood and 
BAL samples have been investigated in the context of COPD disease state or severity271,280–284, 
this work is the first time that signatures of blood and BAL proteins have been used to 
differentiate and hypothesize potential mechanisms associated with COPD disease state or 
severity. This presents the opportunity for us to generate unique insight into cross-tissue 
compartment mechanisms in human subjects that may potentially be involved with COPD 
disease state or severity. 
Though it is clear that the immune system is altered in COPD66, previous evaluation of 
individual immune cell types and cytokines has not yet led to definitive biomarkers or broadly 
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effective treatment options80,82,285. In addition to current literature, our work which we will 
discuss in this chapter suggests that circulating blood cytokines alone are not useful for 
differentiating COPD disease state. However, previous work from the HIV field suggests that 
stimulation of immune cells from whole blood samples can be used to both gain insight into 
adverse immune responses associated with immunological diseases, and to design targeted 
follow-up experiments to test newly generated hypotheses205. This was achieved by collecting 
and culturing PBMCs (which include T cells, B cells, NK cells, and monocytes) in the presence 
of various innate and adaptive immune stimuli, such as lipopolysaccharide (LPS) or anti-
CD3/CD28 beads205. In the second part of this chapter, we describe preliminary results in 
applying this approach to identify systems-level differences in immune cell communication 
networks of smokers, never smokers, and COPD subjects. 
6.2 Results 
6.2.1 Models based on signatures of proteins from multiple tissue compartments led to 
better classification of COPD disease state and severity 
We first wanted to determine whether there were differences in individual cytokines 
measured in BAL samples from smokers, never smokers, and COPD subjects. We measured 
individual expression of cytokines in these groups and investigated if there were any significant 
differences in expression of any of these proteins. Using a one-way ANOVA with Tukey’s post 
hoc test, we saw that 11 out of 25 measured proteins were significantly differentially expressed 
across at least two of the clinical groups; a selection of these results can be seen in Figure 6.1.  
Due to the variation within individual expression of measured BAL proteins, we next 
employed data-driven analysis techniques to try to obtain more biologically meaningful 
separation of the clinical groups when focusing on covariation between proteins. VIP-scores 
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selected and PLSDA visualized a 
signature of 18 BAL cytokines that 
differentiated the three groups with 
75.31% calibration and 71.76% cross-
validation accuracy (Figure 6.2A). 
Samples showed trends towards 
separation on latent variable 1 (LV1), 
with COPD subjects having higher 
scores on LV1 (Figure 6.2B). 
We then determined if the 
classification ability of circulating, 
unstimulated blood cytokines was 
better than that of BAL proteins in 
differentiating COPD disease state. 
VIP scores selected a signature of 22 
Luminex-measured cytokines that differentiated the three groups with 65.69% calibration and 
57.88% cross-validation accuracy (Figure D.1A). Little differentiation could be seen across LV1 
or LV2 (Figure D.1B). Due to the poor performance of this model, we then used the feature 
selection technique LASSO to identify a signature of 24 SOMAmer-measured blood proteins 
that differentiated the groups with 74.56% calibration and 67.59% cross-validation accuracy 
(Figure D.2A and D.2B). While this model outperformed the one based only on plasma 
cytokines, the model based on BAL proteins still had the highest calibration and cross-validation 







Figure 6.1. (A-I) Representative individual cytokine measurements 
from BAL samples from smokers with (red) and without (gray) 
COPD and healthy controls (purple) enrolled in the SPIROMICS 
study. * p < 0.05, ** p < 0.01; one-way ANOVA with Tukey’s post 
hoc test. n = 25 never smokers, 75 smokers, and 82 COPD patients. 
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such as current smoking status were not able to be corrected for when using VIP scores as a 





Figure 6.2. Feature selected PLSDA model based on blood and BAL protein data combined differentiates COPD disease 
state significantly better than models based only on protein data from a single tissue compartment. 
(A) PLSDA scores plot based on BAL proteins moderately separates smokers (grey), never smokers (purple), and COPD subjects 
(red) with 75.31% calibration (Cal) and 71.76% cross-validation (CV) accuracy. (B) PLSDA loadings plot captured 12.27% of 
the variance on latent variable 1 (LV1). (C) PLSDA scores plot based on blood and BAL proteins highlights differentiation 
between the three clinical groups; the model separated the groups with 86.18% Cal and 76.52% CV accuracy. (D) The loadings 
on LV1 captured 7.26% of the variance in the data. (E, F) The cross-tissue compartment model trended towards higher Cal 
accuracy (E) and had significantly higher CV accuracy (F) than models based on blood or BAL proteins alone. Significance in 
both cases calculated by a one-way ANOVA with Tukey’s post-hoc test; ** indicates p < 0.01 and * indicates p < 0.05. 
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We discovered that a model based on protein data from multiple tissue compartments was 
a better classifier of COPD disease state and could be useful in gaining a deeper understanding of 
holistic relationships associated with COPD. We used LASSO to identify a signature of 37 
proteins (31 from the blood and 6 BAL proteins) that differentiated smokers, never smokers, and 
COPD subjects with 86.18% calibration and 76.52% cross-validation accuracy (Figure 6.2C). 
The three groups were separated by scores on LV1 (Figure 6.2D), where the COPD subjects 
(red) had the most positive scores on LV1, the never smokers (purple) had the most negative 
scores on LV1, and the smokers (grey) fell in between the other two groups.  
We next wanted to determine if the PLSDA model based on the combination of blood 
and BAL proteins was a better classifier of COPD disease state than data-driven models based on 
signatures of blood or BAL proteins alone. To illustrate this, we compared the calibration and 
cross-validation accuracies of our cross-compartment model with other feature-selected PLSDA 
models based on single tissue compartments: our model based only on 24 LASSO-identified, 
SOMAmer-measured blood proteins (Figure D.2A and D.2B), and our model based only on 18 
VIP-selected, Luminex-measured BAL proteins (Figure 6.2A and 6.2B). The model based on 
blood and BAL proteins combined trended towards having higher calibration accuracy than the 
model based on blood or BAL proteins alone (Figure 6.2E, one-way ANOVA with Tukey’s post 
hoc test). Additionally, this combination model was found to be significantly better in terms of 
cross-validation accuracy than the blood model alone or the BAL model alone (Figure 6.2F, p < 
0.05 for both comparisons, one-way ANOVA with Tukey’s post hoc test), which indicates that 
the combination model might be able to handle unseen data better than the models based on 
proteins from one tissue compartment.  
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The database for annotation, visualization and integrated discovery (DAVID) determined 
that the positively loaded proteins on LV1 that were comparatively increased in COPD subjects 
and some smokers were significantly enriched for processes related to cytokine activity and the 
immune and defense response (Figure 6.3, enrichment score (ES) 1.94). Proteins that were 
negatively loaded on LV1 and comparatively increased in never smokers and in most of the 
smokers were enriched for processes involving the positive regulation of general cellular 
processes such as those related to metabolism, cell communication, signal transduction, and 
phosphorylation (Figure D.3A, ES 2.27), as well as regulation of the response to external stimuli 
(Figure D.3B, ES 1.92). 
Interestingly, when we examined the correlations between expression of the proteins in 
the blood and BAL combined signature within the smokers, never smokers, and COPD subjects 
separately, we found that the smokers and the COPD subjects had correlations that were weaker 
(lower Pearson’s correlation coefficient value) than those seen in the never smokers but 
contained more hub proteins. The protein correlation network of the never smokers contained 
one protein that had 5 significant correlations to other proteins in the signature (Figure 6.4A). 
Figure 6.3. DAVID identified a cluster of significant pathways (Bonferroni corrected p < 0.05) involving cytokine activity 
and the inflammatory and defense response that was enriched in proteins that were comparatively increased in the COPD 
subjects in the LASSO-identified cross-tissue compartment signature. This cluster had an enrichment score (ES) of 2.57. 
Proteins found in the BAL in the signature are marked as so; unmarked proteins come from the blood samples. 
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However, the correlation network based on the signature proteins’ expression in smokers had 17 
proteins with 5 or more significant correlations (Figure 6.4B), and the network based on COPD 
subjects contained 5 proteins with 5 or more significant correlations (Figure 6.4C). Additionally, 
when comparing the strength of the connections in the networks, we saw that smokers had a 
larger number of significant correlations (77 correlations) than never smokers (53 correlations) 
and COPD subjects (52 correlations), but that the never smokers had correlations that were 
significantly stronger in terms of the absolute value of the Pearson’s correlation coefficient than 
those present in the smoker and COPD subject networks (p < 0.0001 for both comparisons with 
the never smoker network, one-way ANOVA with Tukey’s post hoc test).  
We next used this approach to determine whether a combined signature of blood and 
BAL proteins was able to differentiate COPD patients with differing levels of disease severity 
according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines to 
gain understanding into potential cross-tissue compartment proteomic relationships associated 
Figure 6.4. Protein correlation networks of the LASSO-identified blood and BAL protein signature present in never 
smokers (A), smokers (B), and COPD subjects (C) illustrate highly significant correlations and few hub proteins in the 
never smoker network.  
A B 
C 
Lines connecting two proteins indicate a significant correlation (p < 0.05) as determined by Pearson’s correlation coefficient. 
Brighter and thicker lines indicate a stronger and more significant correlation, respectively, with color bar on the right 
displaying the value of the correlation coefficient. Red indicates a positive correlation. 
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with disease severity. LASSO identified a signature of 38 SOMAmer-measured blood and 3 
Luminex-measured BAL proteins that differentiated the three GOLD stages with 95.05% 
calibration and 78.76% cross-validation accuracy (Figure 6.5A). LV1 separated three stages of 
disease severity, with GOLD 1 subjects having negative scores on LV1, and GOLD 2 and GOLD 
3 subjects having positive scores on LV1, with GOLD 3 having the most positive scores on LV1 
(Figure 6.5B). 
We next examined whether this signature based on blood and BAL proteins was better at 
differentiating the three GOLD stages than models based on blood or BAL proteins alone. We 
Figure 6.5. LASSO-identified signature of blood and BAL proteins differentiates GOLD status significantly better than 




(A) A LASSO-identified signature of blood and BAL proteins was able to differentiate COPD subjects with GOLD 1, 
GOLD 2, and GOLD 3 disease severity classification with 95.05% calibration (Cal) and 78.76% cross-validation (CV) 
accuracy. (B) The loadings plot captured 7.29% of the variance in the data on latent variable 1 (LV1). (C, D) The PLSDA 
model based on a signature of blood and BAL proteins significantly outperformed a model based only on BAL proteins in 
terms of Cal (C) and CV (D) accuracy, and trended towards having higher accuracy than a model based on blood proteins 
alone. Significance in both cases calculated by a one-way ANOVA with Tukey’s post hoc test; ** indicates p < 0.01 
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compared the calibration and cross-validation accuracies of the model based on blood and BAL 
proteins combined with a model based on a LASSO-identified signature of 29 SOMAmer-
measured blood proteins (Figure D.4A and D.4B) and a model based on a VIP-selected 
signature of 13 BAL proteins (Figure D.5A and D.5B). Our model based on blood and BAL 
proteins combined had significantly higher calibration (Figure 6.5C) and cross-validation 
(Figure 6.5D) accuracy than the model based BAL proteins (p < 0.01, one-way ANOVA with 
Tukey’s post hoc test for both comparisons), and trended towards having higher accuracies than 
the model based only on blood proteins. 
6.2.2 PBMCs from smoker, never smoker, and COPD patients secrete distinct cytokine 
patterns in response to innate stimuli 
We first looked at the differences in expression of 29 Luminex-measured proteins in 
response to stimulation with lipopolysaccharide (LPS) across PBMC cultures from smokers, 
never smokers, and COPD subjects using a one-way ANOVA with Tukey’s post-hoc test. The 
only difference in 
expression that was found 
to be significant (p < 0.05) 
was between the never 
smoker and COPD subject 
expression of IP-10; all 
other comparisons were 
found to be not significant. 
This result highlights the 
individual differences in 
Figure 6.6. (A-I) Representative individual cytokine measurements from PBMCs of 
smokers with (red) and without (gray) COPD and healthy controls (purple) after in 
vitro stimulation with LPS. * p < 0.05. 
A B C 
D E F 
G H I 
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response to LPS across the three disease states, which makes it difficult to generate testable 
hypotheses. The significant IP-10 result and a selection of some of the other non-significant 
results can be seen in Figure 6.6.  
We then turned to data-driven modeling techniques to try to identify signatures of 
covarying proteins that could differentiate the PBMC responses to various immune stimuli across 
smoker, never smoker, and COPD subjects. In contrast to our univariate results, we saw a 
PLSDA model coupled with VIP feature selection led to a model that differentiated the PBMC 
responses of smokers (n = 7), never smokers (n = 6), and COPD subjects (n = 3) to a LPS 
stimulus with 98.72% calibration and 70.81% cross-validation accuracy (Figure 6.7A). The 
cross-validation accuracy may be slightly lower in this model due to the fact that there were so 
few COPD subjects, making it difficult to predict their secreted response in unseen cases. While 
we also saw similar results in the PLSDA models of the PBMC responses to other innate stimuli 
(the VIP-selected PLSDA model of stimulation with R848 had 88.19% calibration and 71.96% 
cross-validation accuracy and a model based on stimulation with Poly(I:C) had 88.76% 
Figure 6.7. Data-driven modeling techniques are able to achieve better separation of the PBMC response of smokers, 
never smokers, and COPD subjects to innate immune stimuli as opposed to adaptive. 
A B 
(A) The PLSDA scores plot shows the smokers (grey), never smokers (purple), and COPD subjects (red) clustering in 
different areas of the plot. The VIP-signature of the PBMC’s secretome in response to an LPS stimulus performed with 
98.72% calibration (Cal) and 70.81% cross-validation (CV) accuracy in a PLSDA model. (B) The PLSDA scores plot 
generated based on the PBMC’s secreted response to a co-incubation with anti-CD3/CD28 beads does not separate the 
three clinical groups, performing only with 76.92% Cal and 59.33% CV accuracy. 
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calibration and 69.35% cross-validation accuracy), a VIP-selected PLSA model based on the 
adaptive stimulus of anti-CD3/CD28 beads only had 76.92% calibration and 59.33% cross-
validation accuracy (Figure 6.7B).  
6.3 Discussion 
In this work, we used secreted proteins from in vitro cultures and proteomics data from a 
clinical trial to identify differentiating signatures and gain insight into potential mechanisms 
associated with COPD disease state and progression. Our preliminary analysis of immune cell 
communication networks in COPD suggests that the innate immune response of COPD PBMCs 
may be more different than that of smokers and never smokers, while the adaptive immune 
response of all three groups may be more similar. BAL cytokines were better at differentiating 
COPD disease state than models based only on plasma cytokine or blood protein data. However, 
we saw stronger differentiation of COPD disease state and GOLD status when signatures 
included data from multiple tissue compartments. Proteins that were comparatively increased in 
COPD subjects in the model of COPD disease state were enriched for cytokine activity and the 
immune and defense response. Additionally, in models of both COPD disease state and GOLD 
status, we reported that models based on data from multiple tissue compartments either trended 
towards or were significantly better in terms of calibration and/or cross-validation accuracy than 
models based on single tissue compartments. Overall, these results highlight the usefulness of 
data-driven models to take in a wide variety of clinically-relevant data and identify patterns that 
lead to increased insight into important factors involved in COPD disease state and progression. 
We discovered that a model based on BAL cytokines was clearly better at differentiating 
COPD disease state than a model based on blood cytokines, and was also slightly more accurate 
than a model based on the blood SOMAmer measurements. This last point speaks to how much 
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COPD affects cytokine expression in the lung compared to protein expression in the blood, 
especially considering that only 25 cytokines were measured in the BAL, whereas 1305 blood 
proteins were measured by SOMAmers. The BAL model outperforming models based on blood 
proteins echoes results reported by Halper-Stromberg et al. in their analysis of the SPIROMICS 
cohort as well. They saw that there were a higher number of proteins measured in BAL samples 
than in plasma samples that were associated with variables such as FEV1/FVC, emphysema, 
FEV1 % predicted, and COPD exacerbations
274. Additionally, we created a model based on 
sputum proteins that was able to differentiate stable and AE-COPD better than a model based on 
blood proteins (Chapter 5) in terms of calibration accuracy, but the two models had similar 
cross-validation accuracies. These results suggest that BAL cytokines may serve as better 
differentiators of COPD disease state than unstimulated proteins from the blood, especially when 
the number of measured blood proteins is low. 
We identified that data-driven modeling techniques were able to identify differences in 
the responses of PBMCs from smokers, never smokers, and COPD subjects to innate immune 
stimuli, but not as much to adaptive immune stimuli. These models of cell signaling networks in 
PBMCs post-innate immune stimulation exhibited high calibration accuracy but only moderate 
cross-validation accuracy, which is most likely due to the low number of COPD subjects that 
were included in the analysis (n=3). These were promising results especially in comparison to 
the low calibration and cross-validation accuracy seen in the models of blood proteins in the 
SPIROMICS participants. It is especially promising that PBMC collection is a low-risk 
procedure for patients, but that we saw strong differentiation given our sample size. Although 
these preliminary results are suggestive of greater differences in the immune response of myeloid 
cells across smokers, never smokers, and COPD patients compared to the immune response of T 
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cells, we could not dive deeper into the biological implications of any of our PBMC cell-cell 
signaling signatures due to the low sample size. However, other researchers have been able to 
investigate PBMC-based differences associated with COPD. Kawayama et al. stimulated PBMCs 
from smokers, never smokers, and COPD subjects with LPS and TNF-α, but did not report any 
significant differences in measured cytokines (MMP-9, TNF-α, IL-8, and IL-6) post 
stimulation286. They did notice that COPD PBMCs had the highest change in protein production 
post-stimulation, and suggested that PBMCs in COPD subjects are primed and ready to 
immediately respond to any immune stimuli286. Another study investigated differences in PBMC 
gene expression across smokers and COPD subjects and found that IL-16 mRNA levels were 
negatively correlated with upper lobe emphysema287. Taken together, this is suggestive of the 
usefulness of PBMC collection and study: either stimulation experiments or multi-omics 
analyses of these cells could help us identify, potentially understand, and, in the future, target 
cell signaling pathways that may be dysregulated in COPD. 
Lastly, we have shown that combining data across multiple tissue compartments can lead 
to better differentiation when investigating both COPD disease state and progression as defined 
by GOLD guidelines. Both of our models either trended towards being or were significantly 
better in terms of calibration and cross-validation accuracy than models based on proteins from 
one tissue compartment. According to the prior knowledge database DAVID, the proteins 
comparatively increased in the COPD patients in the multiple tissue compartment signature of 
disease state were enriched for cytokine activity and the immune and defense response. Hogg et 
al. has reported that in a cohort of GOLD 0 – 4 subjects, the number of inflammatory immune 
cells (polymorphonuclear leukocytes, macrophages, CD4+ and CD8+ T cells, and B cells) in 
lung tissue samples were found at higher numbers in patients with higher GOLD classification68. 
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The more inflammatory cells in the lung could possibly be an indicator for increased cytokine 
activity and immune response. These results highlight the importance of cytokine activity 
associated with COPD over smokers and never smokers that is independent of current smoking 
status. Based on protein correlation coefficient networks of the cross-tissue compartment 
signature in the smokers, never smokers, and COPD patients, we have hypothesized that the 
protein network in never smokers is more difficult to perturb. This is due to the never smoker 
network having a smaller number of hub proteins compared to the smoker and COPD network, 
and to it having highly significant correlations present within the network. Although there were 
no processes that were significantly enriched in the signature of COPD GOLD status according 
to DAVID, the signature did contain two complement proteins (complement 7 and 9) that were 
comparatively increased in GOLD 2 and 3. Complement proteins have been identified as being 
differentially expressed across COPD GOLD stages before: Baralla et al. reported that 
complement 4B was significantly decreased in GOLD 2 compared to GOLD 1 when comparing 
expression using two-dimensional gel electrophoresis288. Although these results suggest that 
complement system activity may be associated in some way with COPD GOLD status, our 
model of GOLD status was only based on GOLD 1-3, with only eight GOLD 3 patients being 
included. Thus these results need to be reconfirmed after the addition of more GOLD 3 patients 
to the model. 
This analysis did not come without limitations that we have done our best to work 
around. The biggest limitation associated with all models was the lack of a validation cohort. 
However, we did perform cross-validation on all of our models and feature selection techniques 
whenever possible to prevent model overfitting the best that we could. So far, we have only 
explored BAL normalization to total protein albumin levels, but there are other options that we 
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could explore as was discussed in Chapter 4. Additionally, in the PBMC communication 
network models and the models of AE-COPD based on sputum proteins, the sample size that we 
had access to was very small due to the former being a preliminary study and the latter 
experiencing difficulty in getting subjects to return to the VAAAHS or UMHS during an 
exacerbation. We recognize that the data we worked with was of a small size and have tried to 
focus our results and discussion of these results more on general trends within the models as 
opposed to generating specific hypotheses for mechanistic ways the signature features could be 
involved in differences between clinical groups. In the case of the PBMC network models, we 
are planning on following up on these results in a larger scale cohort of SPIROMICS II subjects 
with new funding that was recently obtained. Based on the success we have had with the PBMC 
models of cell-cell signaling so far and the ease of collection of these samples, it may be of 
interest to translate this system to study other diseases where chronic and dysregulated immune 
pathways may be at play. 
6.4 Methods 
6.4.1 Collection of biological samples from the SPIROMICS cohort 
The Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS, 
ClinialTrials.gov Identifier: NCR01969344) is a multi-center, longitudinal study that was 
designed with overall goal of better understanding the disease in order to help inform the 
development of future treatment options. The study ended up enrolling subjects, a mix of 
smokers, never smokers, and mild/moderate and severe COPD subjects between the ages of 40-
80 who met the lung function criteria for each recruited group without a diagnosis of non-COPD 
obstructive lung disease or unstable cardiovascular disease. Couper et al. described the complete 
details on the inclusion and exclusion criteria for the SPIROMICS study253. Enrolled subjects 
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visited a participating center four times over three years for the collection of biological samples 
(blood, urine), lung function measurements, and questionnaires, and also received quarterly 
follow-up calls for the recording of exacerbation events and other health status updates. Portions 
of blood samples from one of these visits were sent to SomaLogic for the measurement of 1,305 
proteins using their modified aptamer (SOMAmer) technology. Plasma from blood samples that 
were collected closest to the bronchoscopy visits were sent to the SPIROMICS Genomics and 
Informatics Coordinating Center (GIC) for storage at -80°C. 
A subset of SPIROMICS participants (n = 215)254 were also enrolled in the 
Bronchoscopy substudy. Inclusion criteria is described in detail by Freeman et al., and involved 
lung function spirometry results and smoking history289. Out of the COPD subjects recruited to 
the Bronchoscopy substudy, a much larger number had mild to moderate COPD as opposed to 
severe disease in an attempt to lessen the chance of an adverse event due to the bronchoscopy 
procedure. Enrollment in this study required two extra visits: one where induced sputum was 
collected, and a second visit where peripheral blood and BAL samples were collected. BAL was 
performed with sterile saline in the right middle lobe or lingula regions of the lung with 2 
installations of 40 mL followed by 1 installation of 50 mL. Installations were pooled and spun 
down. Cell-free supernatants were aliquoted and stored until sent to the Arnold lab. 
6.4.2 Measurement of proteins in BAL and plasma samples from the SPIROMICS cohort 
Once collected, cell-free BAL samples were sent to the SPIROMICS Genetics and 
Informatics Coordinating Center (GIC) for storage at -80°C. The SPIROMICS GIC then sent 
matched plasma and BAL samples to the Arnold lab at the University of Michigan for protein 
measurements. Luminex FLEXMAP 3D technology was used to measure the concentration of 48 
cytokines and chemokines in the BAL samples, and 47 cytokines and chemokines in the plasma 
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samples. For protein measurements made by Luminex, we used a protocol that used ¼ of the 
recommended number of beads and sample volume to minimize the volumes necessasry for the 
assay, which was inspired by Arnold et al.205 For the BAL samples, we ran them at twice the 
recommended volume due to low cytokine concentrations in these samples. Samples were run in 
duplicate, and the concentration of wells that were below the lower limit of detection were set to 
be equal to that of half of the lowest limit of detection of all cytokines.  
6.4.3 Computational models of SPIROMICS patients 
The first step in our computational analysis of the plasma and BAL proteins measured by 
us and the blood proteins measured by the SPIROMICS investigators was to identify proteins 
whose measurements were not different than the lower limit of detection, as well as samples that 
acted as negative drivers in each data-driven model. For the proteins, we removed proteins from 
analysis if more than 25% of the measurements were found to be below the lower limit of 
detection. None of the SOMAmer©-measured proteins fell into this category, but 23 proteins 
measured in the BAL samples by Luminex and 9 proteins measured in the plasma samples by 
Luminex were removed before continuing on with our computational analysis. Overall, this 
meant that 1,305 SOMAmer-measured proteins, 25 BAL proteins, and 39 plasma proteins were 
initially included in models. We defined samples as being negative drivers of the model if they 
disproportionally drove our data-driven models such that the algorithm derived model 
parameters solely to account for that one sample. We quantitatively characterized these samples 
as those with a Hotelling’s Reduced T2 statistic value > 5 within a principal components analysis 
model (PCA) based on all measured proteins as calculated by the Eigenvector PLS Toolbox 
(Eigenvector, Mason, WA) software within MATLAB (MATLAB, Natick, MA). All protein 
data was mean centered and variance scaled before being used to build the PCA model. The 
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sample with the highest Hotelling’s Reduced T2 statistic value that was > 5 was then removed, 
and a new PCA model was built based on the remaining samples. This process was repeated 
iteratively until all samples met that criteria. This resulted in the following models of COPD 
disease state: (1) A model based on SOMAmer-measured blood proteins alone that contained 47 
never smokers, 102 smokers, and 121 COPD subjects; (2) A model based on BAL proteins alone 
that contained 25 never smokers, 75 smokers, and 82 COPD subjects; (3) A model based on 
Luminex-measured plasma protein alone that contained 25 never smokers, 74 smokers, and 84 
COPD subjects; and (4) A model based on the combination of SOMAmer-measured blood and 
Luminex-measured BAL proteins together that contained 23 never smokers, 71 smokers, and 78 
COPD subjects. When exploring differences in proteomic expression across GOLD status within 
the COPD subjects, this resulted in a model based on blood proteins which contained 45 GOLD 
1, 56 GOLD 2, and 20 GOLD 3 subjects; a model based on BAL proteins alone which contained 
32 GOLD 1, 44 GOLD 2, and 8 GOLD 3 subjects; and blood and BAL proteins combined which 
contained 30 GOLD 1, 40 GOLD 2 and 8 GOLD 3 subjects.  
Once the negative drivers were removed, we moved onto identifying and visualizing 
proteomic signatures that could differentiate COPD disease state and GOLD status using feature 
selection techniques and partial least squares discriminant analysis (PLSDA). Again, all data 
were normalized via mean centering and variance scaling before any models were built or any 
feature selection was performed. Two different feature selection techniques were used: the least 
absolute shrinkage and selection operator (LASSO) was used for models that contained the blood 
protein measurements by SOMAmers© due to the large number of proteins that were measured, 
and VIP scores were used for models based on BAL or plasma proteins alone. For the LASSO 
models, k-fold cross-validation (k=10) was performed to generate the model with the lowest 
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possible mean-squared error for prediction by iteratively excluding 10% of the samples during 
model training and then using this excluded data to test the model later. The batch number 
associated with the SomaLogic assay and current smoking status at enrollment of the 
SPIROMICS clinical trial were also included in each LASSO model with no penalty to correct 
for these differences across all clinical groups. The VIP score feature selection technique was not 
able to correct for confounding demographic or patient history factors. Proteins with VIP scores 
≥ 1 were included in the final PLSDA model. All PLSDA models were additionally cross-
validated using k-fold cross-validation (k=10). All final PLSDA models were also 
orthogonalized in order to improve interpretability. 
Once the models were created, we then compared PLSDA model performance parameters 
to statistically say if one model was indeed better than others. To compare the calibration 
accuracy of multiple PLSDA models with each other, we took our final, cross-validated model 
and calculated the calibration accuracy for each defined class (e.g. smoker, never smoker, and 
COPD subject) by averaging the true positive rate and the true negative rate. We then took the 
calibration accuracies associated with each of these three classes from one model and statistically 
compared them to the accuracies present within the two other PLSDA models using a one-way 
ANOVA with Tukey’s post hoc test, where p < 0.05 was deemed significant. 
To compare the cross-validation accuracy of multiple PLSDA models with each other, 
we split the data into ten groups. We iteratively excluded one group and trained a PLSDA model 
on the remaining 9 groups, for a total of 10 PLSDA models. We tested the model using samples 
from the remaining group, and quantitatively defined the accuracy of the model again by judging 
how accurate the model was at classifying this unseen data. Specifically, we averaged the true 
positive rate and the true negative rate for each of the test set samples for each of the clinical 
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groups (e.g. smoker, never smoker, and COPD subject). We averaged the accuracies of the three 
clinical groups within each of the ten PLSDA models to define the cross-validation accuracy 
associated with that particular test set. We then compared all ten calculated cross-validation 
accuracies from each of the PLSDA models, so all samples would serve within the test set once. 
We performed a similar calculation of cross-validation accuracies of PLSDA models based on 
other types of data, and finally used a one-way ANOVA with Tukey’s post hoc test to compare 
calculated cross-validation accuracies across multiple models. P-values < 0.05 were deemed 
significant.  
The database for annotation, visualization and integrated discovery (DAVID165) was used 
to help identify biological pathways that were significantly enriched among subsets of proteins in 
the LASSO-identified signature. Proteins in the signature were split into two groups based on the 
sign of their loading on LV1, and then run separately in DAVID. The resulting clustering and 
enrichment diagrams from DAVID were created by searching through Gene Ontology (GO) 
biological processes (BP FAT), GO molecular function (MF FAT), and the Kyoto Encyclopedia 
of Genes and Genomes (KEGG). For all analyses, only the clusters and pathways that were 
significant after the application of the Bonferroni correction were reported. 
Protein correlation networks were created for smokers, never smokers, and COPD 
subjects separately. Pairwise Pearson’s correlation coefficient was used to calculate the edges 
connecting the expression of two proteins in the LASSO-identified signature. The brightness and 
thickness of each edge indicate the value of the coefficient and the statistical significance of that 
correlation, respectively. Only significant (p < 0.05) correlations were plotted. Node size is 
proportional to its degree of connectedness. 
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6.4.4 Stimulation of peripheral blood mononuclear cells and measurement of secreted 
proteins 
Practicing clinicians in Dr. Jeff Curtis’s lab at the VA Ann Arbor Healthcare System 
(VAAAHS) collected 24 mL of whole blood from healthy subjects, smokers without airway 
obstruction, and smokers with airway obstruction (COPD subjects). Informed consent was 
obtained from each subject, and the blood collection protocol was approved by the VAAAHS 
IRB. PBMC isolation and stimulation was performed according to methods outlined by Arnold et 
al.205 PBMCs were isolated from whole blood samples within one hour of collection via density 
centrifugation in Ficoll solution. Once isolated, cells were first counted before being stored at -
80°C until stimulation. 
On the day of stimulation experiments, PBMCs were thawed and resuspended in R10 
media at a concentration of 20 million cells/mL. Cells were plated at a final concentration of 2 
million cells/well in a 96-well U-bottom plate, in the presence of either a negative control (R10 
media) or one immune stimulus. Investigated stimuli included R848 (stimulates TLR7 and 
TLR8; replicates a viral infection), LPS (stimulates TLR2 and TLR4; replicates a bacterial 
infection), CD3/CD28 dynabeads (stimulates the adaptive immune response), and Poly(I:C) 
(stimulates TLR3; replicates a viral infection). Cells were incubated for either 72 hours with the 
immune stimulus. Afterwards, adherent and nonadherent cells were collected and separated from 
the culture supernatant. Supernatant and cells were stored separately at -80°C until further 
analysis. 
The concentrations of 29 cytokines and chemokines in the collected supernatants were 
measured using Luminex FLEXMAP 3D technology. For protein measurements in Luminex, we 
used a protocol that used ¼ of the recommended number of beads and sample volume to 
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minimize the required volume for the assay, which was inspired by a protocol detailed in Arnold 
et al.205 Samples were run in duplicate, and the concentration of wells that were below the lower 
limit of detection were set to be equal to half of the lowest limit of detection of all cytokines. 
Wells that were above the highest limit of detection were set to be the highest detectable 
concentration for that particular cytokine.  
6.4.5 Computational models of cytokine secretions of stimulated PBMCs 
Univariate analysis was performed by using a one-way ANOVA with Tukey’s post hoc 
test to statistically compare the expression levels of the cytokines in the PBMC cultures from 
healthy subjects, smokers, and COPD subjects. Significance was defined as p < 0.05. Partial least 
squares discriminant analysis (PLSDA) was used to visualize signatures of covarying secreted 
cytokines that differentiated the healthy, smoker, and COPD PBMC response to various immune 
stimuli. Variable importance in projection (VIP) scores were used to identify protein signatures 
that were most important in differentiating the groups of interest. The final PLSDA models 
shown for these results are based only on proteins with VIP scores that were ≥ 1. All PLSDA 
models were cross-validated to prevent major model overfitting. K-fold cross-validation was 
performed by iteratively excluding ~8% of the samples from each model; this excluded data was 
then used to train the model. All PLSDA models based on VIP-selected features were 
orthogonalized to improve interpretability, and all data were mean centered and variance scaled 
before being used in PLSDA models.  
The one-way ANOVA with Tukey’s post hoc test was performed using GraphPad Prism 
(GraphPad Software, San Diego, CA). All PLSDA models and VIP score calculations were 
performed by the PLS toolbox in MATLAB (Eigenvector, Manson, WA).   
 135 
Chapter 7 Overall Discussion 
 
In this thesis, we have applied data-driven, systems biology-focused computational 
models to identify and explore signatures of covarying cells and proteins from multiple tissue 
compartments that successfully differentiated IPF and COPD disease state and progression. The 
specific conclusions and discussion of results will be presented according to the three aims of 
this work: using data-driven modeling tools to identify blood protein signatures, lung protein 
signatures, and multi-compartment and multi-assay signatures that could differentiate IPF and 
COPD disease state and disease progression.Blood protein models of IPF and COPD disease 
state and progression introduce potential differentiating signatures in peripheral blood 
In work to support this aim, we were able to illustrate how data-driven approaches were 
effective for identifying blood protein signatures to differentiate individuals based on IPF disease 
state and progression status, as well as COPD exacerbation state. 
One key result of this Aim illustrated that protein signatures were more useful than 
individual cytokines in differentiating clinical groups of interest. For example, we identified a 
signature of 61 blood proteins that outperformed previously published single markers of IPF 
progression. This signature also performed better than a previously published index of 6 
proteins136. Likewise, in COPD a signature of 7 serum proteins was able to moderately 
differentiate stable and AE-COPD. This signature trended towards significantly outperforming 
the cross-validation of models based on single proteins that were differentially expressed across 
the two disease states, as well as a model based on all five proteins that were differentially 
expressed across the two groups. While these protein signatures hold promise for the 
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development of prognostic assays, additional investigation and analysis will be required in the 
future to 1) reduce the number of proteins in the signature; 2) validate in new, larger cohorts; and 
3) develop appropriate technology, as discussed below.   
Results of this Aim also illustrated that in general, circulating cytokines were not useful 
for classification of groups (e.g. smokers and COPD subjects, IPF progressors and non-
progressors), but that stronger differentiation could be achieved when either looking at a larger 
panel of proteins (e.g. SOMAscan assay) or when looking at distinctly different disease states. 
For example, in analysis of SPRIOMICS samples, when attempting to differentiate smokers, 
never smokers, and COPD subjects, plasma cytokines only performed with 65.69% calibration 
and 57.88% cross-validation accuracy, compared to the larger panel of SOMAmer-measured 
blood proteins, which performed with 74.56% calibration and 67.59% cross-validation accuracy. 
This indicated that it can be difficult for our modeling techniques to differentiate the systemic, 
unstimulated differences between a healthy group (never smokers) and two groups with 
worsening physiology who are much more similar to each other (smokers and COPD subjects), 
especially when only measuring a small number of proteins. Another example of the strength of 
a large panel of proteins can be seen in our models of the COMET IPF subjects: we saw strong 
separation both when the clinical groups being modeled were very distinct, like our model of 8 
SOMAmer-measured proteins that differentiated healthy and IPF subjects, as well as when the 
clinical groups were similar, like our model of the 61 blood protein signature that differentiated 
IPF progressors and non-progressors. 
Though results here suggest it may be difficult to differentiate clinical groups based on 
circulating cytokines, we have shown that stimulated systems of immune blood cell 
communication networks may hold more promise for a blood diagnostic. Our preliminary 
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analysis of peripheral blood mononuclear cells (PBMCs) from small numbers (all n < 8) of 
smokers, never smokers, and COPD subjects illustrated that cytokine signatures secreted in 
response to innate immune stimuli (LPS, R848, Poly(I:C)) may be effective for differentiating 
these groups. Biologically, these results emphasize how much COPD and its associated airway 
obstruction affects the immune system, even at sites peripheral to the tissue compartment of 
injury. Due to low sample number (n = 3 COPD subjects), we were not able to explore these 
communication networks in depth, although the results suggested that differences associated with 
myeloid cell stimulation were greater across smokers, never smokers, and COPD subjects than 
those seen after T cell stimulation. However, we were encouraged to see that we were able to 
achieve high calibration accuracy and were able to visually separate all three patient groups 
while working with limited data. Additionally, studying these cell-cell communication networks 
can give more information about adverse immune responses present in COPD subjects that could 
inspire new ideas for experimental follow-up with potential therapeutic goals in mind. Overall, 
PBMC simulation experiments suggest a new paradigm for studying network level events that 
are able to differentiate clinical groups with progressive, immunological diseases. 
Lastly, we also saw that data-driven modeling techniques were able to capture temporal 
changes in proteomic expression that were associated with disease progression. We identified a 
signature that was significantly different across three time points of IPF progressors using an 
unsupervised PCA model, but a similar signature was not identified in non-progressors. This 
result highlights the importance of measuring a wide variety of circulating, unstimulated proteins 
in order to obtain signatures that identify significant differences across clinical groups. Overall, 
these models showed that there are temporal changes in the peripheral blood proteome of IPF 
progressors that is not seen in non-progressors, and that our modeling techniques are able to 
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capture these changes. In the future, it will be important to obtain access to separate validation 
cohorts to truly validate our signatures and PLSDA models, as discussed below.  
Another challenge in using the IPF progression signature identified here as a prognostic 
signature is the large size of the signature (61 blood proteins). Proposing to create a prognostic 
test from this many factors would be difficult, as the test might take a longer time to process and 
may cost more, making it somewhat unattractive as a product. A general limitation of this work 
with the COMET cohort can be attributed to this study’s demographics. All 60 IPF subjects that 
were recruited to COMET lived through the end of the 80-week study, which means that our 
reported trends and signatures are associated with mild to moderate IPF, but may not describe 
end-stage disease. 
7.2 Lung protein models of IPF and COPD disease state and progression aid in hypothesis 
generation 
Overall, results from this aim suggest that PLSDA models based on signatures of BAL 
lung cytokines are useful for gaining mechanistic insight and are better for classification than 
circulating, unstimulated blood cytokines or individual proteins. When we measured the same set 
of cytokines in matched plasma and BAL samples collected from subjects enrolled in the 
SPIROMICS study, a signature of BAL cytokines was better at differentiating COPD disease 
state (75.31% calibration and 71.76% cross-validation accuracy) than a signature of plasma 
cytokines (65.69% calibration and 57.88% cross-validation accuracy). We speculate this results 
from increased cytokine and chemokine activity in the COPD lung that is not apparent in blood 
measurements. In support of this hypothesis, another group has also reported that more BAL 
proteins that were associated with COPD-related variables than plasma proteins measured in the 
same subjects274, although these protein measurements were made using untargeted liquid 
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chromatography-mass spectrometry (LC-MS) technology, and not Luminex technology like we 
employed. To our knowledge, results from Aim 2 also represent the first time signatures of BAL 
cytokines were useful for differentiating IPF disease state. The identified signature was a better 
classifier than IFNa2 and IL-7, and classified with the same accuracy as analyses based on IL-15 
and a combination model of all three proteins together. Overall, this suggests that signatures of 
cytokines may be better than individual cytokines in differentiating clinical groups, due to high 
inherent variability in the expression of single cytokines. 
In this aim, we were able to gain mechanistic insight and generate hypotheses into lung-
specific proteomic relationships associated with IPF and COPD disease state and progression. 
Generating biological insight into these lung-associated network relationships may be more 
useful than classification, as the invasive nature of BAL sample collection prevents widespread 
use for diagnostic or prognostic purposes. In IPF, a protein correlation coefficient network based 
on progressors’ expression data indicated the proteins that had the most significant correlations 
to other proteins were chemokines (MCP-1, IL-8, GM-CSF), which suggested that cell 
trafficking into the lung may be associated with IPF progression. Additional examination of the 
other two hub proteins (EGF and G-CSF) also suggested that together these factors may be 
involved in immune cell recruitment to the lung and the associated tissue reorganization and 
fibrosis. In COPD exacerbation, we found that sputum IL-1β, IL-6, and C-reactive protein (CRP) 
were comparatively increased during exacerbation, suggesting pro-inflammatory functions. 
Based on these specific factors, we speculate that this exacerbation-associated inflammation may 
arise from macrophages290. The identified exacerbation signature also suggested a comparative 
increase IL-10, which could indicate attempted suppression of the inflammation present.  
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Lastly, we have also gained mechanistic insight by comparing the models of IPF and 
COPD progression with each other. When we compared the models of disease progression based 
on inflammatory cytokine and chemokine measurements from the lung environment, we saw that 
the PLSDA model of AE-COPD had more than 10% greater cross-validation and calibration 
accuracy than the model of IPF progression. Based on these results, we hypothesize that 
inflammatory cytokines may play a greater role in COPD progression than in IPF, which also 
aligns with current IPF pathogenesis hypotheses291 and clinical trial results47.   
As in Aim 1, we also did not have access to a true validation cohort for these samples. 
Another limitation on nearly all the models of BAL proteins is that most were only moderately 
accurate at differentiating disease state or disease progression, with the exception of the healthy 
and IPF model based on BAL proteins. This could indicate a number of things: that BAL 
cytokines alone are not a strong classifier of lung disease state or progression and more proteins 
with a wider array of functions may need to be measured in each sample, that a different sample 
normalization technique should be used, or that more data need to be included to increase model 
accuracy. In the work presented here, all BAL protein data used as inputs into models and feature 
selection algorithms were first normalized to the total protein albumin concentration in the 
samples as calculated by a bicinchoninic acid (BCA) assay. We did see that models built on the 
BCA-normalized BAL data outperformed models based on raw data output from the Luminex 
assay (non-normalized models not shown). There is no field standard for BAL sample 
normalization, but we have not yet had the chance to explore other normalization techniques. 
However, we have already taken steps towards investigating some of these points. In the future, 
we plan on comparing BCA normalization of BAL samples collected in the SPIROMICS study 
with that of urea normalization292, where the actual volume of the epithelial lining fluid (ELF) 
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collected during the BAL procedure is estimated by assuming equal urea concentration in the 
ELF portion of the BAL and in the plasma of matched samples from the subjects. The limitation 
with the urea normalization method is that both BAL and plasma samples need to be collected 
during the bronchoscopy procedure, which requires foresight when designing the study and 
writing the methods. To investigate if BAL proteins are useful when combined with other data 
types, we have integrated data from multiple tissue compartments and assays into the same 
models; results from these models will be discussed in the following section. 
7.3 Integrated blood and lung protein and cellular models of IPF and COPD disease state 
and progression lead to better classification and increased insight to mechanism 
Results from Aim 3 across both IPF and COPD disease state and disease progression 
suggest that models based on protein data from multiple tissue compartments trend toward being 
or are significantly better at classification than models based on data from single tissue 
compartments. We identified a signature of 51 blood and 3 BAL proteins that differentiated IPF 
progressors and non-progressors with high accuracy. In addition to significantly outperforming 
nearly all models based on single or combination of proteins identified in univariate analyses, 
this model also had significantly better calibration and cross-validation accuracy than a model 
based on a signature of BAL cytokines. Likewise, we saw that signatures of blood and BAL 
proteins that differentiated COPD disease state had significantly better cross-validation accuracy 
than models based on blood or BAL proteins alone, and that a cross-tissue compartment model 
differentiating COPD GOLD status (a measure of disease severity) was significantly better in 
terms of calibration and cross-validation accuracy than models based on BAL proteins alone. 
These results suggest that the systemic and the pulmonary environments are both important to 
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consider when trying to obtain the best differentiation between clinical groups, especially 
between those with subtle differences. 
On top of performing with high accuracy, our models based on integrated signatures of 
blood and lung proteins and cellular markers have the potential to give new biological insight. 
Our approach is unique because by investigating and emphasizing the covariation between 
expressed proteins in clinical groups using computational data-driven modeling techniques, we 
can potentially begin to piece together larger networks of interactions that are present throughout 
the human body during disease. In our cross-tissue compartment model of IPF progression, we 
used a prior knowledge database (DAVID) and discovered that proteins that were comparatively 
increased in non-progressors were enriched for the regulation of the immune and defense system 
response. Additionally, we speculated that IPF non-progressors have greater control over their 
proteomic processes, and that this results in a network with few drivers that is difficult to perturb 
based on the low number of hub proteins in the non-progressor protein correlation network. We 
have hypothesized that the IPF progressors are a heterogeneous group, as seen by the correlation 
network with many hub proteins and less significant correlations, and that potential subgroups or 
endotypes of progressors may be identified by differences in proteomic expression. 
We generated hypotheses for mechanisms associated with COPD disease state and 
progression with our cross-tissue compartment models as well. For our model of COPD disease 
state, we again used DAVID and discovered that the proteins that were comparatively increased 
in COPD subjects were enriched for cytokine activity and the immune and defense response, 
which could be related to the high levels of inflammation reported in COPD subjects in other 
studies212,293,294. Additionally, we created correlation networks based on the signature protein 
expression in smokers, never smokers, and COPD subjects separately. Similar to IPF progression 
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results, we saw that the never smokers had stronger correlations compared to smokers and COPD 
subjects, and that the never smokers had fewer hub proteins than the other groups. This led to the 
hypothesis that never smokers have proteomic signaling networks that are more stable and 
difficult to perturb. A VIP-selected signature of serum and sputum proteins and blood cell 
markers was able to differentiate stable and AE-COPD, and also led to potential mechanistic 
insight into exacerbations. Based on the proteins and cells that were comparatively increased 
during exacerbation, we hypothesized that parallel increases in serum adhesion cytokines 
(sICAM-1 and sVCAM-1) and sputum inflammatory chemokines (MCP-2 and IP-10) are both 
critical to help inflammatory immune cells (such as CD15+ neutrophils) traffic into the lung 
during exacerbation. The percentage of CD4+ T cells was found to be comparatively increased in 
the stable state in this signature, and based on this and results from a previous study of this 
data91, we also hypothesize that CD4+ T cells are some of the first cells to traffic to the lung 
during exacerbation. However, this result is then curious when compared to our preliminary 
analysis of cytokine secretions from stimulated PBMCs from smokers, never smokers, and 
COPD subjects in which we did not report strong differentiation after stimulating the T cells in 
vitro. This could speak to a potential change in T cell function associated with exacerbation, or 
this could be related to only looking at COPD as opposed to the two non-diseased groups. 
Overall, we speculate that this influx of immune cells to the lung during exacerbation helps 
create the inflammatory environment that is characteristic of AE-COPD events295,296.  
By comparing results from models based on IPF and COPD, we have reported some 
differences which should help us in planning experiments when moving forward with this work. 
Due to the larger number of SOMAmer-measured proteins, we expected blood proteins would 
dominate each cross-tissue compartment signature, even though IPF and COPD are lung-focused 
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diseases. However, we noticed that when we compared the number of BAL proteins chosen in 
IPF and COPD models that there was a higher percentage of BAL proteins chosen in the models 
of COPD disease state (16.22% of the cross-tissue compartment signature was made up of BAL 
proteins) and GOLD status (7.31%) than in the model of IPF progression (5.56%). These results 
indicate that BAL cytokines may be more important in differentiating COPD disease state than 
IPF progression. We thus hypothesize that lung cytokines play a larger role in COPD than in IPF, 
a conclusion which is similar to that seen in Aim 2, and that in the future we should look into 
measuring more non-cytokine proteins in IPF BAL samples to see if this helps improve 
differentiation and mechanistic insight.  
Unexpectedly, we did see some similar biological results in results across the COPD and 
IPF analyses. We reported similar trends in our protein correlation networks of IPF progression 
and COPD disease state, where the “sicker” groups (e.g. IPF progressors or the SPIROMICS 
smokers and COPD subjects) exhibited a large number of weakly significant correlations, 
whereas the “healthier” group (either IPF non-progressors or non-smoking controls for COPD) 
had protein networks that were characterized by correlations that were more significant. 
Additionally, in our models where BAL proteins were combined with SOMAmer-measured 
blood proteins, the LASSO feature selection technique almost always chose at least one 
complement protein as being one of the most important differentiating factors across IPF or 
COPD disease state or progression. This is curious because only 23 complement proteins were 
measured out of 1129 proteins total in the blood in the IPF samples, and 26 complement proteins 
out of 1305 were measured in the blood in the COPD samples. Specifically, inactivated 
complement component 3b was chosen in the blood protein signature that differentiated IPF 
disease state and was also involved in differentiating both IPF progressors and non-progressors 
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in the trajectory PCA models. The complement 5b and 6 complex was chosen as part of the 
cross-tissue compartment signature that differentiated IPF progressors and non-progressors. In 
our models of COPD, complement 2 was comparatively increased in the never smokers in the 
cross-tissue compartment model of disease state, and complements 7 and 9 were associated with 
higher GOLD stage in the model of COPD progression. Various complement proteins 
(complement 4b111,297, complement C1R111) have previously been reported as differentially 
expressed in healthy and IPF, although these studies show that higher expression of these 
proteins is not always consistently associated with one group. Higher complement 3 expression 
has been linked to the MUC5B promoter variant rs3570590 in humans with IPF182. Complement 
3 (C3) and 4 (C4) have been reported to be decreased in the blood of COPD subjects compared 
to controls298,299. Sun et al. confirmed that lower C3 levels were associated with COPD and 
emphysema through models of protein quantitative trait loci (pQTL) and expression QTL 
(eQTL) SNPs in the SPIROMICS and COPDGene cohort, and suggested that the relationship 
between C3 protein levels and disease state may be mediated by genetic variants300. Overall, our 
data-driven modeling techniques have helped us generate biological hypotheses common to both 
IPF and COPD that deserve to be explored in the future. 
Limitations associated with this analysis are similar to Aims 1 and 2 and involve the lack 
of a true validation cohort to test our models. Additionally, validation cohorts become difficult 
obtain when multiple omics analyses are performed on multiple samples from the same subjects. 
For example, to our knowledge, there is currently no cohort available that we could use to 
validate our model of AE-COPD events due to the need to have measured serum and sputum 
proteins (preferably by Luminex) and blood cell markers by flow cytometry. Additionally, many 
models presented in this section rely on proteomic data from BAL measurements, which requires 
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an invasive procedure to obtain, though BAL is still a relatively low risk procedure188. Patient 
safety must and will always be considered before enrolling subjects in studies or collecting any 
BAL samples, but we have shown in this analysis that BAL samples do provide value. Our 
models that combined protein data from multiple tissue compartments performed with the 
highest accuracy, and integrated signatures have the potential to give new biological insight. By 
investigating the covariation between expressed proteins in clinical groups using computational 
data-driven modeling techniques, we can potentially begin to piece together larger interactions of 
networks between multiple organ systems that are present in the human body during disease, 
which could lead to a deeper understanding of disease state and disease progression. 
7.4 Future work 
As discussed above, one of the most important steps in the future of this work involves 
model validation in a separate cohort, especially if this approach is to be used to develop 
prognostic signatures. We did perform cross-validation during feature selection and model 
building whenever it was possible, but this does not replace a true validation cohort. This may be 
difficult due to the nature of the SomaLogic data: to our knowledge, currently the SomaLogic 
platform is not available for academic use, and we and other researchers have reported that 
SOMAmer-based measurements sometimes136,301,302, but not always130,197,301,302, correlate with 
antibody-based measurement techniques. Looking at cohorts that are currently available that 
could potentially be used to validate these models, Todd et al. recently published a study where 
they used multiple models to differentiate the SOMAmer-measured blood proteome of healthy 
and IPF subjects 111. Data from this study could potentially be used for validation of our model of 
healthy and IPF, as long as it is confirmed that the IPF diagnosis process was the same in each 
study. Recently, COPDGene264 investigators were able to send blood samples for measurement 
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with the SOMAscan assay301, making it a promising cohort for validation of our models of 
COPD disease state. However, models that differentiate disease state are not the most clinically 
relevant, as these groups are normally easy to tell apart without performing tests. To create a 
clinically relevant diagnostic signature, we would need access to SOMAmer-measured proteins 
from subjects with other lung diseases that are commonly misdiagnosed as IPF, such as other 
idiopathic interstitial pneumonias such as nonspecific interstitial pneumonia (NSIP)291, or the 
immune disorder chronic hypersensitivity pneumonitis (HP)303. In IPF, it would be useful to 
obtain protein data from cohorts of HP or NSIP subjects for comparison.  
To validate the IPF progression signature, we would need other IPF cohorts with 
SomaLogic data where progression could be tracked similarly as in the COMET study. The IPF-
PRO study304, which also had blood SOMAmer protein measurements collected111, may be able 
to serve as a validation cohort; otherwise the PROFILE cohort study170, which had blood Myriad 
RBM protein measurements collected109, may also be able to serve as a validation cohort. For 
our models of cell-cell communication in COPD disease state, our lab will be able to perform the 
PBMC studies on a larger scale due to new collaborations with the SPIROMICS II visits, though 
validation of the original signatures presented here will probably not occur because they were 
created based on so few samples. 
Once our signatures were validated in a separate cohort, there would be additional 
challenges associated with developing the assays that would be used in making diagnostic or 
prognostic decisions. This would include determining how sensitive the models are to the 
method of protein measurement (e.g. Aptamer vs. antibody), and if other systems besides the 
SomaLogic platform and Luminex technology could be used and still result in the same level of 
differentiation. This also involves identifying a technology that could be used to measure protein 
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signatures vs. absolute cut-offs of individual cytokines. Additionally, we would need to 
determine how the test results would be used in decision-making: either directly by the clinician 
as an index with a cut-off for group classification136, or by an outside company that would 
convey classification results to the clinicians. Steps following these decisions would then involve 
much more validation and eventually working with governmental agencies for approval. 
In terms of moving forward in gaining insight into mechanism, one potential option is to 
move into animal models of disease. For IPF disease state research, the most common model of 
pulmonary fibrosis used is the bleomycin (BLM) murine model305, and some researchers have 
developed a multi-BLM dose murine model that better models progression of pulmonary 
fibrosis306. Though these animal models do not capture all aspects of human IPF, they have been 
used extensively in the past to gain basic insight into IPF disease state and progression. The most 
common animal model used to study COPD involves exposing animals (dogs, guinea pigs, rats, 
mice, etc.) to high levels of cigarette smoke over a period of at least 3 to 6 months307, but like the 
animal models used to study IPF, this model does not recapitulate all aspects of COPD. 
Researchers commonly administer bacterial (such as nontypeable Hemophilus influenzae308 or 
LPS309) or viral infections310 to model AE-COPD events in these animals. When moving into 
animal models of disease state and progression, first we would need to identify murine homologs 
of the human proteins in our signature and confirm the differentiating ability of these proteins in 
our groups of animals. Once we either reconfirmed the human signature in the animal models or 
identified animal-specific differentiating signatures, we could perform new experiments testing 
the importance of some of the higher loaded proteins in the PLSDA loadings plot or the hub 
proteins in the correlation networks by blocking signaling pathways downstream of that 
cytokine. We could then explore if these changes that were made caused the animals to cluster in 
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a different area of the PLSDA scores plot or not. We could also use animal models to investigate 
cellular signatures that are associated with clinical groups due to the ease of sample collection. 
Moving into animal models of pulmonary fibrosis and COPD to investigate omics differences 
between corresponding clinical groups would allow for a more specific level of mechanistic 
exploration than what is possible in humans, although this comes at the price of then having to 
validate results in humans again later on. 
There is still much to be done with samples that have currently been collected. To our 
knowledge, BAL samples collected during the COMET and SPIROMICS studies still exist. It 
could be useful to measure additional proteins in BAL samples using Luminex technology, as the 
SomaLogic platform is currently not available for academic use. For example, existing pre-
mixed Luminex kits focused on the Th17 response could be intriguing to explore based on 
COPD endotype research that has been published84,88. Pre-mixed Luminex assays could also be 
useful for measurements of complement proteins including complement 3b/iC3b and 
complement 4, which would be of interest based on the large number of blood complement 
proteins that were chosen in our models. We were only able to measure 29 cytokines in the 
COMET samples, so gaining information about the concentration of a wider variety of signaling 
molecules could help increase the classification ability of our identified signatures. Measuring 
proteins with growth factor or tissue reorganization functions could be valuable in further 
evaluation of IPF, as evolving evidence from failed anti-inflammatory drug trials suggests that 
other factors may play a more central a role in disease natural history than cytokines 
alone47,311,312. However, multiple freeze-thaw cycles could make future measurements from these 
samples problematic, and must be taken into account before moving forward. 
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Additional analysis of data that has already been collected could also be of high value. 
One potential direction could be in identifying novel subgroups (“endotypes”) within a disease 
state, and relying more on unsupervised analytical approaches that are focused on the diseased or 
progressing subpopulation alone. For example, it could be useful to create additional 
unsupervised models of IPF progressors to explore how these patients cluster without the non-
progressors being present. I would want to explore if we continue to see the same three groups of 
progressors that we saw in the hierarchical cluster when using other unsupervised clustering 
algorithms, as well as applying supervised approaches to explore the biological mechanisms 
associated with each of the proteins increased in these groups using prior knowledge databases. 
Currently, COPD clinicians and researchers are focusing on two areas where I believe that 
unsupervised approaches could be of help: 1. The identification of potential COPD endotypes, 
and 2. Exploration and definition of potential differences in clustering of smokers without airway 
obstruction and COPD subjects. Based on interest in the early COPD disease state262, it would be 
interesting to explore how smokers and COPD subjects cluster together in an unbiased way, and 
if any of these identified clusters are associated with clinical variables, such as number of pack 
years smoked, history of asthma or respiratory symptoms, or spirometry measurement ranges. 
There are also new approaches, both computationally and in experimental design/sample 
collection, that could be taken in this area of pulmonary signature identification and should be 
explored. It was promising for us to have been able to build these cross-tissue compartment 
models of disease state and disease progression: we were able to computationally explore and 
define human proteomic and cellular relationships that are otherwise difficult to construct and 
study. While in this thesis we mostly focused on proteomic relationships that differentiated 
clinical groups, we have recently gained access to more omics data that were collected during the 
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SPIROMICS study that would be fascinating to integrate with our proteomics data to study more 
multi-omics mechanisms associated with disease state and progression. Specifically, there is 
transcriptomic data collected from epithelial cell brushings in the SPIROMICS participants, and 
in the future there will also be flow cytometry and microbiome measurements of the BAL 
samples as well. Incorporating all of these different types of data into a single model could give 
us a deeper understanding of COPD disease state and would be of great interest. We could 
approach all of these data types using the methods detailed in this thesis, or we could also 
explore other multi-omics integration and analysis tools. One methodology of interest includes 
multi-omics factor analysis (MOFA), which can be described as a versatile and generalized PCA 
analysis built to handle multi-omics data313, and is better able to include a larger number of 
patient omic samples into models than PCA. When we performed PCA or PLSDA on our multi-
omics or cross-tissue compartment data in this work, we were only able to include subjects who 
had successful measurements of all omics samples included in the model, which accounted for 
changes in the sample size used in our models of AE-COPD (Chapter 3 and 5). A MOFA model 
would have been able to include any subject that had at least one of the omics sample 
measurements. Another new approach that we could explore involves the type of samples we 
collect from subjects. We emphasized throughout this work the importance of collecting samples 
and proteomic data from the tissue compartment of interest, but we also recognize that these 
procedures are invasive to some extent, and are not always in the subject’s best interest. 
However, some researchers have reported differences in the concentrations of cytokines 
measured in the exhaled breath condensate (EBC) that related to disease state in IPF314 and 
COPD315,316. We would be curious to see what sort of proteomic measurements we could make 
from EBC samples using Luminex technology, and if these measurements translate into strong 
 152 
differentiating signatures. If we discover that cytokines are not easily detectable in EBC, 
switching our protein measurement approaches to those based on mass spectrometry or focusing 
on volatile organic compounds instead of cytokines317 may lead to the generation of omics data 
that we could still model using our data-driven techniques. If so, that could mean that a much 
less invasive procedure could be performed that still allows for surveying of the lung 
environment. However, previous studies that focused on fatty acid318 and 16S rRNA 
measurements319 of EBC samples have shown how difficult it is to ensure that omics 
measurements of EBC samples are actually associated with a true biological signal, and thus it 
might be a safer move to first analyze previously collected EBC protein data before collecting 
new samples. 
7.5 Conclusion 
In conclusion, we have shown that we are able to identify proteomic and cellular 
signatures that can differentiate disease state and progression of IPF and COPD, and that these 
signatures are biologically relevant starting points for generating new hypotheses for 
mechanisms of action associated with disease and inspiring new directions for follow-up 
experiments. Our data-driven methods of signature identification may prove to be useful tools in 
identifying differentiating diagnostic and prognostic signatures that could hold clinical value if 
they are validated in separate cohorts. Ultimately, we hope that these signatures can be validated 
in human or murine models of IPF and COPD, enabling us to employ mechanistic models of the 
most important pathways and binding events to quantitatively investigate system perturbations 
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Table A.S1. Study population demographics 
 IPF Normal controls P value* 
Mean age in yrs.  
(SD) 
64.56 (7.74) 69.97 (8.78) 0.0037 
Male No.  (%) 41 (68.33) 20 (66.67) 0.8733 
Smoking status    
Never 19 (31.66) N/A _ 
Ex 40 (66.66) N/A _ 
Current 1 (1.66) N/A _ 
*Students t-test and Pearson χ2 squared test respectively. SD: standard deviation 
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Table A.S2. List of relevant co-morbidities and their frequencies with the COMET IPF 
patient cohort. 
























































CAD-coronary artery disease: MI – myocardial infarction: GERD – gastroesophageal reflux 
disease: OSA – obstructive sleep apnea: Pulm HTN – pulmonary hypertension.  
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Table A.S3. List of upregulated proteins in the IPF peripheral proteome compared to control 
Protein UniProt ID Gene ID 
Afamin P43652 AFM 
Aflatoxin B1 aldehyde reductase member 2 O43488 AKR7A2 
AH receptor-interacting protein O00170 AIP 
Alpha-soluble NSF attachment protein P54920 NAPA 
Aminoacylase-1 Q03154 ACY1 
Apolipoprotein A-I P02647 APOA1 
Beta-Ala-His dipeptidase Q96KN2 CNDP1 
Bone morphogenetic protein 1 P13497 BMP1 
C5a anaphylatoxin P01031 C5 
Cathepsin B P07858 CTSB 
cGMP-specific 3',5'-cyclic phosphodiesterase O76074 PDE5A 
Chloride intracellular channel protein 1 O00299 CLIC1 
Coagulation Factor V P12259 F5 
Complement C1r subcomponent P00736 C1R 
Complement C4 P0C0L4 C4A  
Cyclin-dependent kinase 8:Cyclin-C complex P49336, P24863 CDK8 CCNC 
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A Q9HCR9 PDE11A 
Dual specificity mitogen-activated protein kinase kinase 4 P45985 MAP2K4 
Endothelin-converting enzyme 1 P42892 ECE1 
Fibronectin P02751 FN1 
Glyceraldehyde-3-phosphate dehydrogenase P04406 GAPDH 
Glycogen synthase kinase-3 alpha/beta P49840, P49841 GSK3A GSK3B 
Growth hormone receptor P10912 GHR 
Growth/differentiation factor 11 O95390 GDF11 
GTP-binding nuclear protein Ran P62826 RAN 
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Intercellular adhesion molecule 5 Q9UMF0 ICAM5 
MAP kinase-activated protein kinase 2 P49137 MAPKAPK2 
Matrilysin P09237 MMP7 
Methionine aminopeptidase 2 P50579 METAP2 
Nascent polypeptide-associated complex subunit alpha Q13765 NACA 
Peptidyl-prolyl cis-trans isomerase D Q08752 PPID 
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform: 
Phosphatidylinositol 3-kinase regulatory subunit alpha complex 
 
P42336, P27986 PIK3CA PIK3R1 
Plasma serine protease inhibitor P05154 SERPINA5 
Proprotein convertase subtilisin/kexin type 7 Q16549 PCSK7 
Protein kinase C alpha type P17252 PRKCA 
Protein kinase C beta type (splice variant beta-II) P05771 PRKCB 
Proto-oncogene tyrosine-protein kinase Src P12931 SRC 
P-Selectin P16109 SELP 
Pyruvate kinase PKM P14618 PKM2 
Ras-related C3 botulinum toxin substrate 1 P63000 RAC1 
Ribosome maturation protein SBDS Q9Y3A5 SBDS 
Small glutamine-rich tetratricopeptide repeat-containing protein alpha O43765 SGTA 
Sorting nexin-4 O95219 SNX4 
Sphingosine kinase 1 Q9NYA1 SPHK1 
Tumor necrosis factor ligand superfamily member 13B Q9Y275 TNFSF13B 
Tyrosine-protein kinase BTK Q06187 BTK 
Tyrosine-protein kinase CSK P41240 CSK 
Tyrosine-protein kinase Tec P42680 TEC 
Uniprot Accession ID listed. Detailed descriptions of proteins available at http://www.uniprot.org/  
N=48 proteins 




Table A.S4. List of downregulated proteins in the IPF peripheral proteome compared to control. 
Protein UniProt ID Gene ID 
Allograft inflammatory factor 1 P55008 AIF1 
Alcohol dehydrogenase [NADP(+)] P14550 AKR1A1 
Alkaline phosphatase, tissue-nonspecific isozyme P05186 ALPL 
Annexin A1 P04083 ANXA1 
Annexin A2 P07355 ANXA2 
Complement C3 P01024 C3 
Complement C3b, inactivated P01024 C3 
Complement C4b P0C0L5 C4B 
Carbonic anhydrase 3 P07451 CA3 
Calcium/calmodulin-dependent protein kinase type II subunit beta Q13554 CAMK2B 
Calcium/calmodulin-dependent protein kinase type II subunit delta Q13557 CAMK2D 
Macrophage-capping protein P40121 CAPG 
Caspase-10 Q92851 CASP10 
Calpastatin P20810 CAST 
C-C motif chemokine 14 Q16627 CCL14 
C-C motif chemokine 23 P55773 CCL23 
Cyclin-dependent kinase inhibitor 1B P46527 CDKN1B 
Cryptic protein P0CG37 CFC1 
Cofilin-1 P23528 CFL1 
Chymase P23946 CMA1 
C-reactive protein P02741 CRP 
Macrophage colony-stimulating factor 1 P09603 CSF1 
Granulocyte-macrophage colony-stimulating factor P04141 CSF2 
Cystatin-C P01034 CST3 
Cathepsin S P25774 CTSS 
C-X-C motif chemokine 11 O14625 CXCL11 
Interleukin-8 P10145 CXCL8 
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Protein UniProt ID Gene ID 
Discoidin domain-containing receptor 2 Q16832 DDR2 
Eukaryotic translation initiation factor 4 gamma 2 P78344 EIF4G2 
Eukaryotic translation initiation factor 5 P55010 EIF5 
Eukaryotic translation initiation factor 5A-1 P63241 EIF5A 
Ephrin type-A receptor 2 P29317 EPHA2 
Tissue Factor P13726 F3 
Ficolin-1 O00602 FCN1 
Tyrosine-protein kinase Fyn P06241 FYN 
Growth/differentiation factor 5 P43026 GDF5 
Aspartate aminotransferase, cytoplasmic P17174 GOT1 
Glucose-6-phosphate isomerase P06744 GPI 
Glutathione S-transferase P P09211 GSTP1 
Histone H2A.z P0C0S5 H2AFZ 
Hepatitis A virus cellular receptor 2 Q8TDQ0 HAVCR2 
Hepatoma-derived growth factor-related protein 2 Q7Z4V5 HDGFRP2 
Histone H1.2 P16403 HIST1H1C 
High mobility group protein B1 P09429 HMGB1 
Heme oxygenase 2 P30519 HMOX2 
Heterogeneous nuclear ribonucleoproteins A2/B1 P22626 HNRNPA2B1 
Heterogeneous nuclear ribonucleoprotein A/B Q99729 HNRNPAB 
Estradiol 17-beta-dehydrogenase 1 P14061 HSD17B1 
Heat shock 70 kDa protein 1A/1B P08107 HSPA1A 
Serine protease HTRA2, mitochondrial O43464 HTRA2 
ICOS ligand O75144 ICOSLG 
Insulin-like growth factor-binding protein 1 P08833 IGFBP1 
Insulin-like growth factor-binding protein 2 P18065 IGFBP2 
Interleukin-16 Q14005 IL16 
Interleukin-2 P60568 IL2 
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Protein UniProt ID Gene ID 
Interleukin-3 P08700 IL3 
Integrin alpha-I: beta-1 complex P56199, P05556 ITGA1 ITGB1 
Killer cell immunoglobulin-like receptor 2DL4 Q99706 KIR2DL4 
Importin subunit alpha-1 P52292 KPNA2 
Lipopolysaccharide-binding protein P18428 LBP 
Neutrophil gelatinase-associated lipocalin P80188 LCN2 
Lactotransferrin P02788 LTF 
Dual specificity mitogen-activated protein kinase kinase 1 Q02750 MAP2K1 
Dual specificity mitogen-activated protein kinase kinase 2 P36507 MAP2K2 
Mitogen-activated protein kinase 13 O15264 MAPK13 
Myoglobin P02144 MB 
Matrix metalloproteinase-9 P14780 MMP9 
Myeloperoxidase P05164 MPO 
Moesin P26038 MSN 
Nicotinamide phosphoribosyltransferase P43490 NAMPT 
NudC domain-containing protein 3 Q8IVD9 NUDCD3 
Oxidized low-density lipoprotein receptor 1 P78380 OLR1 
Protein DJ-1 Q99497 PARK7 
Phosphatidylethanolamine-binding protein 1 P30086 PEBP1 
Prefoldin subunit 5 Q99471 PFDN5 
Phosphoglycerate mutase 1 P18669 PGAM1 
Peptidoglycan recognition protein 1 O75594 PGLYRP1 
Elafin P19957 PI3 
Phospholipase A2, membrane associated P14555 PLA2G2A 
Urokinase plasminogen activator surface receptor Q03405 PLAUR 
NADPH--cytochrome P450 reductase P16435 POR 
Myeloblastin P24158 PRTN3 
Proteasome subunit alpha type-2 P25787 PSMA2 
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Protein UniProt ID Gene ID 
Prostaglandin G/H synthase 2 P35354 PTGS2 
Tyrosine-protein phosphatase non-receptor type 1 P18031 PTPN1 
Tyrosine-protein phosphatase non-receptor type 11 Q06124 PTPN11 
Tyrosine-protein phosphatase non-receptor type 6 P29350 PTPN6 
RNA-binding protein 39 Q14498 RBM39 
Resistin Q9HD89 RETN 
Ubiquitin P62979 RPS27A 
Ubiquitin+1, truncated mutation for UbB P62979 RPS27A 
40S ribosomal protein S7 P62081 RPS7 
Protein S100-A9 P06702 S100A9 
Serum amyloid A-1 protein P0DJI8 SAA1 
Scavenger receptor class F member 1 Q14162 SCARF1 
alpha-1-antichymotrypsin complex P01011 SERPINA3 
Plasma protease C1 inhibitor P05155 SERPING1 
Pulmonary surfactant-associated protein D P35247 SFTPD 
SHC-transforming protein 1 P29353 SHC1 
Sialic acid-binding Ig-like lectin 14 Q08ET2 SIGLEC14 
Small nuclear ribonucleoprotein F P62306 SNRPF 
FACT complex subunit SSRP1 Q08945 SSRP1 
Heterogeneous nuclear ribonucleoprotein Q O60506 SYNCRIP 
Trefoil factor 3 Q07654 TFF3 
Metalloproteinase inhibitor 1 P01033 TIMP1 
Tumor necrosis factor receptor superfamily member 1B P20333 TNFRSF1B 
Tumor necrosis factor ligand superfamily member 14 O43557 TNFSF14 
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DNA topoisomerase 1 P11387 TOP1 
Triosephosphate isomerase P60174 TPI1 
SUMO-conjugating enzyme UBC9 P63279 UBE2I 
Ubiquitin-conjugating enzyme E2 N P61088 UBE2N 
Ubiquitin-fold modifier 1 P61960 UFM1 
Vacuolar protein sorting-associated protein VTA1 homolog Q9NP79 VTA1 
X-ray repair cross-complementing protein 6 P12956 XRCC6 
Tyrosine-protein kinase Yes P07947 YES1 














Table A.S5. List of all significant proteins in analysis of IPF proteome versus healthy. Color code information at bottom. 
Uniprot ID 
Color 









Bonferroni Correction Age-adjusted FDR 
P17252  PRKCA 2.844150745 2.7443155 1.36E-14 0.000194363 4.3293E-14 0.001000972 
P02647  APOA1 1.542341061 1.544871222 1.451E-06 0.001467444 4.2806E-09 0.001282799 
O95390  GDF11 1.628565596 1.608156622 7.663E-12 0.000359572 1.1845E-07 0.000855199 
P09237  MMP7 2.654602809 2.747872619 2.054E-18 0.000126336 2.5766E-10 0.001720117 
P01031  C5 1.654531862 1.675076486 5.828E-07 0.001282799 7.3906E-06 0.001681244 
P63000  RAC1 1.610302077 1.574044262 1.098E-06 0.001389699 6.2295E-06 0.00191448 
Q9Y275  TNFSF13B 2.129450761 2.191299147 3.817E-19 9.71817E-05 4.4978E-11 0.000272109 
P07858  CTSB 1.665079978 1.742647874 3.293E-13 0.000242954 3.113E-11 0.000437318 
P50579  METAP2 2.400193949 2.369123805 4.876E-10 0.000515063 2.655E-08 0.002147716 
P00736  C1R 4.387258094 4.463494883 7.042E-22 5.8309E-05 6.7295E-17 0.001574344 
P13497  BMP1 2.462088383 2.418442708 4.891E-16 0.000165209 4.7633E-14 0.002196307 
P49336, P24863  CDK8 CCNC 1.642587894 1.64618749 5.658E-19 0.000116618 8.7935E-11 0.00292517 
P41240  CSK 1.955228256 1.939577175 5.987E-10 0.000524781 2.9947E-06 0.001137026 
P05154  SERPINA5 2.493816792 2.438316738 4.487E-18 0.000136054 2.0621E-20 0.001525753 
P49840, P49841  GSK3A GSK3B 3.734712707 3.634606001 3.89E-27 9.71817E-06 6.23E-18 0.001389699 
P42680  TEC 2.558122735 2.478830736 2.333E-16 0.000145773 2.3177E-08 0.001156463 
P49137  MAPKAPK2 1.868501241 1.883819574 4.897E-08 0.00090379 1.7658E-06 0.002400389 
O00170  AIP 1.715314482 1.675073096 9.679E-15 0.000174927 6.676E-09 0.000719145 
P04406  GAPDH 1.669919932 1.639169965 5.773E-06 0.001856171 5.3425E-07 0.000942663 
Q13765  NACA 2.276481926 2.165538354 3.917E-21 7.77454E-05 6.6077E-12 0.00047619 
O43765  SGTA 1.859855557 1.803317323 1.199E-08 0.000767736 2.8969E-07 0.002001944 
O95219  SNX4 2.060637667 1.939104225 7.436E-09 0.000709427 1.9616E-08 0.002137998 
P02751  FN1 2.058884999 2.1387836 5.309E-12 0.000340136 2.7176E-08 0.001059281 
O43488  AKR7A2 2.382612119 2.339107573 2.438E-11 0.000388727 1.7054E-07 0.00159378 
P14618  PKM2 2.372734125 2.397160175 2.892E-13 0.000233236 5.4956E-09 0.002254616 
P62826  RAN 10.78442484 8.501570061 9.529E-21 8.74636E-05 3.8826E-11 0.001467444 
P54920  NAPA 2.259133786 2.144386113 1.622E-13 0.000204082 1.6544E-09 0.002983479 













Bonferroni Correction Age-adjusted FDR 
Q16549  PCSK7 2.06801082 1.986426465 5.236E-22 4.85909E-05 6.9419E-12 0.000291545 
P12259  F5 1.568462646 1.611038214 1.518E-11 0.000369291 1.0352E-06 0.000349854 
O00299  CLIC1 3.059946004 2.993311375 6.309E-12 0.000349854 6.6552E-09 2.91545E-05 
Q9UMF0  ICAM5 1.759344079 1.804719167 2.014E-11 0.000379009 1.3082E-07 0.000281827 
Q08752  PPID 3.742581674 3.511759899 1.307E-12 0.000281827 3.2523E-06 0.0003207 
P45985  MAP2K4 1.747910459 1.715622054 4.992E-09 0.000680272 9.5677E-08 0.000330418 
P12931  SRC 3.854282773 3.709558785 1.198E-22 3.88727E-05 1.027E-18 0.000252672 
O76074  PDE5A 4.43765169 3.978480542 9.751E-26 1.94363E-05 8.5254E-15 0.000447036 
P10912  GHR 1.777326642 1.767808273 1.284E-10 0.000447036 2.1388E-10 0.000728863 
Q03154  ACY1 4.904977655 4.13058665 6.462E-13 0.000272109 4.2266E-06 0.000155491 
P42336, P27986  PIK3CA PIK3R1 1.595594423 1.612386386 5.423E-19 0.0001069 6.2975E-11 0.001972789 
Q06187  BTK 10.44813268 9.363373991 2.252E-24 2.91545E-05 8.0073E-14 0.001068999 
Q96KN2  CNDP1 2.772175242 2.868771762 5.328E-13 0.000262391 5.454E-10 0.001127308 
Q9Y3A5  SBDS 2.559809181 2.525581685 1.145E-14 0.000184645 8.1077E-10 0.000612245 
P16109  SELP 1.755253189 1.688921305 5.013E-11 0.000398445 4.4751E-09 0.001292517 
P08649  C4A C4B 2.163849532 2.152620093 2.106E-13 0.000223518 1.7857E-12 0.000894072 
P43652  AFM 1.516790465 1.509684337 4.459E-09 0.000660836 1.8907E-10 0.001613217 
Q9HCR9  PDE11A 2.693926113 2.629765299 4.46E-10 0.000505345 4.4336E-07 0.000262391 
P05771  PRKCB 2.549572043 2.527742077 2.072E-13 0.0002138 1.944E-07 0.000621963 
P42892  ECE1 1.496922719 1.545032257 2.628E-08 0.000864917 1.3217E-07 0.002439261 
Q9UHD0  IL19 1.536009374 1.522027626 6.889E-08 0.000942663 2.5591E-05 0.001146744 
P23280  CA6 2.120863591 2.199196968 8.504E-07 0.001350826 9.6872E-05 0.000242954 
Q8N1Q1  CA13 2.14243776 2.090315543 3.449E-08 0.000874636 0.00011986 0.001428571 
P07996  THBS1 1.722022566 1.66082076 2.042E-06 0.001564626 0.00124037 0.002954325 
Q9NQU5  PAK6 1.78765298 1.782944743 9.87E-07 0.001379981 3.1333E-05 0.001049563 
Q8N5S9  CAMKK1 1.689904266 1.68676957 9.496E-07 0.001370262 0.00133575 0.001477162 
Q99714  HSD17B10 2.648891087 2.544580128 1.222E-07 0.001039845 0.00027562 0.001234208 
Q08209, P63098  PPP3CA PPP3R1 1.996632503 2.050362653 2.685E-07 0.001175899 3.7241E-05 3.88727E-05 
P03956  MMP1 1.880033667 1.868914014 6.063E-08 0.000932945 9.6125E-05 0.001448008 













Bonferroni Correction Age-adjusted FDR 
P36888  FLT3 1.633132296 1.62729439 1.988E-07 0.00111759 0.00026356 0.000602527 
P12277, P06732  CKB CKM 3.424539483 2.772971246 9.364E-09 0.000748299 0.00031418 0.001341108 
O75636  FCN3 1.486624762 1.505689722 4.105E-06 0.001739553 0.00219711 0.00877551 
O43557  TNFSF14 0.437387768 0.433556681 2.631E-09 0.000612245 3.9442E-15 0.001098154 
P62306  SNRPF 0.589209938 0.585044542 3.073E-09 0.000631681 2.0066E-16 0.001671526 
P18065  IGFBP2 0.561250316 0.560919529 1.127E-06 0.001399417 8.7262E-10 0.000641399 
P14780  MMP9 0.580646533 0.581799239 8.175E-06 0.001963071 6.1719E-07 0.000340136 
P05164  MPO 0.66653812 0.664052177 3.288E-07 0.001195335 3.5821E-06 0.000116618 
P55010  EIF5 0.264516494 0.257394258 1.575E-10 0.000466472 2.9209E-26 0.00068999 
P30519  HMOX2 0.302673799 0.309421198 1.115E-08 0.000758017 2.4311E-15 0.00079689 
Q03405  PLAUR 0.714503307 0.711668768 3.972E-06 0.001729835 6.9874E-07 0.000553936 
P01024  C3 0.531153018 0.521491138 3.962E-12 0.0003207 6.326E-28 0.000631681 
P16435  POR 0.193507136 0.203838807 1.288E-07 0.001049563 1.2994E-16 0.001554908 
P43026  GDF5 0.527925041 0.526377553 1.399E-07 0.001098154 5.7904E-16 0.000369291 
P01024  C3 0.594138865 0.588274349 2.357E-08 0.000855199 7.0592E-16 0.000631681 
Q14005  IL16 0.23033519 0.237400985 4.271E-09 0.000651118 2.2301E-17 0.000660836 
P12956  XRCC6 0.179825644 0.192845513 9.608E-08 0.000971817 4.8595E-14 0.001758989 
P55008  AIF1 0.344025162 0.34967201 5.447E-08 0.000913508 7.8303E-12 6.80272E-05 
P52292  KPNA2 0.576832085 0.585079807 5.707E-09 0.00068999 1.2065E-17 0.001166181 
Q02750  MAP2K1 0.359077237 0.362158859 4.702E-07 0.001234208 8.6888E-13 8.74636E-05 
P11387  TOP1 0.161052587 0.172640307 7.554E-06 0.001943635 2.8135E-13 0.000544218 
P63279  UBE2I 0.402202186 0.406545614 1.118E-07 0.001000972 9.1848E-12 0.000913508 
P07947  YES1 0.530683894 0.535492527 5.545E-08 0.000923226 1.0937E-15 0.000515063 
P16403  HIST1H1C 0.18202697 0.179435862 2.033E-12 0.000301263 1.1917E-21 0.000991254 
P18031  PTPN1 0.513454609 0.518122474 4.335E-06 0.001749271 2.7091E-11 0.000145773 
P20810  CAST 0.625591416 0.647812276 1.392E-10 0.000456754 1.1152E-10 0.000466472 
P02144  MB 0.444987418 0.457379403 1.781E-06 0.001516035 1.3409E-12 0.000680272 
P60568  IL2 0.602649926 0.607874718 8.102E-07 0.001341108 8.832E-12 7.77454E-05 
P25774  CTSS 0.691366271 0.70449585 1.438E-06 0.001457726 2.5524E-06 1.94363E-05 













Bonferroni Correction Age-adjusted FDR 
O43464  HTRA2 0.727295489 0.719331748 7.34E-07 0.001321672 2.8688E-09 0.000485909 
O75594  PGLYRP1 0.385704603 0.406150492 1.661E-06 0.001506317 1.0747E-11 0.000126336 
Q13554  CAMK2B 0.448493259 0.46201085 3.863E-06 0.001720117 8.3106E-06 0.000651118 
Q06124  PTPN11 0.325170474 0.320946853 7.107E-11 0.000417881 7.5569E-24 0.00133139 
Q13557  CAMK2D 0.448876214 0.457971263 1.144E-06 0.001409135 3.2017E-08 0.000923226 
P10145  CXCL8 0.034225488 0.036256866 3.956E-08 0.000894072 7.9872E-23 0.000194363 
P56199, P05556  ITGA1 ITGB1 0.298316266 0.315384647 5.57E-07 0.001263362 1.0694E-12 5.8309E-05 
P24158  PRTN3 0.241989732 0.250856356 2.183E-06 0.001584062 1.1768E-09 0.00058309 
Q16832  DDR2 0.59816339 0.593148426 1.398E-06 0.001448008 8.3643E-13 0.001088435 
O00602  FCN1 0.487691807 0.491252641 4.684E-06 0.001788144 2.947E-09 0.000388727 
P36507  MAP2K2 0.399325508 0.409209093 3.71E-09 0.000641399 1.0395E-20 0.000301263 
P46527  CDKN1B 0.390461304 0.389275226 1.256E-09 0.000592809 8.6472E-14 0.001205053 
P09603  CSF1 0.349185705 0.345595517 5.652E-06 0.001846453 2.4947E-11 0.001253644 
P35354  PTGS2 0.300945517 0.304112877 8.668E-10 0.000563654 3.2731E-23 4.85909E-05 
P06241  FYN 0.15968612 0.158580485 9.413E-11 0.0004276 3.0673E-28 0.001039845 
P62081  RPS7 0.185649796 0.187803316 6.968E-10 0.000553936 4.3763E-22 0.0005345 
P18669  PGAM1 0.380200082 0.367406052 2.737E-10 0.000485909 2.1317E-13 9.71817E-06 
P08107  HSPA1A 0.329230499 0.325625349 3.616E-13 0.000252672 5.5044E-21 0.000184645 
P01011  SERPINA3 0.457669471 0.44651438 5.712E-07 0.001273081 9.634E-12 0.000670554 
P14550  AKR1A1 0.591448395 0.596031761 3.696E-06 0.001690962 1.6211E-07 0.000505345 
P23528  CFL1 0.669498441 0.658275648 7.5E-06 0.001933916 1.3489E-09 0.000204082 
O60506  SYNCRIP 0.291191938 0.297780019 9.354E-08 0.000962099 4.8968E-20 0.0001069 
Q99471  PFDN5 0.254728054 0.25020284 6.318E-09 0.000699708 1.7807E-24 0.000563654 
P06744  GPI 0.529843615 0.523601892 1.48E-08 0.00079689 2.6058E-12 0.001933916 
P30086  PEBP1 0.628052496 0.616272435 4.374E-06 0.001758989 1.2629E-08 0.000738581 
Q14498  RBM39 0.17003682 0.17844853 1.313E-07 0.001059281 1.2501E-14 0.000592809 
P29350  PTPN6 0.339639104 0.338090817 9.057E-10 0.000573372 2.0333E-16 0.000408163 
P02741  CRP 0.625041071 0.602656298 1.204E-06 0.001418853 5.8331E-08 0.000233236 
Q9UIK4  DAPK2 0.400809219 0.401459963 2.019E-08 0.000826045 1.0825E-07 0.000952381 













Bonferroni Correction Age-adjusted FDR 
Q99729  HNRNPAB 0.345921247 0.35846041 1.945E-06 0.001554908 4.6961E-09 0.001953353 
P62979  RPS27A 0.470375766 0.461535957 5.172E-07 0.001243926 9.9226E-13 0.0002138 
Q7Z4V5  HDGFRP2 0.060924947 0.055653979 6.293E-11 0.000408163 4.0153E-34 0.001243926 
P14061  HSD17B1 0.176376578 0.186493411 1.353E-07 0.001088435 4.8554E-20 0.002410107 
P08700  IL3 0.62221433 0.627986419 3.837E-06 0.001710398 1.9802E-11 0.000223518 
P09211  GSTP1 0.544764141 0.534249412 3.899E-07 0.001205053 3.0047E-13 0.000165209 
P17174  GOT1 0.524455222 0.517574344 1.944E-09 0.000602527 5.2867E-19 0.000310982 
P07355  ANXA2 0.298075338 0.296106201 3.332E-10 0.000495627 4.6371E-22 0.001788144 
P40121  CAPG 0.231802025 0.233433389 1.208E-09 0.00058309 1.4771E-12 0.00244898 
O15264  MAPK13 0.299068474 0.301080845 1.696E-08 0.000806608 5.1201E-11 0.001875607 
P26038  MSN 0.351191486 0.349889679 2.743E-09 0.000621963 3.0007E-12 0.002478134 
P43490  NAMPT 0.240390948 0.256498616 3.815E-08 0.000884354 2.7028E-14 0.001584062 
Q99497  PARK7 0.310701688 0.322106754 1.307E-08 0.000777454 1.2199E-18 0.00324587 
O75144  ICOSLG 0.219547354 0.223111787 1.566E-07 0.001107872 2.0022E-09 0.00180758 
Q99706  KIR2DL4 0.478349129 0.479635576 1.145E-07 0.001030126 7.8372E-11 0.002099125 
Q14162  SCARF1 0.516331552 0.508016155 1.754E-08 0.000816327 6.8641E-19 0.003313897 
P06702  S100A9 0.591697735 0.586341331 1.214E-06 0.001428571 1.0594E-07 0.001195335 
P0C0L5  C4A C4B 0.358507662 0.369051932 1.363E-12 0.000291545 3.8228E-20 0.000524781 
P09429  HMGB1 0.379602216 0.375656719 2.211E-08 0.000835763 4.4323E-16 0.000495627 
P29353  SHC1 0.39845923 0.390325715 6.392E-10 0.000544218 3.9594E-20 0.00170068 
P04083  ANXA1 0.491332759 0.484731275 2.239E-08 0.000845481 7.6468E-10 0.000174927 
Q08945  SSRP1 0.064935707 0.074339255 1.314E-07 0.001068999 7.0746E-21 0.00234208 
Q92851  CASP10 0.733486915 0.746854294 4.988E-06 0.00180758 1.6671E-06 0.001457726 
P22626  HNRNPA2B1 0.304653849 0.304147983 1.089E-10 0.000437318 3.7583E-14 0.001321672 
Q05397  PTK2 0.361679962 0.378753188 8.674E-09 0.000738581 2.6631E-05 0.000379009 
P01033  TIMP1 0.679269263 0.66674616 0.000391 0.002905734 6.6026E-08 0.008357629 
P01034  CST3 0.63498025 0.648738355 0.0021138 0.003488824 3.7008E-06 0.00808552 
P02788  LTF 0.646580172 0.660962703 0.0002031 0.002633625 3.8306E-06 0.004723032 
P05186  ALPL 0.730903722 0.736706819 7.331E-05 0.002303207 1.5228E-06 0.007609329 













Bonferroni Correction Age-adjusted FDR 
P07451  CA3 0.595832363 0.560995319 0.0029284 0.003654033 2.8427E-06 0.001350826 
P63241  EIF5A 0.639598496 0.626260436 4.906E-05 0.002264334 1.829E-08 0.004752187 
P61088  UBE2N 0.679152378 0.668632317 9.424E-05 0.002380952 3.7967E-06 0.002779397 
P0C0S5  H2AFZ 0.085008123 0.094716988 1.043E-05 0.002001944 2.6092E-14 0.004344023 
Q9NP79  VTA1 0.68463685 0.665210265 1.045E-05 0.002011662 5.6174E-11 0.005344995 
P25787  PSMA2 0.390509178 0.357843285 0.0047528 0.003906706 1.1165E-07 0.005004859 
P05155  SERPING1 0.407843012 0.377329305 0.002597 0.003586006 1.7868E-08 0.001078717 
P04141  CSF2 0.716695601 0.70886671 0.0024597 0.003566569 1.5111E-06 0.005218659 
P08833  IGFBP1 0.393702902 0.408439401 0.000134 0.002478134 1.192E-06 0.009339164 
P80188  LCN2 0.192644603 0.212966828 0.0001084 0.002419825 2.3708E-10 0.004003887 
P62979  RPS27A 0.748787706 0.725982264 0.0001239 0.002458698 1.3893E-10 0.0002138 
Q16627  CCL14 0.730237589 0.725946814 0.0004162 0.002944606 7.5672E-06 0.006297376 
O14625  CXCL11 0.480301473 0.471102974 0.0003025 0.00281827 1.7786E-07 0.004266278 
Q9HD89  RETN 0.53666193 0.538277838 0.0002682 0.002750243 1.1095E-07 0.007832847 
P18428  LBP 0.601598528 0.621936449 0.0001787 0.00260447 4.7373E-08 0.010447036 
P20333  TNFRSF1B 0.528556645 0.530989059 0.0001396 0.00249757 2.0522E-09 0.004596696 
P23946  CMA1 0.422400525 0.449911378 0.000103 0.002410107 6.0735E-08 0.008551992 
P78380  OLR1 0.376747719 0.387146365 1.569E-05 0.002060253 4.2928E-09 0.001729835 
P61960  UFM1 0.61686735 0.606344498 1.583E-05 0.002069971 1.0983E-09 0.00281827 
P78344  EIF4G2 0.517757776 0.509215443 5.586E-05 0.002274052 1.092E-08 0.004013605 
Q8IVD9  NUDCD3 0.555472185 0.548221386 1.009E-05 0.001992225 1.1417E-10 0.003119534 
P60174  TPI1 0.693640403 0.683253702 8.747E-05 0.002361516 3.7814E-06 0.006287658 
P0DJI8  SAA1 0.173531112 0.180295633 0.0004928 0.00303207 3.3565E-08 0.00090379 
Q07654  TFF3 0.478602321 0.492382656 0.0051497 0.003974733 8.1428E-06 0.005228377 
P13726  F3 0.592836215 0.609717233 0.0001829 0.002614189 2.7012E-07 0.002827988 
P19957  PI3 0.359454756 0.367402763 8.107E-05 0.002332362 1.1063E-10 0.00526725 
P14555  PLA2G2A 0.164508441 0.178116603 0.0004127 0.002934888 2.7444E-09 0.002322643 
P29317  EPHA2 0.543657766 0.539472754 0.0029097 0.003644315 2.3118E-06 0.007152575 
Q08ET2  SIGLEC14 0.653055432 0.645056946 0.0003386 0.002857143 8.2826E-06 0.004897959 













Bonferroni Correction Age-adjusted FDR 
P13686  ACP5 1.504767826 1.489334666 4.532E-09 0.000670554 9.3819E-07 0.000777454 
P20273  CD22 1.184673275 1.176234949 8.388E-09 0.000728863 3.2038E-06 0.003605442 
P51665  PSMD7 1.227734879 1.221843412 6.226E-10 0.0005345 7.0956E-06 0.002050534 
Q07817  BCL2L1 1.490277914 1.479585533 2.427E-12 0.000310982 5.7369E-08 0.000884354 
P06396  GSN 1.285528406 1.306069247 3.753E-06 0.00170068 7.1603E-07 0.001418853 
P04196  HRG 1.418870563 1.442868446 2.642E-07 0.001166181 1.6043E-07 0.001360544 
Q9HCK4  ROBO2 1.407713095 1.395479599 1.126E-07 0.00101069 1.6629E-08 0.001516035 
P12268  IMPDH2 1.338326362 1.339255747 2.562E-10 0.00047619 5.2757E-06 0.00313897 
P22223  CDH3 1.385373136 1.399310188 1.063E-07 0.000981535 2.2775E-07 0.003634597 
P07225  PROS1 1.272634163 1.275797707 2.912E-07 0.001185617 4.6845E-09 0.002176871 
O43291  SPINT2 1.485466338 1.458185513 1.299E-06 0.00143829 1.8954E-06 0.001982507 
Q9BY41  HDAC8 1.424686176 1.425858407 2.406E-16 0.000155491 1.5161E-09 0.006598639 
P08697  SERPINF2 1.31047173 1.30667218 1.367E-08 0.000787172 3.6237E-11 0.002934888 
P02748  C9 0.781050273 0.782880587 1.145E-07 0.001020408 1.3663E-07 0.002332362 
P29622  SERPINA4 1.269072953 1.257079381 8.1E-06 0.001953353 3.5722E-06 0.001496599 
Q96IY4  CPB2 0.819875158 0.824769315 4.543E-06 0.001778426 4.0513E-07 0.003449951 
P31785  IL2RG 1.545659909 1.496723647 6.757E-07 0.001311953 0.00018474 0.0004276 
P26951  IL3RA 1.508301381 1.468159905 2.326E-06 0.00159378 0.00142495 0.00143829 
O76036  NCR1 0.741569652 0.755075196 5.621E-06 0.001836735 2.8209E-05 0.00212828 
P02649  APOE 1.325399966 1.282131162 2.048E-07 0.001137026 0.000283 0.001622935 
P10721  KIT 1.489125587 1.416727689 7.463E-09 0.000719145 9.22E-06 0.001652089 
P09758  TACSTD2 1.420541839 1.416748142 7.103E-08 0.000952381 0.00034927 0.001506317 
P00533  EGFR 1.30263973 1.283543266 6.012E-06 0.001895044 1.9617E-05 0.001399417 
Q9BYF1  ACE2 1.343109036 1.351129252 7.681E-07 0.00133139 0.00036686 0.006180758 
P02649  APOE 1.244447984 1.206073828 7.474E-06 0.001924198 0.0024964 0.001622935 
P02649  APOE 1.286022867 1.239419842 2.083E-06 0.001574344 0.00025421 0.001622935 
P17931  LGALS3 0.752839331 0.772008464 2.628E-07 0.001156463 1.0971E-05 0.000398445 
P35475  IDUA 1.411818675 1.445766652 5.303E-07 0.001253644 7.8693E-05 0.000748299 
P01374, Q06643  LTA LTB 1.393305269 1.389026313 1.467E-06 0.001477162 9.2873E-05 0.004664723 













Bonferroni Correction Age-adjusted FDR 
Q9Y4X3  CCL27 1.173722536 1.162169851 3.663E-06 0.001681244 6.6273E-05 0.00122449 
P07585  DCN 1.20880279 1.189205245 5.211E-06 0.001817298 0.00010196 0.001885326 
Q9NP95  FGF20 1.438391531 1.407985353 5.916E-06 0.001875607 0.00576751 0.002390671 
P08684  CYP3A4 1.445797436 1.410315476 3.527E-06 0.001661808 5.9022E-05 0.00111759 
P29279  CTGF 1.32159639 1.299436776 5.526E-06 0.001827017 0.00012742 0.002585034 
P56470  LGALS4 1.363080837 1.386548727 2.305E-07 0.001146744 0.0004329 0.001642371 
Q15582  TGFBI 1.377537653 1.384270242 1.785E-06 0.001525753 0.00011283 0.001273081 
Q8IWV2  CNTN4 1.266326604 1.257256862 4.96E-06 0.001797862 1.4765E-05 0.001107872 
O94779  CNTN5 1.258655438 1.254045937 1.594E-06 0.001496599 8.4023E-05 0.002837707 
P06493, P14635  CDC2 CCNB1 1.198173718 1.181337678 3.301E-06 0.001613217 0.00089827 0.005578231 
Q92876  KLK6 0.864513016 0.866147653 2.492E-06 0.001603499 0.00035015 0.006375121 
O00626  CCL22 1.424081215 1.429480123 3.309E-06 0.001622935 0.00020088 0.004635569 
P01282  VIP 1.424445332 1.413234053 5.966E-06 0.001885326 0.00344855 0.002089407 
Q6UXD5  SEZ6L2 1.407069992 1.369992374 8.816E-06 0.001972789 0.0005441 0.009193392 
P68036  UBE2L3 1.467831972 1.427595832 3.606E-06 0.001671526 0.00063943 0.009115646 
Q96GD0  PDXP 1.490673622 1.447598284 7.077E-06 0.00191448 0.00047606 0.000835763 
P08620  FGF4 1.23892107 1.229893786 6.193E-07 0.001302235 0.00118849 0.001661808 
Q99075  HBEGF 1.293217012 1.291360122 4.647E-07 0.00122449 0.00106179 0.000758017 
P20783  NTF3 1.414871631 1.405958216 5.997E-07 0.001292517 0.00121293 0.000456754 
P32004  L1CAM 1.422955729 1.402037028 4.477E-07 0.001214772 1.0997E-05 0.002361516 
O43323  DHH 1.427120242 1.403360929 1.827E-06 0.001535471 0.00075255 0.000864917 
O43320  FGF16 1.401626175 1.370275971 1.549E-06 0.00148688 0.00060477 0.002419825 
O75356  ENTPD5 1.27036547 1.282597991 3.47E-06 0.001652089 1.6184E-05 0.001020408 
Q4KMG0  CDON 1.438856529 1.395132851 6.493E-06 0.001904762 1.3063E-05 0.000573372 
P10909  CLU 1.268085243 1.273973382 4.497E-06 0.001768707 9.0924E-05 0.000826045 
Q9NZU1  FLRT1 1.438468618 1.404044634 9.319E-07 0.001360544 0.00032809 0.002069971 
P21217  FUT3 1.457634251 1.441771268 2.029E-07 0.001127308 0.00057164 0.000874636 
Q12884  FAP 1.355855033 1.36028669 3.434E-06 0.001642371 0.00025698 0.000136054 
Q02241  KIF23 1.439636723 1.387282427 3.31E-06 0.001632653 0.00061253 0.000417881 













Bonferroni Correction Age-adjusted FDR 
P48061  CXCL12 0.779402388 0.782938513 9.425E-06 0.001982507 6.6164E-06 0.00447036 
P29401  TKT 0.76346032 0.750233644 0.0004592 0.003002915 7.2265E-06 0.009737609 
 
Color Code 
  Upregulated in IPF AND Age-adjusted AND non-age-adjusted significant 
  Upregulated in IPF AND non-age significant 
 Age-adjusted AND/OR non-age-adjusted significant but not biologically relevant 
  Downregulated in IPF AND Age-adjusted AND non-age-adjusted significant 
  Downregulated in IPF AND Age-adjusted significant 











Table A.S6. ClueGO analysis of biological roles of upregulated protesin in IPF plasma. 















s Associated Genes Found 





9 2.9E-6 210.0E-9 12.82 5.00 [ECE1, GSK3A, GSK3B, PDE5A, PRKCA] 
ErbB signaling pathway KEGG_10.02.2016 4.0E-9 160.0E-9 17.0E-15 8.05 7.00 





-9 39.0E-6 17.0E-15 5.00 6.00 
[PIK3CA, PIK3R1, PRKCA, PRKCB, RAC1, 
SPHK1] 
VEGF signaling pathway KEGG_10.02.2016 
5.1E-
12 210.0E-12 17.0E-15 13.11 8.00 
[MAPKAPK2, PIK3CA, PIK3R1, PRKCA, PRKCB, 
RAC1, SPHK1, SRC] 
B cell receptor signaling 
pathway KEGG_10.02.2016 
49.0E-
9 2.0E-6 17.0E-15 8.22 6.00 [BTK, GSK3B, PIK3CA, PIK3R1, PRKCB, RAC1] 
Fc epsilon RI signaling 
pathway KEGG_10.02.2016 
32.0E-
9 1.3E-6 17.0E-15 8.82 6.00 
[BTK, MAP2K4, PIK3CA, PIK3R1, PRKCA, 
RAC1] 
Fc gamma R-mediated 
phagocytosis KEGG_10.02.2016 
210.0E
-9 8.6E-6 17.0E-15 6.45 6.00 
[PIK3CA, PIK3R1, PRKCA, PRKCB, RAC1, 
SPHK1] 
Thyroid hormone signaling 
pathway KEGG_10.02.2016 
860.0E
-9 35.0E-6 17.0E-15 5.08 6.00 [GSK3B, PIK3CA, PIK3R1, PRKCA, PRKCB, SRC] 
AGE-RAGE signaling pathway 
in diabetic complications KEGG_10.02.2016 
340.0E
-9 14.0E-6 17.0E-15 5.94 6.00 [FN1, PIK3CA, PIK3R1, PRKCA, PRKCB, RAC1] 
Bacterial invasion of 
epithelial cells KEGG_10.02.2016 2.4E-6 99.0E-6 17.0E-15 6.41 5.00 [FN1, PIK3CA, PIK3R1, RAC1, SRC] 









-15 17.0E-12 17.0E-15 4.69 
13.0
0 
[APOA1, CLIC1, CSK, F5, FN1, PIK3CA, PIK3R1, 
PRKCA, PRKCB, RAC1, SELP, SRC, TEC] 
regulation of cellular 




-9 28.0E-6 17.0E-15 8.20 5.00 [GSK3A, PIK3R1, PRKCA, PRKCB, SRC] 
Complement and coagulation 
cascades KEGG_10.02.2016 1.3E-6 53.0E-6 3.9E-6 7.25 5.00 [C1R, C4B, C5, F5, SERPINA5] 
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Table A.S7. ClueGo analysis of the biological roles of downregulated proteins in IPF plasma. 

















GOA_09.02.2016_16h18 67.0E-9 11.0E-6 740.0E-9 6.10 10.00 
[C3, CRP, F3, GSTP1, LBP, PTGS2, SAA1, 
SERPINA3, SERPING1, TIMP1] 
Fc receptor signaling 
pathway 
GO_ImmuneSystemProcess
-GOA_09.02.2016_16h18 650.0E-12 110.0E-9 3.4E-15 4.09 17.00 
[CAMK2B, CAMK2D, CDKN1B, CFL1, CSF2, 
FYN, IL2, IL3, MAP2K1, MAP2K2, PEBP1, 
PSMA2, PTPN11, RPS27A, SHC1, UBE2N, 
YES1] 
response to peptide 
hormone 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 10.0E-15 1.8E-12 3.4E-15 4.07 26.00 
[ANXA1, CAMK2B, CAMK2D, CDKN1B, CSF2, 
FYN, GOT1, GSTP1, IGFBP1, IGFBP2, IL2, IL3, 
MAP2K1, MAP2K2, NAMPT, PEBP1, POR, 
PSMA2, PTPN1, PTPN11, PTPN6, RETN, 
RPS27A, SHC1, TFF3, TIMP1] 
cellular response to 
fibroblast growth factor 
stimulus 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 4.1E-9 720.0E-9 3.4E-15 4.26 15.00 
[CAMK2B, CAMK2D, CDKN1B, CSF2, CXCL8, 
FYN, IL2, IL3, MAP2K1, MAP2K2, PEBP1, 
PSMA2, PTPN11, RPS27A, SHC1] 
response to insulin 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 11.0E-12 1.9E-9 3.4E-15 4.18 20.00 
[CAMK2B, CAMK2D, CSF2, FYN, GOT1, 
GSTP1, IGFBP1, IGFBP2, IL2, IL3, MAP2K1, 
MAP2K2, NAMPT, PEBP1, PSMA2, PTPN1, 
PTPN11, RETN, RPS27A, SHC1] 
Fc-epsilon receptor signaling 
pathway 
GO_ImmuneSystemProcess
-GOA_09.02.2016_16h18 3.8E-9 660.0E-9 3.4E-15 4.29 15.00 
[CAMK2B, CAMK2D, CDKN1B, CSF2, FYN, 
IL2, IL3, MAP2K1, MAP2K2, PEBP1, PSMA2, 
PTPN11, RPS27A, SHC1, UBE2N] 
cellular response to insulin 
stimulus 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 97.0E-12 17.0E-9 3.4E-15 4.27 18.00 
[CAMK2B, CAMK2D, CSF2, FYN, GOT1, 
GSTP1, IGFBP1, IL2, IL3, MAP2K1, MAP2K2, 
NAMPT, PEBP1, PSMA2, PTPN1, PTPN11, 
RPS27A, SHC1] 
insulin receptor signaling 
pathway 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 380.0E-12 66.0E-9 3.4E-15 4.61 16.00 
[CAMK2B, CAMK2D, CSF2, FYN, IGFBP1, IL2, 
IL3, MAP2K1, MAP2K2, NAMPT, PEBP1, 
PSMA2, PTPN1, PTPN11, RPS27A, SHC1] 
epidermal growth factor 
receptor signaling pathway 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 150.0E-12 27.0E-9 3.4E-15 4.49 17.00 
[CAMK2B, CAMK2D, CDKN1B, CSF2, FYN, 
IL2, IL3, ITGA1, MAP2K1, MAP2K2, MMP9, 




GOA_09.02.2016_16h18 160.0E-9 28.0E-6 1.8E-6 4.26 12.00 
[AIF1, ANXA1, C3, CFL1, CRP, FCN1, FYN, 
HMGB1, LBP, PRTN3, SFTPD, YES1] 
peptidase regulator activity 
GO_MolecularFunction-
GOA_09.02.2016_16h18 150.0E-9 26.0E-6 14.0E-12 4.85 11.00 
[C3, C4B_2, CAST, CDKN1B, CST3, PEBP1, 




GOA_09.02.2016_16h18 160.0E-9 28.0E-6 14.0E-12 5.56 10.00 
[C3, C4B_2, CAST, CST3, PEBP1, PI3, 
SERPINA3, SERPING1, TIMP1, TNFSF14] 
regulation of endopeptidase 
activity 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 490.0E-15 86.0E-12 14.0E-12 4.96 20.00 
[C3, C4B_2, CAST, CDKN1B, CST3, F3, GPI, 
HMGB1, HTRA2, MMP9, PARK7, PEBP1, PI3, 
PLAUR, POR, S100A9, SERPINA3, SERPING1, 
TIMP1, TNFSF14] 
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s Associated Genes Found 
negative regulation of 
endopeptidase activity 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 69.0E-12 12.0E-9 14.0E-12 5.73 15.00 
[C3, C4B_2, CAST, CST3, GPI, MMP9, PARK7, 
PEBP1, PI3, PLAUR, POR, SERPINA3, 
SERPING1, TIMP1, TNFSF14] 
regulation of cysteine-type 
endopeptidase activity 
involved in apoptotic 
process 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 110.0E-9 20.0E-6 14.0E-12 4.98 11.00 
[CDKN1B, F3, GPI, HMGB1, HTRA2, MMP9, 
PARK7, PLAUR, POR, S100A9, TNFSF14] 
positive regulation of 
leukocyte activation 
GO_ImmuneSystemProcess
-GOA_09.02.2016_16h18 21.0E-9 3.8E-6 25.0E-9 4.12 14.00 
[AIF1, ANXA1, FYN, HAVCR2, HMGB1, 
IGFBP2, IL2, LBP, PTPN11, PTPN6, S100A9, 
TIMP1, TNFSF14, YES1] 
leukocyte proliferation 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 4.0E-9 710.0E-9 25.0E-9 4.70 14.00 
[AIF1, ANXA1, CSF1, FYN, GSTP1, HMGB1, 





GOA_09.02.2016_16h18 180.0E-9 32.0E-6 25.0E-9 4.21 12.00 
[AIF1, ANXA1, CSF1, FYN, HMGB1, IGFBP2, 
IL2, PTPN6, S100A9, SFTPD, TIMP1, 
TNFSF14] 
T cell proliferation 
GO_ImmuneSystemProcess
-GOA_09.02.2016_16h18 280.0E-9 49.0E-6 25.0E-9 5.24 10.00 
[AIF1, ANXA1, FYN, HMGB1, IGFBP2, IL2, 
PTPN6, SFTPD, TIMP1, TNFSF14] 
regulation of T cell 
activation 
GO_ImmuneSystemProcess
-GOA_09.02.2016_16h18 83.0E-9 14.0E-6 25.0E-9 4.06 13.00 
[AIF1, ANXA1, FYN, HAVCR2, HMGB1, 
IGFBP2, IL2, PTPN11, PTPN6, SFTPD, TIMP1, 
TNFSF14, YES1] 
positive regulation of T cell 
activation 
GO_ImmuneSystemProcess
-GOA_09.02.2016_16h18 150.0E-9 26.0E-6 25.0E-9 4.85 11.00 
[AIF1, ANXA1, FYN, HMGB1, IGFBP2, IL2, 
PTPN11, PTPN6, TIMP1, TNFSF14, YES1] 
regulation of leukocyte 
proliferation 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 11.0E-9 1.9E-6 25.0E-9 5.43 12.00 
[AIF1, ANXA1, CSF1, GSTP1, HMGB1, 
IGFBP2, IL2, IL3, PTPN6, S100A9, SFTPD, 
TIMP1] 
positive regulation of 
leukocyte proliferation 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 250.0E-9 44.0E-6 25.0E-9 6.25 9.00 
[AIF1, ANXA1, CSF1, HMGB1, IGFBP2, IL2, 
IL3, S100A9, TIMP1] 
cellular response to 
interferon-gamma 
GO_ImmuneSystemProcess
-GOA_09.02.2016_16h18 280.0E-9 50.0E-6 150.0E-12 6.16 9.00 
[AIF1, CAMK2B, CAMK2D, CCL14, CCL23, 
PTPN1, PTPN11, PTPN6, SYNCRIP] 
ERK1 and ERK2 cascade 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 91.0E-12 15.0E-9 150.0E-12 5.62 15.00 
[C3, CAMK2D, CCL14, CCL23, EPHA2, 
GSTP1, HMGB1, MAP2K1, MAP2K2, 
PLA2G2A, PTPN1, PTPN11, PTPN6, S100A9, 
TIMP1] 
regulation of ERK1 and ERK2 
cascade 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 4.3E-9 750.0E-9 150.0E-12 5.22 13.00 
[C3, CAMK2D, CCL14, CCL23, EPHA2, 
GSTP1, HMGB1, PLA2G2A, PTPN1, PTPN11, 
PTPN6, S100A9, TIMP1] 
granulocyte chemotaxis 
GO_ImmuneSystemProcess
-GOA_09.02.2016_16h18 2.0E-9 350.0E-9 22.0E-9 8.77 10.00 
[ANXA1, CCL14, CCL23, CSF1, CXCL8, 
DAPK2, ITGA1, LBP, S100A9, SAA1] 
neutrophil chemotaxis 
GO_ImmuneSystemProcess
-GOA_09.02.2016_16h18 120.0E-9 21.0E-6 22.0E-9 8.42 8.00 
[CCL14, CCL23, CXCL8, DAPK2, ITGA1, LBP, 
S100A9, SAA1] 
positive regulation of 
leukocyte chemotaxis 
GO_ImmuneSystemProcess
-GOA_09.02.2016_16h18 55.0E-9 9.7E-6 74.0E-24 9.30 8.00 
[AIF1, CSF1, CXCL11, CXCL8, DAPK2, 
HMGB1, LBP, TNFSF14] 
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s Associated Genes Found 
inflammatory response 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 26.0E-18 4.6E-15 74.0E-24 4.20 30.00 
[AIF1, ANXA1, C3, C4B_2, CCL14, CCL23, 
CMA1, CRP, CSF1, CTSS, CXCL11, CXCL8, F3, 
GSTP1, HAVCR2, HMGB1, IL2, LBP, MAPK13, 
OLR1, PARK7, PGLYRP1, PLA2G2A, PTGS2, 
S100A9, SAA1, SERPINA3, SERPING1, 
TIMP1, TNFRSF1B] 
positive regulation of 
response to external 
stimulus 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 20.0E-18 3.6E-15 74.0E-24 7.03 22.00 
[AIF1, C3, CCL14, CCL23, CSF1, CTSS, 
CXCL11, CXCL8, DAPK2, F3, HAVCR2, 
HMGB1, IL16, IL2, LBP, MAPK13, PARK7, 
PLA2G2A, PTGS2, S100A9, SCARF1, 
TNFSF14] 
positive regulation of 
defense response 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 4.9E-12 860.0E-12 74.0E-24 4.38 20.00 
[C3, CCL14, CCL23, CTSS, FCN1, FYN, 
HAVCR2, HMGB1, IL2, LBP, LTF, MAP2K1, 
MAPK13, PGLYRP1, PLA2G2A, PSMA2, 
PTGS2, RPS27A, S100A9, UBE2N] 
positive regulation of 
chemotaxis 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 9.7E-9 1.7E-6 74.0E-24 7.46 10.00 
[AIF1, CSF1, CXCL11, CXCL8, DAPK2, F3, 
HMGB1, IL16, LBP, TNFSF14] 
regulation of response to 
wounding 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 23.0E-18 4.1E-15 74.0E-24 5.59 25.00 
[ANXA1, ANXA2, C3, CCL14, CCL23, CMA1, 
CTSS, F3, GSTP1, HMGB1, IL2, LBP, 
MAP2K1, MAP2K2, MAPK13, PARK7, 
PGLYRP1, PLA2G2A, PLAUR, PTGS2, S100A9, 
SAA1, SCARF1, SERPING1, TNFRSF1B] 
positive regulation of 
response to wounding 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 3.0E-12 520.0E-12 74.0E-24 8.09 14.00 
[ANXA1, C3, CCL14, CCL23, CTSS, F3, 
HMGB1, IL2, LBP, MAPK13, PLA2G2A, 
PTGS2, S100A9, SCARF1] 
regulation of inflammatory 
response 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 800.0E-15 140.0E-12 74.0E-24 5.70 18.00 
[ANXA1, C3, CCL14, CCL23, CMA1, CTSS, 
GSTP1, IL2, LBP, MAPK13, PARK7, PGLYRP1, 
PLA2G2A, PTGS2, S100A9, SAA1, SERPING1, 
TNFRSF1B] 
positive regulation of 
inflammatory response 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 3.9E-9 680.0E-9 74.0E-24 8.20 10.00 
[C3, CCL14, CCL23, CTSS, IL2, LBP, MAPK13, 
PLA2G2A, PTGS2, S100A9] 
TNF signaling pathway KEGG_10.02.2016 380.0E-9 66.0E-6 4.2E-6 7.27 8.00 
[CASP10, CSF1, CSF2, MAP2K1, MAPK13, 
MMP9, PTGS2, TNFRSF1B] 
Proteoglycans in cancer KEGG_10.02.2016 48.0E-9 8.5E-6 530.0E-9 5.42 11.00 
[CAMK2B, CAMK2D, ITGB1, MAP2K1, 
MAP2K2, MAPK13, MMP9, MSN, PLAUR, 
PTPN11, PTPN6] 
positive regulation of 
tyrosine phosphorylation of 
Stat5 protein 
GO_BiologicalProcess-
GOA_09.02.2016_16h18 110.0E-9 20.0E-6 140.0E-15 25.00 5.00 [CSF2, FYN, IL2, IL3, TIMP1] 
cytokine activity 
GO_MolecularFunction-
GOA_09.02.2016_16h18 1.1E-12 190.0E-12 140.0E-15 6.81 16.00 
[CCL14, CCL23, CSF1, CSF2, CXCL11, CXCL8, 
GDF5, GPI, HMGB1, IL16, IL2, IL3, NAMPT, 
S100A9, TIMP1, TNFSF14] 
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cytokine receptor binding 
GO_MolecularFunction-
GOA_09.02.2016_16h18 31.0E-9 5.4E-6 140.0E-15 4.42 13.00 
[CCL14, CCL23, CSF1, CSF2, CXCL11, CXCL8, 
GDF5, IL2, IL3, S100A9, SHC1, TIMP1, 
TNFSF14] 

















GOA_09.02.2016_16h18 5.5E-9 970.0E-9 140.0E-15 4.17 15.00 
[CSF2, DDR2, EPHA2, FYN, IL2, IL3, ITGB1, 
MAP2K1, MAP2K2, PTPN1, PTPN6, S100A9, 




GOA_09.02.2016_16h18 210.0E-9 37.0E-6 140.0E-15 4.68 11.00 
[CSF2, FYN, IL2, IL3, ITGB1, PTPN1, PTPN6, 

































Figure A.S2. Principal Component Analysis (PCA) showed that the largest, unbiased difference in the IPF-Healthy 
dataset is between the IPF and healthy groups, with comorbidities in the IPF patients having little effect. 
(a) A PCA model based on all 1129 measured blood proteins captured 27.26% of the total variance in the data, with PC1 
explaining 14.16% of the variance and PC2, 13.10%. In this model, the healthy patients score in the negative region of PC1, 
and the IPF patients score mostly in the positive area of PC1. IPF patients with GERD do not cluster together within the IPF 
group; these patients are mixed evenly with the IPF patients who do not have GERD. (b) Similarly, when looking at IPF 
patients with obstructive sleep apnea (OSA), it can be seen that these patients are spread throughout the IPF grouping in the 







Figure A.S3. Kappa statistics from the upregulated proteome. 
Level of agreement between gene terms is measured by Kappa statistics (default <4). Red scale depicts level of agreement 






Level of agreement between gene terms is measured by Kappa statistics (default < 4). Blue scale depicts level of agreement from very high (1) to very low (-1) 
Figure A.S4. Kappa statistics from the downregulated proteome. 
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negative regulation of catalytic activity 0.0246
peptidase inhibitor activity 0.0095
endopeptidase regulator activity 0.009
peptidase regulator activity 0.0164
endopeptidase inhibitor activity 0.0082
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Supplemental methods: Sample acquisitions and measurements 
Peripheral blood samples were collected from 60 COMET patients at three time points 
(week 0/baseline, week 48 and week 80) in EDTA-containing vacutainers and were shipped 
overnight from individual sites to the University of Michigan. Blood samples were centrifuged 
and plasma was stored at -80°C until transported to SomaLogic (Boulder, CO). Slow off-rate 
modified aptamers (SOMAmer©) technology was used to measure 1129 proteins present in blood 
samples at each collection time point.   
Bronchoscopy was performed at enrollment in patients who were clinically stable and 
without evidence of active infection. BAL samples were collected and pooled from 4 
installations of 50 mL sterile isotonic saline aliquots. Cell-free fluid was stored at -80°C. 
Luminex FlexMAP 3D (Luminex Corporation, Austin, TX) technology was used to measure 29 
cytokines/chemokines in the BAL samples. Samples below the lower limit of detection were set 
to be ½ the lowest minimum detectable concentration across the standard curves of all analytes. 
Before inclusion in any analyses, all BAL protein concentrations were normalized to total protein 




Table B.S1. Demographic and lung function test descriptions from progressors and non-
progressors whose baseline blood protein measurements were used in creating models 
based on blood proteins alone. 
  Non-progressor (N=25) Progressor (N=34) P-value 
Age  63.72 64.86 0.5855 
Sex (Male) 76% 61.76% 0.2551 
Number Never Smokers 7 12 0.5614 
Number Former Smokers 17 22 0.796 
Number Current Smokers 1 0 0.2469 
FVC % Predicted 68.19 70.78 0.5511 
DLCO % Predicted 44.75 47.61 0.441 
 
Table B.S2. Demographic and lung function test descriptions from progressors and non-
progressors whose baseline BAL protein measurements were used in creating models based 
on BAL proteins alone. 
  Non-progressor (N=20) Progressor (N=31) P-value 
Age  62.43 65.43 0.1924 
Sex (Male) 16 (80%) 20 (64.5%) 0.2446 
Number Never Smokers 6 (30%) 11 (35.48%) 0.6922 
Number Former Smokers 13 (65%) 20 (65.42%) 0.9725 
Number Current Smokers 1 (5%) 0 0.2165 
FVC % Predicted 66.88% 71.84% 0.3248 
DLCO % Predicted 45.78% 47.42% 0.6803 
 
Table B.S3. Pearson’s correlation between proteins measured by SOMAmer aptamers and 
by ELISA in a subset of the COMET samples. 
  
Pearson's correlation 
coefficient  P-value 
CCL22 0.672 0.006 
CCL18 0.706 0.003 
CCL2 0.566 0.028 
IL-10 -0.208 0.456 













Figure B.S1. The PLSDA model based on LASSO-identified signature of blood proteins is accurately able to differentiate 
IPF progressors and non-progressors. 
 
(a) LASSO identified a signature of 61 blood proteins that differentiated progressors and non-progressors with 100% 
calibration and 96.53% cross-validation accuracy. (b) The associated loadings on latent variable 1 (LV1) captured 6.28% of the 
total variance in the data. Proteins that are loaded negatively on LV1 are comparatively upregulated in IPF progressors, and 







(a) The cross-validated PLSDA model reported a sensitivity of 97.06% and a specificity of 99.56% for the progressors. 
(b) The cross-validated PLSDA model reported a sensitivity of 96% and specificity of 97.38% for the non-progressors. C: 
Calibrated; CV = Cross-validated; AUC = area under curve. 
 
Figure B.S2. The receiver operator characteristic (ROC) curves associated with the PLSDA model based on the 









Figure B.S3. PLSDA model based on VIP-selected signature of BAL proteins is moderately able to differentiate IPF 
progressors and non-progressors, with 78.55% calibration and 67.82% cross-validation accuracy. 
 
(a) The PLSDA scores plot of the 12 feature BAL protein signature highlights moderate separation between baseline 
progressors and non-progressors, with progressors generally having negative scores on LV1 and non-progressors having 
positive scores. (b) The associated loadings on LV1 captured 16.49% of the total variance in the data. Proteins that are 
loaded negatively on LV1 are comparatively upregulated in IPF progressors, and positively loaded proteins have a 











Figure B.S4. The receiver operator characteristic (ROC) curves associated with the PLSDA model based on the VIP-
selected signature of BAL proteins. 
 
(a) The cross-validated PLSDA model reported a sensitivity of 83.87% and a specificity of 54.94% for the progressors. (b) 
The cross-validated PLSDA model reported a sensitivity of 49.94% and specificity of 83.87% for the non-progressors. C: 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure B.S5. Direct comparison of expression of the blood and BAL proteins in the LASSO-identified signature in both 
progressors and non-progressors. 
  
Significance according to a two-sample t-test is marked on each graph, with ** indicating p < 0.01 and * indicating p < 0.05. 
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Figure B.S6. The receiver operator characteristic (ROC) curves associated with the PLSDA model based on the 
LASSO-identified signature of blood BAL proteins. 
 
(a) The cross-validated PLSDA model reported a sensitivity of 100% and a specificity of 100% for the progressors. (b) 
The cross-validated PLSDA model reported a sensitivity of 100% and specificity of 100% for the non-progressors. C: 





Figure B.S7. The receiver operator characteristic (ROC) curves associated with the PLSDA model based on the 28 
proteins that were identified as being significantly differentially expressed across progressors and non-progressors in 
the volcano plot. 
 
(a) The cross-validated PLSDA model reported a sensitivity of 88.29% and a specificity of 87.56% for the progressors. (b) 
The cross-validated PLSDA model reported a sensitivity of 90% and specificity of 90% for the non-progressors. C: 
Calibrated; CV = Cross-validated; AUC = area under curve. 
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a b 
Figure B.S8. Comparison of calibration and cross-validation accuracy in the PLSDA models based on blood proteins 
alone, BAL proteins alone, and blood and BAL proteins combined shows that the blood only and the combination model 
are both significantly better than the model based on BAL proteins alone. 
 
(a)  Comparison of the calibration accuracies in the three PLSDA models. ** indicate p < 0.01 after administration of 
Cochran’s Q test with McNemar’s post hoc test. (b) Comparison of the cross-validation accuracies of the same three PLSDA 
models shown in panel a. *** indicates p = 0.0001, and **** indicates p < 0.0001 after administration of a one-way ANOVA 




Figure B.S9. Statistical comparison of calibration and cross-validation accuracies of PLSDA models with similar number 
of features included in each signature showed only trends towards being significantly different from each other. 
 
(a) Statistical analysis of the calibration accuracies via Cochran’s Q test showed that the shortened signature based on blood 
and BAL proteins combined approached being significantly better than the BAL VIP and the shortened blood signature (p = 
0.052, McNemar’s post hoc test). (b) When comparing cross-validation accuracies of the three models, none were significantly 












































































































































































































































































1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 0 1 0 0 positive regulation of response to stimulus 4.68E-08
1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 0 1 0 1 0 0 0 1 0 0 response to external stimulus 8.52E-05
1 1 1 1 1 1 1 1 1 0 1 1 1 0 0 1 1 1 0 0 0 0 0 1 1 cell surface receptor signaling pathway 0.002974
1 1 1 1 1 1 1 1 1 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 positive regulation of cellular protein metabolic process 0.02651
1 1 1 1 1 1 1 1 1 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 positive regulation of protein metabolic process 0.046396
1 1 1 1 1 0 1 1 1 1 1 0 1 0 0 0 0 1 0 0 0 1 0 0 0 cell proliferation 0.058653
1 1 1 1 1 1 1 1 0 1 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 positive regulation of multicellular organismal process 0.028502
1 1 1 1 1 1 0 1 1 1 0 0 1 1 0 0 1 0 1 0 0 0 0 0 0 regulation of response to external stimulus 2.06E-06
1 1 1 1 1 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 positive regulation of protein phosphorylation 0.025269
1 1 1 1 1 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 positive regulation of phosphorylation 0.03636
1 1 1 1 1 1 0 1 0 1 1 0 1 1 0 0 0 1 1 0 0 0 0 0 0 regulation of multicellular organismal development 0.026881
0 1 1 1 1 1 1 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 receptor binding 0.003002
1 1 1 1 1 0 1 1 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 positive regulation of cell proliferation 0.017344
0 0 0 1 1 1 1 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 cytokine receptor binding 9.62E-08
1 1 1 0 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 cell chemotaxis 0.007705
0 1 0 1 1 0 1 1 0 1 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 tokine-cytokine receptor interaction 0.000223
0 0 1 0 1 0 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 growth factor activity 0.001478







































































































































1 1 1 1 1 1 0 1 1 0 1 0 1 1 0 positive regulation of immune system process 0.005574
1 1 1 1 1 1 0 0 0 1 0 1 1 1 0 regulation of defense response 0.002697
1 1 1 1 1 1 0 0 0 1 0 1 0 0 1 inflammatory response 0.018036
1 1 1 1 1 1 0 0 0 1 0 1 0 0 0 regulation of inflammatory response 0.001707











Indicates no involvement 
in process 
 Figure B.S10. Additional DAVID enrichment analyses of the proteins in the LASSO-signature that were found to be comparatively upregulated in the non-progressors. 
 
(a) This cluster was mostly enriched for processes involving cell signaling and regulation of basic cell processes, with an enrichment score of 2.57. (b) This cluster was also 
enriched for processes involving the function and regulation of the immune, defense and inflammatory responses, with an enrichment score of 2.50. Black squares indicate protein 



























































































































































































Pathway Bonferroni Corrected P-value
1 1 1 1 1 1 1 1 1 1 1 regulation of response to stress 0.005438115
Figure B.S11. DAVID enrichment analysis of the proteins that were comparatively upregulated in the progressors in the 
LASSO-identified signature based on blood and BAL proteins measured in COMET IPF patients. 
 
The enrichment score of this cluster is 2.05. Black squares indicate protein involvement in a particular pathway, while white 










































































Figure B.S12. Hierarchical cluster based on the combination signature did not cluster according to the following 
clinical and pulmonary variables: A. smoking status, B. how progression occurred in that specific patient, C. presence 
of honeycombing in the CT scan, D. presence of ground glass in the CT scan, E. DLCO increase or decrease over the 
80-week time period of the COMET study, F. MUC5b genotyping results, G. TOLLIP genotyping results, and H. 
MUC5b and TOLLIP genotyping results together. 
Color bars are shown to the left of each figure, with red indicating higher protein expression level from the mean, white 
unchanged, and blue a lower expression. AE-IPF: acute exacerbations of IPF, DLCO: diffusing capacity of the lungs for 
carbon monoxide, FVC: forced vital capacity. 
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Figure B.S13. The LASSO-identified trajectory PCA signature chosen to separate the non-progressors across the 
three time points captured 24.26% of the natural variance in the data across the first two principal components. 
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APPENDIX C. Supplement to: Inference of Cellular Immune Environments in 
Sputum and Peripheral Blood Associated With Acute Exacerbations of COPD 
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* indicates significance (p < 0.05) after application of a paired Wilcoxon signed rank test. Patient number is indicated in the legend, with number references for multiple 
exacerbation visits. Unconnected dots represent measurements that were only made in one state (and were excluded from statistical analysis but included in the fold change 
calculation).  Proteins that were not present in any individuals in any state overlap and appear as a single line.  These measurements were not included in the PLSDA 
analysis. 
 










* indicates significance (p < 0.05) after application of a paired Wilcoxon signed rank test. Patient number is indicated in the legend, with number references for multiple 
exacerbation visits. Unconnected dots represent measurements that were only made in one state (and were excluded from statistical analysis but included in the fold change 
calculation).  Proteins that were not present in any individuals in any state overlap and appear as a single line.  These measurements were not included in the PLSDA analysis. 
the PLSDA analysis. 











* indicates significance (p < 0.05) after application of a paired Wilcoxon signed rank test. Patient number is indicated in the legend, with number references for multiple 
exacerbation visits. Unconnected dots represent measurements that were only made in one state (and were excluded from statistical analysis but included in the fold change 
calculation). Proteins that were not present in any individuals in any state overlap and appear as a single line.  These measurements were not included in the PLSDA analysis. 






No model had significantly higher cross-validation accuracy according to Tukey’s multiple comparison test (one-way 
ANOVA). 
The volcano plots illustrate serum proteins that are both differentially expressed (x axis) and significantly different (y axis) 
between the stable and exacerbated state.  Points in red indicate significantly different expression between the stable and 
exacerbated state via paired Wilcoxon signed rank test, with significance being defined as p < 0.05.   
Figure C.S4. Volcano plot based on all stable and exacerbation serum protein measurements (A) compared to volcano 
plot created after first averaging the serum protein concentrations from all of the stable points and all of the exacerbation 
measurements collected across multiple visits from patient A, from patient C, and from patient E separately (B) before 
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Figure C.S5. Comparison of the cross-validation accuracies associated with each training and test set created during 
cross-validation of the PLSDA models based on VIP-identified serum proteins, serum and sputum proteins, and serum 




Protein abundance is shown on a colorimetric scale, with red indicating overabundant, white unchanged, and blue under 
abundant protein level compared to the mean. Color bar scale is to the left of the figure. 
Figure C.S6. Hierarchical clustering of the patient samples included in the PLSDA model is ultimately unable to 





This PLSDA scores plot is the same as the one as shown in Figure 4A, except the samples are now colored by which patient 
they came from. Each point is additionally labeled to convey information about the state of the patient for that sample (i.e. 
stable or exacerbated), as well as with information about which visit the point is referring to, in the cases where multiple 
exacerbations were captured for one patient. 
Figure C.S7. An investigation of the effect of including multiple paired stable and exacerbation measurements from the 
same patient in a PLSDA model based on serum and sputum proteins and blood flow marker data showed that there is 






Correlation coefficients were calculated using Spearman’s rank correlation. Color bar scale is shown to the right of the figure. 
Figure C.S8. A correlation coefficient heat map based on the change in concentration between the stable and exacerbated 
state of all measured blood cell markers and serum and sputum proteins highlights how cellular concentrations could 
potentially affect protein concentration during exacerbation. 
 213 







(A) There is no differentiation between smokers (grey), never smokers (purple), and COPD subjects (red) in the PLSDA scores 
plot. This model had a 65.69% calibration and 57.88% cross-validation accuracy. (B) Latent variable 1 (LV1) captured 28.97% 
of the variance in the data. 
Figure D.1. Signature of VIP-selected, Luminex-measured plasma cytokines is unable to differentiate COPD disease state 
in a PLSDA model. 
(A) PLSDA scores plot based on SOMAmer-measured blood proteins moderately separates the three groups with 74.56% 
calibration and 67.59% cross-validation accuracy. (B) PLSDA loadings plot captured 12.62% of the variance on LV1. Proteins 
that are positively loaded on LV1 are comparatively increased in most of the COPD subjects and around half of the smokers. 
Figure D.2. Signature of SOMAmer-measured blood proteins is able to differentiate COPD disease state moderately 






















































































































































































































Pathway Bonferroni corrected P-value
1 1 1 1 1 1 1 1 1 1 0 0 1 0 1 1 regulation of protein metabolic process 0.003462898
1 1 1 1 1 1 1 1 1 1 0 0 1 0 1 0 regulation of cellular protein metabolic process 0.015297948
1 1 1 1 1 1 1 1 1 1 0 0 0 0 1 0 positive regulation of cellular protein metabolic process 0.001275865
1 1 1 1 1 1 1 1 1 1 0 0 0 0 1 0 positive regulation of protein metabolic process 0.002224591
1 1 1 1 1 1 1 1 1 0 1 0 0 0 0 0 positive regulation of multicellular organismal process 0.014824832
1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 positive regulation of protein phosphorylation 0.004124438
1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 positive regulation of phosphate metabolic process 0.013929143
1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 positive regulation of phosphorylation 0.005816171
1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 positive regulation of phosphorus metabolic process 0.013929143
1 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 positive regulation of protein modification process 0.02600925
1 1 1 1 1 0 1 1 0 1 1 1 0 1 1 1 positive regulation of response to stimulus 0.000330764
1 1 1 1 1 0 1 1 0 1 0 1 0 1 0 0 positive regulation of cell communication 0.02898437
1 1 1 1 1 0 1 1 0 1 0 1 0 1 0 0 positive regulation of signaling 0.030197501
1 1 1 1 1 0 1 1 0 1 0 1 0 1 0 0 positive regulation of signal transduction 0.014573905
1 0 1 1 1 1 1 0 1 0 1 0 0 0 0 0 positive regulation of cell differentiation 0.034061891
0 1 1 1 1 0 1 1 0 1 0 1 0 1 0 0 positive regulation of intracellular signal transduction 0.005071393
0 1 0 0 0 1 1 1 1 0 0 0 0 0 0 0 positive regulation of peptidyl-tyrosine phosphorylation 0.04397408
A 
B 
Figure D.3. DAVID identified a cluster of significant pathways (Bonferroni corrected p < 0.05) involving (A) metabolic 
process regulation (enrichment score 2.27) and (B) regulation of stimulus response (ES 1.92) that were enriched in the 






Figure D.4. LASSO-identified signature of 29 SOMAmer-measured blood proteins differentiates COPD severity 
moderately well. 
A B 
(A) A signature of 29 SOMAmer-measured blood proteins differentiated three GOLD stages of COPD severity with 84.74% 
calibration and 77.77% cross-validation accuracy. (B) LV1 captured 7.938% of the variance in the data. COPD subjects with a 
higher GOLD classification had more positive scores on LV1. 
Figure D.5. Feature selected signature of 13 Luminex-measured BAL cytokines is not a strong differentiator of COPD 
disease severity. 
A B 
(A) A VIP-selected signature of 13 BAL cytokines differentiated three GOLD stages of COPD severity with 69.53% 
calibration and 62.09% cross-validation accuracy. (B) LV1 captured 25.3% and LV2 captured 11.61% of the variance in 
the data. GOLD 3 subjects tended to have positive scores on LV1 and LV2. LV2 also separated GOLD 1 and GOLD 2 
subjects. 
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APPENDIX E. Brief Results of Other Non-Published Experiments 
 
Introduction 
 This appendix briefly reviews modeling approaches and situations that were explored 
during the course of this thesis, but were ultimately not followed up on, be it for having low 
model accuracy or for not contributing much biological insight to the field.  
 
Biological differences in IPF patients requiring a diagnostic biopsy 
 In the COMET IPF cohort, 35 of the 60 recruited IPF patients received a biopsy to 
confirm diagnosis of IPF due to lack of clear usual interstitial pneumonia (UIP) patterns visible 
on chest computed tomography (CT) scans. We wanted to explore if there were distinct 
proteomic signatures in individuals who had to undergo a biopsy vs. those who were diagnosed 
with non-invasive mechanisms. Identification of a proteomic signature common to both IPF 
groups could suggest a basis for a new, less invasive diagnostic method, and potentially 
eliminate the need for diagnostic lung biopsies. We first set out to determine whether 
unsupervised approaches could identify differences between the two IPF groups and healthy 
patients. When we performed hierarchical clustering to investigate the differences between the 
healthy patients and the IPF patients who did or did not get biopsies (Figure E.1A), most of the 
healthy patients were grouped together, whereas there were no obvious differences in proteomes 
of the biopsy and no biopsy proteomes. We then used principal component analysis (PCA) 
(another unsupervised approach) to look at inherent differences between these three groups of 
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patients (Figure E.1B). Again, healthy patients clustered differently than all IPF patients, with 
no biopsy and biopsy groups occupying the same area in the multivariate space, suggesting little 
inherent differences between blood proteomes in these two groups of patients. Both PCA and 
hierarchical clustering suggested that the blood proteome of healthy patients was quite different 
from that of patients diagnosed with IPF, and additionally that the blood proteomes of IPF 
patients were similar, regardless of diagnostic method. This has implications in how IPF is 
diagnosed: if a person is exhibiting symptoms of IPF according to CT scans, then a diagnosis of 
IPF by biopsy might not be necessary. We next turned to the supervised LASSO technique to 
identify a signature that differentiated the patients who did and did not receive a biopsy; when 
visualized using PLSDA, this signature had a calibration and cross-validation accuracy of 
77.43%. This may suggest there could be differences in the plasma proteome between IPF 
patients who do need a biopsy for diagnosis vs. those who don’t, but this result would need to be 
A. Unsupervised hierarchical clustering of the three groups of patients based on 1129 proteins measured in the SOMAlogics 
assay did not show major differences between IPF patients who had received a biopsy vs. those who had not, but did separate 
healthy patients out from the IPF patients well. This indicates that the IPF patients had similar blood proteomes overall. 
Abundance of each protein is shown in color, with red indicating overabundant proteins, white unchanged, and blue 
underabundant proteins when compared to the mean expression (color bar to left of scale). B. PCA, another unsupervised 
method used to visualize inherent differences between data points, was also used to explore the differences in the blood 
proteome of healthy and IPF patients who did or did not receive a diagnostic biopsy. Again the healthy patients are seen to be 
visually distinct from the IPF patients, and there seemed to be little difference between the IPF patients who had received a 
biopsy and those who had not. 
Figure E.1. Unsupervised methods of classification highlighted differences between healthy and IPF patients, but did 
not capture proteomic differences between IPF patients who had received a biopsy to confirm diagnosis versus those 






investigated and validated in another cohort before a more definitive conclusion could be 
reached.  
 
IPF endotype investigation 
 Due to the heterogeneity present in the disease course of IPF, it is possible that patients 
may present similar losses in lung function that are actually caused by different 
pathophysiological mechanisms320. If disease subgroups or endotypes could be identified that are 
associated with specific biomarkers, this could help in the discovery of new diagnostic or 
treatment options for IPF and could lead to more personalized treatment options for patients. We 
attempted to identify potential endotypes within the 60 IPF patients recruited in the COMET 
cohort using unsupervised hierarchical clustering. Based on the dendrogram separating the IPF 
patients and the visual expression patterns of all 1129 proteins measured in the SOMAscan 
assay, we identified three clusters of IPF patients (Figure E.2). Although we explored proteomic 
Abundance of each protein is shown in color, with red indicating overabundant proteins, white unchanged, and blue 
underabundant proteins when compared to the mean expression (color bar to left of scale). 
 
Figure E.2. Hierarchical clustering of all 60 COMET IPF patients based on expression of all 1129 proteins measured in 
the SOMAlogics assay identified three groups of IPF patients with distinct proteomic expression, as outlined in the black 
boxes. 
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differences in these three groups using LASSO and PLSDA and clinical differences (such as 
differences in radiology, PFTs, and comorbidities), we did not discover novel differences, and 
did not follow up on these identified groups. 
 
Validation of proteomic signature that differentiated healthy and COMET IPF patients 
 One difficulty with working with human data is that cohorts that employ the same assays 
across a similar patient population can be difficult to fund or obtain, which makes it difficult to 
validate a proteomic signature for a diagnostic or prognostic purpose. However, our contacts at 
MedImmune were able to share SOMAmer data from healthy, IPF and COPD patients not 
enrolled in the COMET study shared with us for validating our signatures that differentiated 
Latent variable 1 (LV1) accounted for 71.48% of the variance in the data, and latent variable 2 (LV2) accounted for 6.15% of 
the variance in the data. 
 
Figure E.3. Validation of the 8 protein signature that differentiated COMET control/healthy (dark blue) and IPF 
(lighter blue) patients174 was not successful in another cohort (COPD Study cohort) of control (green) and IPF (yellow) 
patients shared with us by MedImmune, although this could have been due to unknown demographic and diagnostic 
guidelines.  
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healthy and COMET IPF patients. However, when we tested our model using this unseen healthy 
and IPF data (called “COPD study” in Figure 5.3), we did not see clustering patterns that we 
expected: the new healthy and IPF patients were located in between the COMET IPF and healthy 
patients, with the new control patients scoring slightly more positive on LV1 and thus clustering 
nearer to the COMET IPF patients (Figure E.3). We did not receive any demographic data 
associated with these new patients, which made us unable to account for clinical or demographic 
parameters that may differ across the two cohorts. In addition, we did not know the exact 
guidelines that were used when diagnosing the IPF patients, which could have led to greater 
differences in the proteome of the IPF patients from the two cohorts. We did investigate how the 
model classified the COPD patients, and saw that they tended to cluster on the scores plot 
relatively closely to the COMET control patients (data not shown), but we did not explore this 
relationship any further. 
 
Separation of IPF patients based on radiological variables 
 A subset of the COMET IPF patients received high resolution computed tomography 
(HRCT) scans as part of the IPF diagnosis process. Using the measured ALV score relating to 
the ground glass opacity seen in the HRCT scan and the INT score, which quantifies the fibrosis 
level in the HRCT scan321, we used partial least squares regression (PLSR) to identify a signature 
of baseline blood proteins measured by the SOMAscan assay that could differentiate across the 
continuous range of these two scores (model based on ALV scores seen in Figure E.4; INT 
model not shown). We identified signatures using LASSO that accurately differentiated patients 
based on ALV and INT scores with high accuracy (94.2% R2 and 83.3% Q2 values on the ALV 
model). However, when we further investigated these signatures, we found that these identified 
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proteins were novel in their association with IPF. Based on this lack of supporting evidence in 
the literature, we decided not to follow up on these models.  
 
Temporal models of IPF progression 
We created a variety of models while investigating temporal differences in the blood 
proteome of IPF progressors and non-progressors. While we ended up publishing the trajectory 
PCA models of the progressors and non-progressors, we also explored PLSDA models of the 
blood proteome at week 48 and week 80 separately (data not shown), though we did not develop 
these models further because they were not as clinically useful as the signature based on week 0 
protein expression. We also explored a PLSDA model where we used LASSO to identify a 
signature of blood proteins from both the week 0 and the week 48 time points that separated the 
two groups with 88.48% calibration and cross-validation accuracy. The scores plot for this model 
can be seen in Figure E.5A, with latent variable one capturing 27.86% of the variance between 





A. LASSO identified a signature that differentiated patients across a range of continuous ALV scores, with a calibration R2 of 
94.2% and a cross-validation R2 of 83.3%. B. The loadings plot indicates protein contributions of the LASSO-identified 
signature, with positive loadings positively associated with patients with higher ALV scores, and negative loadings 
comparatively reduced in patients with higher ALV scores. 
 
Figure E.4. LASSO/PLSR identified a signature of proteins that best differentiated patients by HRCT ALV score. 
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model based solely on week 48 proteins. It was interesting to note that out of the 13 proteins 
LASSO identified in this signature, eight of them are from week 48, and this includes the top two 
positively and negatively loaded proteins. This suggested to us that the proteins at later time 
points are more important in classifying the two groups. Proteins that were found to be 
comparatively upregulated in the progressors were mostly from the week 48 time point (6 out of 
7). Some of the top loaded proteins in the progressors include apolipoprotein B, E-cadherin and 
TFPI (Figure E.5B), which was intriguing to us because these proteins were also chosen in the 
baseline (week 0) only (Chapter 3) and the week 48 only models as well. While we were able to 
hypothesize potential mechanisms involving these proteins that may be associated with 
progression, we did not follow up on these results because using data from the week 48 time 
point was not as clinically useful because progression should be attempted to be slowed or halted 





Figure E.5. A PLSDA model based on blood proteins from baseline (Tmpt 1) and 48 weeks (Tmpt 2) separates 
progressors and non-progressors well and contains mostly proteins from week 48 in the LASSO-identified signature. 
A. The LASSO-identified signature differentiated IPF progressors from non-progressors with 88.48% calibration and cross-
validation accuracy in a PLSDA model. Latent variable 1 captured 27.86% of the variance in the data. B. The protein 
loadings associated with this model; proteins loaded negatively are comparatively upregulated in progressors, while proteins 
loaded positively are comparatively downregulated in progressors. 
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Proteomic signatures associated with method of IPF progression 
In the COMET study, patients who were classified as progressors experienced at least 
one of four events throughout the course of the 80-week study: (1) An acute exacerbation of IPF 
(AE-IPF), (2) A lung transplant, (3) A drop of 10% or more in FVC, or 4. A drop if 15% or more 
in DLCO measurements. Some patients even experienced a drop in both FVC and DLCO values 
that would classify them as progressors, but no patients that went through a lung transplant had 
blood samples measured by SomaLogic. We were interested in exploring if the way in which 
patients experienced IPF progression was related to their peripheral blood protein expression. 
We used LASSO and PLSDA to identify and visualize a signature of 20 blood proteins that 
differentiated patients who experienced an AE-IPF, a drop in just DLCO or FVC only, or a drop 
in both DLCO and FVC in the 80 weeks of the COMET study. The PLSDA model performed 
with high calibration and moderate cross-validation accuracy (95.26% calibration and 82.91% 
cross-validation accuracy), especially considering that the AE-IPF patients and the both FVC and 
DLCO patients had low numbers (n = 1 and n = 4, respectively) (Figure E.6A, Figure E.6B). In 
addition, when we looked at the individual expression of the proteins in the signature using 
hierarchical clustering, we did not see strong evidence for unsupervised clustering that 
corresponded well with our clinical groups (Figure E.6C), so we did not pursue these models 
further. 
 
Validation of the blood protein IPF progression signature with later time points of blood 
protein data from the COMET cohort 
After we identified a signature of blood proteins from week 0 (Tmpt1) of the COMET 
study that differentiated IPF progressors and non-progressors (Chapter 3), we wanted to validate 
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this signature using the protein expression data from these patients at the two other time points in 
A B 
C 
Figure E.6. A PLSDA model based on a LASSO-identified blood protein signature from baseline separates progressors 
according to how they progressed in the COMET study moderately well. 
A. The LASSO-identified signature differentiated IPF progressors by how they progressed (AE-IPF, drop in only DLCO or 
only FVC, or drops in both DLCO and FVC throughout the 80 weeks of the COMET study) 11.52% calibration and cross-
validation accuracy in a PLSDA model. Latent variable 1 captured 16.45% of the variance in the data, and latent variable 2 
captured 7.89% of the variance. B. The protein loadings associated with this model; proteins loaded in each quadrant are 
comparatively increased in the group that is scored in the same quadrant. C. Hierarchical clustering of the proteins in the 
LASSO signature did not result in groups that corresponded strongly with the clinical progression groups. 
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the study, week 48 (Tmpt2) and week 80 (Tmpt3). We saw on the scores plots after applying the 
model to the data from week 48 and week 80 that overall, this signature based on week 0 protein 
expression was still able to separate the same patients at later points throughout the COMET 
study. Using positive and negative scores on LV1 as the dividing mark between IPF progressors 
and non-progressors, we saw that there were only two progressors and two non-progressors 
misclassified based on the week 48 expression of these proteins (Figure E.7A), while at the 
later, week 80-time point, there were three progressors and three non-progressors misclassified 
(Figure E.7B). While this was promising to us and suggested that the signature we identified 
may be still useful in differentiating IPF progressors and non-progressors even throughout the 
course of disease progression, we acknowledge that in this case we were validating our original 
signature using data from the same patients at later time points. This is not the same as using a 
completely separate and unrelated validation cohort, which could result in biases towards a 
positive validation of our signature. Thus we decided not to continue further with these results. 
 
A B 
Figure E.7. Validation of our week 0 blood protein signature that differentiated COMET IPF progressors and non-
progressors using protein expression data from the COMET patients at A. week 48, and B. week 80. 
Nonprog: non-progressor. Prog: progressor. Tmpt 1 = week 0. Tmpt 2 = week 48. Tmpt 3 = week 80. 
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Signature of blood and BAL proteins and blood cell markers that differentiated IPF 
progressors and non-progressors 
 A subset of blood samples collected at baseline/week 0 of the COMET study were used 
to measure common cell marker phenotypes in the IPF progressors and non-progressors using 
flow cytometry. We then investigated a signature of blood and BAL proteins and blood cell 
markers that could differentiate IPF progression. However, when we applied LASSO to this 
combined dataset, the best signature that we found that differentiated the subset of COMET-IPF 
progressors and non-progressors with all three measurements (n = 11 progressors and 8 non-
progressors) was only based on blood and BAL proteins (data not shown). Because there were no 
cell markers selected by LASSO, we could not move forward with any cellular-based 
hypotheses, and due to the low sample size of patients who also had flow cytometry data, we did 
not pursue this model further. 
 
Data-driven models from mouse models of pulmonary fibrosis 
 We had also been interested in applying our systems-focused analysis to mouse models 
of pulmonary fibrosis so we could infer the most important proteomic relationships associated 
with bleomycin-caused pulmonary fibrosis. Working with animal models would allow us to 
formulate hypotheses based on the identified proteomic relationships and test our hypotheses in 
the same system to validate our models. Working with our collaborator Dr. Beth Moore, we 
collected blood plasma, BAL, and lung homogenate samples from C57Bl/6 mice who were 21 
days post injection with either the fibrosis-causing agent bleomycin (n=11), or with saline (n=5), 
and measured the concentrations of 32 cytokines in these samples using the Luminex platform. A 
hydroxyproline assay was used to quantify collagen levels in the lung homogenate.  The 
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pulmonary fibrotic mice had significantly more collagen formation than the control mice 
(P<0.0001). A PLSDA model of BAL samples (100% calibration and CV accuracy) was better 
able to differentiate saline- and bleomycin-treated mice than a PLSDA model of plasma samples 
(85.45% calibration and 75.45% CV accuracy, data not shown), and a model combining 
measurements from both samples also classified the groups with very high accuracy. This 
signature of combined plasma and BAL cytokines differentiated saline- and bleomycin-treated 
mice with 100% cross-validation and calibration accuracy (Figure E.8A). In this signature 
(Figure E.8B), there were increases in BAL chemokines (G-CSF, MCP-1, MIG and IP-10) 
relative to plasma chemokines in bleomycin-treated mice, suggesting that a specific gradient of 
chemokines (elevation in lung compared to plasma) was associated with lung fibrosis. 
Interestingly, both of these inflammatory cytokines signal through heterodimer receptors 
containing the same subunit (gp130). IL-6 had been known to be associated with bleomycin-
induced pulmonary fibrosis322, although to our knowledge, LIF being associated with fibrosis 
A B 
Figure E.8. PLSDA and VIP scores identified protein signatures and hubs that classified control and pulmonary fibrotic 
mice. 
A. A PLSDA model based on the VIP-selected signature differentiated control (purple) and pulmonary fibrotic (cyan) mice with 
100% cross-validation and calibration accuracy. B. The loadings plot indicates the weights and contributions of the VIP-
signature, with positively loaded proteins being comparatively upregulated in pulmonary fibrotic mice, and negatively loaded 
proteins being comparatively reduced in pulmonary fibrotic mice. 
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was a novel finding. Additionally, other researchers have reported that blocking gp130 signaling 
with the drug tunicamycin323 caused an increase in fibrosis and lung collagen deposition in 
bleomycin-exposed mice, although this study was focused on the endoplasmic reticulum (ER) 
stress caused by tunicamycin324. Due to the gp130 signaling pathway being involved in many 
other basic cellular functions325 besides what was discussed in ER stress study and the overall 
lack of novel results from our data-driven model, we decided to shift our focus on to other 
projects that investigated pulmonary fibrosis in the lungs of human patients. 
 
Protein measurements in sputum samples were able to differentiate stable and AE-COPD 
Sample collection was achieved thanks to a published prospective observational trial 
(ClinicalTrials.gov NCT00281216) has previously been described by Freeman et al.91, and in 
Chapter 5. In brief, patients were recruited at the VAAAHS and the UMHS. All parts of the 
study were approved by the IRB at each location; written consent was obtained from each 
subject; and all parts of the study adhered to the Declaration of Helsinki. Patients were followed 
for up to three years and were seen at least four times a year for spirometry, clinical evaluations, 
questionnaires, and collection of peripheral blood and spontaneously expectorated sputum. 
Exacerbations in these subjects were defined if the subject reported an increase in cough, 
sputum, or shortness of breath, and if a study physician ordered antibiotics or oral steroids after 
ruling out pneumonia. Only if a diagnosis of AE-COPD was made were sputum and peripheral 
blood samples collected at these unexpected visits. After all data and sample collection occurred, 
then each subject began their treatment for their AE-COPD. 
Spontaneously expectorated sputum was immediately processed in a 9:1 mixture of 
distilled water to Sputolysin® (EMD Millipore, Billercia, MA), and the resulting supernatant was 
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stored at -80°C until protein measurements were made. The Luminex 200 system® (Luminex 
Corporation, Austin, TX) was used to measure the concentration of 32 cytokines, with ELISA 
being employed to measure GDF-15, IL-18, IL-23p19, and IFN-β.  
Data processing involved removing samples from analysis that were missing more than 
25% of the sputum protein measurements, as well as then removing proteins from inclusion in 
future models if more than two samples had measurements that were missing for that protein. We 
then used PLSDA to identify signatures of sputum cytokines that differentiated stable and AE-
COPD. All data were mean-centered and variance scaled before being modeled using PLSDA. 
From this PLSDA model, we used VIP scores to select the cytokines that were most influential 
(defined as cytokines with VIP scores ≥ 1) in differentiating the clinical groups of interest, and 
then created a new PLSDA model based only on the VIP-selected features. Each PLSDA model 
was cross-validated to avoid model overfitting and to quantitatively define model accuracy. K-
fold cross-validation was performed by splitting the data into seven groups and iteratively 
training the model on six of the groups while using the seventh group to test the model. All 
A B 
(A) PLSDA and VIP scores identified a signature of 12 sputum proteins that differentiated the stable (purple) from 
exacerbation (orange) states with 91.67% calibration and 78.33% cross-validation accuracy. (B) The loadings plot illustrates 
the protein contributions to the VIP-selected signature, with negative loadings positively associated with AE-COPD, and 
positive loadings comparatively reduced. 
 
Figure E.9. A PLSDA model based on VIP-selected proteins from the sputum resulted in differentiation between stable 
and exacerbation measurements. 
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missing data points in the data were filled in by the Eigenvector software’s “best guess.” All 
final PLSDA models were orthogonalized to improve interpretability. All PLSDA models and 
VIP scores were created or calculated using the PLS toolbox (Eigenvector, Manson, WA) in 
MATLAB (MATLAB, Natick, MA). 
A VIP-selected PLSDA model based on sputum proteins was able to differentiate stable 
and acute exacerbations of COPD (AE-COPD) with 91.67% calibration and 78.33% cross-
validation accuracy (Figure E.9A). LV1 separated stable (purple; positive scores on LV1) and 
AE-COPD (orange; negative scores on LV1) (Figure E.9B). Many proteins that were 
comparatively increased during exacerbation had inflammatory functions (IL-8, IL-6, IL-1β). 
While this model performed with high calibration accuracy, we decided not to explore it further 
due to the lower cross-validation accuracy of this model compared to models of AE-COPD based 
on serum cytokines alone and serum and sputum cytokines in combination with blood flow 
markers which were discussed in Chapter 5. 
 
Classification of smokers, never smokers, and COPD subjects according to clinical 
measurements 
While we have reported success by using blood and lung proteins to differentiate COPD 
GOLD status in the SPIROMICS cohort, we were curious to explore if blood and lung proteins 
were also able to differentiate the SPIROMICS cohort COPD patients by numeric clinical 
measurements of interest, such as the number of reported exacerbations, FEV1 values measured 
before the patients underwent the bronchoscopy, and pack years of smoking. Overall, when just  
looking at the Luminex plasma and Luminex BAL proteins measured separately, we did not see 
strong separation across latent variable 1 for any of the mentioned clinical measurements in any 
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of the partial least squares regression (PLSR) models we created. Figure E.10A shows one of 
the best performing models for the Luminex BAL data (R2 calibration measurement of 0.2478 
and Q2 cross-validation measurement of 0.1619), which involved differentiating COPD patients 
based on FEV1 measurements, and Figure E.10B shows one of the best blood Luminex models 
(R2 calibration measurement of 0.4246 and Q2 cross-validation measurement of 0.1766), which 
attempted to differentiate COPD patients based on number of pack years smoked. We 
hypothesized that these models performed so poorly for two reasons: (1) The overall small 
number of proteins measured by the Luminex compared to other proteomic technologies, such as 
SOMAmer aptamers; and (2) The fact that the SPIROMICS COPD bronchoscopy substudy 
purposefully tried to recruit patients with less severe COPD (e.g. GOLD stage 1 and 2) due 
A B 
Figure E.10. Unable to resolve COPD patients based on quantitative clinical measurements using blood or BAL proteins 
alone. 
A. PLSR model based on BAL proteins measured by Luminex technology did not separate COPD patients well by FEV1 
measurements, with an R2 calibration measurement of 0.25 and a Q2 cross-validation measurement of 0.16, where values 
closer to 1 indicate a better separation. B. PLSR model based on plasma proteins measured by Luminex technology did not 
separate COPD patients well by the number of pack years smoked, with an R2 calibration measurement of 0.42 and a Q2 
cross-validation measurement of 0.18, where measurements closer to 1 indicate a more accurate separation. 
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prioritizing patient health when exposing them to a relatively invasive procedure. Due to the 
makeup of the patients included in the study, we did not have a large enough sample of patients 
with high FEV1 or large number of pack years smoked to accurately differentiate them from the 
larger number of patients with moderate disease. In addition, when we included smokers and 
never smokers with the COPD patients, we saw even worse separation by these quantitative 
clinical measurements. Thus, we decided not to move forward separating patients by these values 
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